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Breast cancer is the most common cancer in women in the UK. In over 90% of cases mortality 
is due to tumour recurrence and metastasis, which are hard to treat because most tumours 
become resistant to conventional therapies. During tumour progression, changes to the breast 
cancer microenvironment and extracellular matrix result in part from altered secretomes of 
neoplastic cells. There is a need to identify the molecular pathways that control these 
changes.   
Previous research in Professor Adams’ laboratory showed that Protein Disulphide-Isomerase 
A3 (PDIA3) supports a pro-metastatic phenotype in breast cancer cell lines through effects on 
secreted proteins. In this study, pharmacological inhibition of PDIA3 in MDA-MB-231 invasive 
breast cancer cells is shown to decrease cell area, focal adhesions and to alter F-actin 
organisation. Formation of 3-dimensional spheroids was also decreased. By comparing the 
activities of conditioned media from control or PDIA3-inhibited MDA-MB-A231 
cells, secreted PDIA3-dependent or heparin-binding proteins were shown to be necessary for 
cell spreading.    
Comparative TMT-based quantitative proteomic analysis of the PDIA3-dependent, heparin-
binding fractions of conditioned media identified that PDIA3 inhibition significantly decreased 
(≥ 2-fold) 80 proteins, 48 of which were extracellular proteins, including lysyl-oxidase like 
2 (LOXL2) (p=0.003). However, pharmacological inhibition of LOXL2 in MDA-MB-231 
cells with β-aminopropionitrile did not affect 3-dimensional spheroid formation.   
Analysis by Gene Ontology and other computational tools highlighted that 20 of these proteins 
are components of Extracellular Structure Organisation and 17 proteins are involved in 
Epithelial-to-Mesenchymal Transition. The extracellular proteins also showed pathway 
enrichment for Platelet Degranulation. The altered abundance of selected extracellular 
proteins was validated by immunoblotting.    
These results demonstrate a PDIA3-dependence of secreted proteins of A231 cells that have 
known roles in a pro-metastatic phenotype. Future investigation into the role of PDIA3 in 
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The main aim of this project is to investigate the role of Protein disulphide-isomerase A3 (PDIA3) 
in promoting phenotypes of breast cancer cells that are associated with pro-metastatic activity, 
including adhesion and F-actin organisation. To date, there is some evidence that PDIA3 is 
upregulated in some breast cancer cells and promotes a pro-metastatic phenotype through its 
effects on secreted proteins (Halperin et al., 2014; Jessop et al., 2007; Santana-Codina et al., 
2013; Young, unpublished, 2018). Therefore, the introductory chapter will cover aspects of breast 
cancer metastasis, the tumour microenvironment, extracellular matrix and details about PDIA3.  
1.1 Breast Cancer and Metastasis  
Mortality from breast cancer is greater than any other cancer in women worldwide. In the UK, 
breast cancer causes many deaths from cancer in women, second only to lung cancer (Ferlay et 
al., 2015) (Figure 1.1). In most cases, mortality is due to tumour recurrence and metastasis, 
because the metastatic tumours become resistant to conventional therapies (Han et al., 2019). 
Cancer metastasis involves the migration of cells away from a primary tumour, to invade local 
tissues and lymph nodes or transport of tumour cells around the body by the hematopoietic 
system, namely the blood vessels or lymphatic system. At a secondary site, a migrated tumour 
cell can adhere to a new tissue environment and undergo rapid proliferation to form a new tumour. 
Common secondary sites of breast cancer colonisation include the bone, brain, liver and 
lungs (Patanaphan et al., 1988). To date there is no cure for metastatic breast cancer and there 
is an urgent need for a better understanding of the molecular mechanisms of metastasis.   
1.1.1 Classification of Breast Cancer 
Breast cancer is a heterogenous disease that can arise from any cell in the mammary gland. For 
this reason, there are many different classifications of breast cancer.  Histologically, breast 
cancer can be divided into ductal carcinoma in situ (DCIS), which presents with tumour formation 
at a pre-malignant stage, or invasive ductal carcinoma (IDC), which presents as breast cancer 
when the basement membrane has been breached and there may have been a migration of 
breast cancer to local lymph nodes or other tissues (Malhotra et al., 2010). 
Original molecular subclassifications of breast cancer were based on the expression of oestrogen 
receptor (ERα), progesterone receptor (PR) or amplification of Erbb2 (HER2). Accordingly, there 
are three immunohistochemical subgroups: ERα-positive, HER-2-positive (HER-2 enriched) and 
triple-negative (Triple Negative Breast Cancer (TNBC)) which is lacking of expression of all three 
receptors (Perou et al., 2000). TNBC is the most prone to metastasis and has the poorest 
prognosis of the breast cancer subtypes (Li et al., 2017). In the past it was this classification that 







Figure 1.1 Mortality Statistics for Breast Cancer in Females. Data from The World Health 




More recently, breast cancer has been classified in a more detailed manner according to breast 
cancer gene expression signatures; the subgroups made according to gene expression and 
clustering. There are five subgroups of breast cancer that largely overlap with the 
immunohistochemical subgroups. The refined subclassifications of breast cancer are luminal A 
and luminal B, Her2-enriched, claudin-low, and basal-like. Luminal breast cancer arises from 
luminal epithelial cells in the breast duct. The basal-like subclassification of breast cancer 
is similar to TNBC and TNBC encompasses most basal-phenotype breast cancers (Eliyatkın et 
al., 2015). Amongst these subclassifications basal-like breast cancer is most prone to metastasis 
and relapse in chemotherapy is frequent (Carey et al., 2010).  
More recently, genomic expression profiling has split TNBC into a further six subclassifications 
which include two basal‐like, immunomodulatory, mesenchymal, mesenchymal stem‐like, and 
luminal androgen receptor subtypes. All of these subtypes have genomic abnormalities that affect 
proteins with functions in cell motility, proliferation, immune cell processes and metabolism 
(Collignon et al., 2016). 
Currently, TNBC accounts for 15% of all breast cancer cases: breast cancer mortality is dropping 
in all subgroups except TNBC (Al-Mahmood et al., 2018). TNBC is notoriously difficult to treat, it 
is clinically very aggressive and has a high propensity for brain/visceral metastasis and 
recurrence. Once a tumour cell has left the primary tumour, TNBC can be very hard to detect. 
Sometimes TNBC can lie dormant for many years and eventually reappear at a distant organ as 
a secondary tumour site (Irvin and Carey, 2008).  
The vast genetic, cellular and extracellular matrix (ECM) changes that allow for tumour cell 
migration and extravasation in TNBC remain poorly understood (Neophytou et al., 2018). There 
is a need to identify the cellular changes that allow TNBC to metastasise. In the following sections 
I will discuss changes in tumour cell phenotype and microenvironment that have roles in 
supporting metastasis. 
 
1.2 Epithelial-to-Mesenchymal Transition in Breast Cancer  
1.2.1 Epithelial-to-Mesenchymal Transition  
Based on the current understanding of cancer metastasis, for a breast cancer cell to metastasise 
it must first undergo an epithelial-mesenchymal transition (EMT), a reversible molecular process 
that allows cell migration.  Normally, breast epithelial cells are held in place by an array of 




of tight and adherens junctions based on occludins, claudins and cadherins, respectively, and an 
intact basement membrane linked to cells via α6β4 integrins (Saunders and McClay, 2014). The 
loss of the epithelial-like phenotype during EMT is accompanied by the loss of cell-surface E-
cadherins. These are calcium ion (Ca2+)-dependent, transmembrane glycoproteins that attach 
adjacent epithelial cells together and also link intracellularly to the actin cytoskeleton through 
protein complexes, commonly containing catenin proteins (Ohashi et al., 2017). Acquisition of a 
mesenchymal phenotype is accompanied by gain of N-cadherin (a different type of cadherin 
family receptor to E-cadherin). Other markers of a mesenchymal phenotype that are increased 
include vimentin (an intermediate filament component of the mesenchymal cell cytoskeleton), 
fibronectin (normally heavily secreted by mesenchymal cells such as fibroblasts) and increased 
expression of matrix metalloproteinases that can degrade the basement membrane. 
Mesenchymal-like cells also adopt a more spindle-shaped morphology with a wide ‘leading’ edge 
and pinched ‘trailing’ edge (Figure 1.2) (Kalluri and Weinberg, 2009). 
EMT is an essential process for breast cancer cells to become invasive. EMT facilitates DCIS to 
progress to invasive IDC and increases the chances of basement membrane breaching. In the 
most recent model of cancer progression, once the basement membrane has been degraded by 
extracellular proteases and cells have undergone an EMT, they become free to move out of the 
epithelial layer and into connective tissue and/or blood vessels, a process known as intravasation. 
Metastatic breast cancer cells in vessels then have the means to be transported to distant tissues 
and around the body. Circulating tumour cells (CTCs) (cells from a primary tumour that have 
escaped into the blood stream) then have the potential to extravasate and colonise another site, 
either in their tumour of origin or in a new organ (Kalluri and Weinberg, 2009). It is not well 
understood why certain organs are more favoured by CTCs as sites of colonisation, but there is 
some suggestion that it may be because of availability of growth factors or favourable 
microenvironment conditions. This hypothesis is known as the ‘soil and seed hypothesis’; the 
current understanding is that some organs are ‘made ready’ for metastatic growth or already have 
a pre-metastatic niche set up (Cox et al., 2012). CTCs leave blood vessels and enter new tissues 
by a process called extravasation. To form a secondary tumour, CTCs must attach and regain an 
epithelial-like phenotype (Ramakrishna and Rostomily, 2013). A mesenchymal-epithelial 
transition (MET) occurs if the new stromal environment is favourable. Successful MET results in 





















1.2.2 Signalling Pathways  
EMT is orchestrated by transcriptional activity. It is thought that over one hundred genes could be 
involved in EMT, including genes for growth factors, cell surface adhesion, proteases and 
cytoskeletal organisation (Goossens et al., 2017). The main transcription factors that drive EMT 
are repressive of genes that promote an epithelial phenotype and inducive of genes that promote 
a mesenchymal phenotype. There are many transcription factors involved in breast cancer EMT, 
the most well studied are SLUG, SNAIL, GATA3, Zeb1 and TWIST.  The differing levels of EMT 
transcription factor expression in breast cancer has been attributed as leading to certain organ 
tropisms, for example, expression of SNAIL correlates with lymph node metastasis (Blanco et al., 
2002).  
EMT is not a cell-autonomous process. The transcription factors required for EMT are themselves 
activated by signalling pathways that can be initiated by extracellular ligands binding to their 
cognate receptors. Therefore, EMT is controlled by a cohort of ligands derived from stromal origin 
in the tumour microenvironment (Dongre and Weinberg, 2019).   
There are several pathways that influence the EMT program. Transforming growth factor beta 
(TGFβ) is known to induce intracellular cell signalling in breast cancer cells that induces cell 
growth, motility and proliferation. TGFβ has also been shown to induce a mesenchymal-like 
phenotype since it increases fibronectin and vimentin abundance in breast cancer cells.  This is 
thought to occur because binding of TGFβ to its receptor tyrosine kinase activates an intracellular 
downstream SMAD signalling cascade. SMAD signalling leads to a phosphorylated SMAD 
complex that migrates into the nucleus and activates the transcription of SLUG and SNAIL. The 
abundance of these transcription factors is then linked with EMT (Xu et al., 2009).  
Binding of extracellular WNT to its receptor, frizzled, also causes the transcription of EMT 
transcription factors.  WNT-induced intracellular signalling leads to stabilisation of β-catenin and 
increased nuclear -catenin, which then modulates transcriptional activity. NOTCH binding to 
Delta-like or jagged receptors also promotes the expression of SNAIL (Xiao et al., 2016). 
Complexity of EMT regulation is increased because there is a degree of crosstalk between these 
intracellular signalling pathways. For example, phosphorylated SMAD proteins of the TGFβ 
signalling pathway can interact with β- catenin and intracellular NOTCH (Luo, 2017). The TGFβ 
pathway can activate other intracellular signalling pathways involved in EMT transcription factor 
control such as Ras/Raf/ Mek/Erk and the Pi3k/Akt/ mTOR/NFKβ pathways (Dongre and 




1.2.3 Breast Cancer Stem Cells and Phenotypic Plasticity  
To form a tumour at a secondary site a disseminated tumour cell must undergo MET (the reverse 
of EMT). This involves another extensive change in cellular phenotype. It is thought that MET 
occurs because EMT is controlled by changes in gene transcription, and so it is a plastic state 
that can be reversed (Jayachandran et al., 2016). Once MET has occurred, extensive cell 
proliferation and clonal expansion can lead to formation of a secondary tumour. The full process 
of metastasis requires vast changes in tumour cellular properties and a large degree of cellular 
plasticity. It has been observed that the two phenotypes needed for successful colonisation of a 
secondary site are very similar to the defining characteristics of a cancer stem cell (CSC). These 
characteristics of a CSC are self-renewal and ability to differentiate.  
This has led to the idea that much of breast cancer metastasis can be attributed to the behaviour 
of stem cells. Indeed, EMT does increase the expression of stemness genes; the expression of 
EMT transcription factors Snail, Twist and TGF will induce stemness in immortalised human 
mammary epithelial cell lines (Luo et al., 2015).  
More recently, it has been debated whether EMT and MET are discrete entities, because cancer 
cells can metastasise without fully losing an epithelial phenotype. Figure 1.2 depicts a partial 
EMT where cancer cells share markers for both epithelial and mesenchymal phenotypes. It has 
been suggested that these cells are the most versatile and have the greatest degree of plasticity 
(Weidenfeld and Barkan, 2018).  
Studies on solid mouse tumours showed that only a subpopulation of breast cancer cells are 
capable of forming a tumour at a secondary site. It was hypothesised that these cells were breast 
cancer stem cells (Liu et al., 2010). Further studies reported that EMT transcription factors 
(SLUG/Zeb1) are expressed in adult stem cells and that aberrant activation of TGF increases 
stemness in TNBC (Xu et al., 2018). These results provide evidence that breast cancer stem-like 
cells exist.  
 
1.3 Tumour Microenvironment  
Increasingly, the intracellular molecular mechanisms that govern cancer metastasis are being 
considered in the context of the tumour microenvironment (TME). The TME is the environment 
within and surrounding a tumour and consists of cellular and non-cellular components. Stromal 
cells found in the tumour microenvironment include cancer-associated fibroblasts, immune cells, 




extracellular matrix (ECM) and cytokines. It is also important to consider  blood vessel growth, 
pH, levels of hypoxia,  hormones and cytokine signalling (Soysal et al., 2015). The tumour 
microenvironment has a role to play in every stage of cancer progression, which can be split into 
local (nearby tumour cells), regional (cells in the stroma) or distant (upon metastasis to other 
organs) (Figure 1.3) (Yuan et al., 2016).  
Each cell type in the TME can influence cell behaviour through secreted proteins. Each type of 
stromal cell has its own unique secretome made up of signalling molecules including: 
chemokines, cytokines, growth factors and ECM proteins. These all contribute to the overall 
tumour microenvironment. In addition, each secretome can change depending on local TME 
conditions. Once in the TME, secreted proteins can bind to cognate receptors on recipient cells 
and influence downstream intracellular signalling pathways, such as NOTCH, WNT and TGF, 
that may change epigenetic or genetic programmes and affect cell behaviour. These signalling 
pathways also control EMT and MET and so the TME impacts on cell plasticity.  
Extracellular signalling molecules can act on the same cell that secreted them or on other cells, 
and leads to changes in cells, known as autocrine or paracrine signalling, respectively. For 
example, an overabundance of TGFβ in the TME due to secretion from malignant cells can act 
on breast cancer cells in general and influence EMT, angiogenesis, metastasis and fibroblast 
activation (Bierie and Moses, 2006). IL-6 in the breast cancer tumour microenvironment increases 
stemness via JAK/STAT3 signalling (Sağlam et al., 2015). 
Autocrine and paracrine signalling is also part of the normal physiology in the mammary gland. 
The TME can be protective against the development of tumours under certain circumstances and 
therefore can act as a tumour suppressor. For example, myoepithelial cells in the breast 
microenvironment lay down basement membrane, which acts as a physical barrier to slow the 
invasion of breast cancer cells and prevent formation of IDC (Barsky and Karlin, 2005).  
However, after the origin of a tumour, the microenvironment can become ‘hijacked’ and change 
into an environment that favours cancer progression. For instance, favourable conditions may be 
generated at distant sites to support adhesion of circulating cancer cells that undergo MET and 
proliferate to form a secondary tumour. In this way, the TME is the soil that nourishes the seed (a 
circulating cancer cell) (Ramakrishna and Rostomily, 2013). The TME may also protect neoplastic 






Figure 1.3 Schematic of the Breast Cancer Tumour Microenvironment. Conditions in the ECM and cell signalling that contribute to 




This can happen by an increase in immune suppressive cytokines or, there is also a suggestion that, 
immune surveillance can contribute to selective survival of dominant malignant cells that hasten the 
development of a solid primary tumour (Dunn et al., 2004; Kalluri and Zeisberg, 2006; Ricciardi et 
al., 2015).  
1.3.1 Metastasis  
Breast cancer tumours have tropisms to metastasise to certain organs. Common sites of metastasis 
include the bone, brain, liver and lungs (Kimbung et al., 2015). Specific organ tropisms occur 
because organs provide a microenvironment that has physical and biochemical properties that prime 
CTCs to create a secondary niche. One of the most important steps in forming a new colony of 
tumour cells is for CTCs to undergo MET. For bone tropism, it is thought that in the hemopoietic 
system CTCs are sustained in their mesenchymal status by autocrine signalling. However, when a 
CTC arrives in the bone and adheres to stromal cells in bone marrow, the adhesion favours MET 
(Xie et al., 2018). Then the cancer cells release parathyroid hormone-related peptide (PTHrP) that 
activates osteoblasts (bone-forming cells) (Soki et al., 2012). This creates a favourable environment 
for proliferation and differentiation of breast cancer cells and so a secondary tumour is able to form 
(Pulido et al., 2017) 
There are also suggestions that organ tropism depends on a specific receptor-ligand interaction. C-
X-C motif chemokine 12 (CXCL12) is a chemokine that is secreted by stromal cells in organs that 
are often targets of breast cancer metastasis. The receptor of CXCL12 is C-X-C chemokine receptor 
type 4 (CXCR-4) that is expressed on breast cancer cells. It has been suggested that paracrine 
signalling through the CXCL-12-CXCR-4 axis dictates organ tropisms by a long distance homing 
mechanism (Roato and Ferracini, 2018).  
1.3.2 Cancer-Associated Fibroblasts  
Cancer-associated fibroblasts (CAF) make up a large population of stromal cells in the TME. CAF 
secrete large amounts of ECM proteins, signalling growth factors and exosomes (McAnulty, 2007). 
CAF are recruited to tumours by cytokine and chemokine signalling from the neoplastic cells. When 
recruited into a tumour, CAF have a large impact on the composition of the TME, to the extent that 
they have been termed, ‘the architects of cancer pathogenesis” (Marsh et al., 2013).  CAF-secreted 
products affect stromal autocrine and paracrine signalling in the TME. In turn, secreted proteins 
affect the immune system, angiogenesis, ECM production and surrounding neoplastic cells (Santi et 
al., 2018). Bidirectional paracrine signalling between cancer cells and CAF can change the 
transcription profile of both cells alike and is likely to enhance tumour progression. Currently, CAF 
are thought to promote breast cancer tumour progression and metastasis (Houthuijzen and Jonkers, 
2018).  
There is debate about the origin of CAF. They may arise from tissue-resident fibroblasts or from 




et al., 2011). To contribute to the proteinaceous TME, fibroblasts must to be activated by paracrine 
signalling from cancer cells, including TGF-1, PDGF and IL-6 signalling (Shao et al., 2000; 
Giannoni et al., 2010). However, activation of fibroblasts can also happen via environmental stimuli 
such as hypoxia and ECM stiffness. These extracellular signals alter gene expression by epigenetic 
mechanisms by binding to extracellular receptors and causing intracellular signalling cascades (Hu 
et al., 2005). Fibroblasts may also become activated by gaining certain single nucleotide 
polymorphisms leading to a change in the expression and secretion of ECM components such as 
collagens, lysyl-oxidase (LOX) and matrix metalloproteinases (MMPs) (Du and Che, 2017; Liu et al., 
2019). 
CAF also secrete copious amounts of growth factors and cytokines that contribute to cancer cell 
proliferation. Fibroblast growth factor 7 (FGF7) and hepatocyte growth factor (HGF) are both 
increased in CAF compared to normal fibroblasts. FGF7 is a mammary growth factor that increases 
cell proliferation and HGF increases tumour growth in vivo (Palmieri et al., 2003; Tyan et al., 2012). 
Breast cancers that are ER-positive rely on oestrogen signalling for growth and there is some 
evidence that CAF may maintain breast cancer tumour growth by rapid oestrogen metabolism. 
Activity of 17 -estradiol dehydrogenase (an enzyme involved in the metabolism of oestrogen) in the 
TME is increased in CAF stroma and would increase the rate of oestrogen metabolism (Adams et 
al., 1988). Metabolites of oestrogen can then enter cells and modulate ligand activated gene 
transcription that can lead to an increase in malignancy, for example, cyclin D1 is increased in 
abundance leading to unregulated breast cancer proliferation (Liang and Shang, 2013). IL-6 
expression is increased in CAF and IL-6 is associated with cancer growth, progression and 
chemotherapy-resistance by fundamental roles in immune response, cell metabolism and 
inflammation (Masjedi et al., 2018). CXCL12 is also increased in the stroma and secreted by CAF 
(Orimo et al., 2005).  
CAF are thought to be involved in many other aspects of cancer metastasis from enhancing the 
plasticity of neoplastic cells, inducing an EMT, changing ECM composition, promoting angiogenesis, 
dictating organ tropisms and secreting pro-inflammatory cytokines (e.g. IL-1β, IL-8, IL-10, TNF)  
that orchestrate a pathological immune response (Kalluri and Zeisberg, 2006; Wang et al., 2019; 
Buchsbaum and Oh, 2016). The large amount of crosstalk and involvement in multiple signalling 
pathways of CAF means that the role of CAF in pathogenesis is complex and the precise 
mechanisms remain unclear (Buchsbaum and Oh, 2016).  
1.3.3 Exosomes  
Exosomes are extracellular vesicles of approximately 30-120nm diameter that originate from an 
endosomal origin. They are released by stromal cells by the multivesicular body fusing to the plasma 




another means of cell-cell communication in the TME, playing a complex and pivotal role in cancer 
progression and metastasis (Vader et al., 2014).  
Exosomes contain cargo that can influence aspects of the TME, including the major 
histocompatibility complex class 1 (MHCI), miRNA, DNA, enzymes and molecular chaperones (Jia 
et al., 2017). The discovery that exosomes contained genetic information means that RNA or DNA 
can be transferred between cells and potentially change cell behaviour. Exosomes have been 
demonstrated to affect behaviour of cells in the TME, for example, upon delivery of exosome-derived 
miR-9 in breast cancer, fibroblasts show more CAF-like behaviour (Baroni et al., 2016). Exosomes 
communicate with cells by cargo release to the ECM or by binding to receptors on recipient cells, 
fusion to the plasma membrane and being endocytosed (Ogorevc et al., 2013).  
The exact composition of exosome components reflects the status of the donor cell, for example, 
hypoxia in the TME enhances the release of exosomes that contain cargo that promotes metastasis 
(Kucharzewska et al., 2013). More specifically to breast cancer, exosomes from two different breast 
cancer cell lines, MCF-7 and MDA-MB-231 (subsequently referred to as A231) were found to contain 
different proportions of exosome cargos. MCF-7 exosomes contained more nucleic acids, whilst 
A231 exosomes contained a higher proportion of MMPs. Also, the miRNA content of MCF-7 and 
A231 exosomes was different. Gene Ontology revealed that in both cell lines the miRNAs were 
associated with metastasis (Kruger et al., 2014). Despite these differences there are some proteins 
that are characteristic of exosomes such as annexins, cytoskeletal proteins (vimentin, talin, actin, 
tubulin), tetraspanins and heat shock proteins. These are now viewed as markers for identifying 
exosomes (Jia et al., 2017).  
There is also evidence that exosomes are critical in forming the pre-metastatic niche (Guo et al., 
2019). In the TME, exosomes can facilitate cancer migration.  Exosomes found in the conditioned 
media of TNBC cells induce cell proliferation, metastasis in vivo, and increase sensitivity to ‘anoikis’ 
(cell death without a home) in naïve recipient cells. Exosomes may stimulate cancer cell migration: 
exosomes are released after breast cancer detachment from the basement membrane and 
concentrate on the surface of the detached cell to mediate cell adhesion to the ECM (O’Brien et al., 
2013).  
Exosomes can also travel outside the TME by transportation in the lymphatics or blood vessels. This 
led to the notion that exosomes can ‘prime’ secondary site of tumour colonisation to form a pre-
metastatic niche. Therefore, exosomes are thought to affect organ tropisms (dos Anjos Pultz et al., 
2017). There is evidence that this is in part due to integrin expression on exosomes. αvβ5 integrin 
on exosomes enhanced exosome accumulation in the liver, whilst α6β4 integrin was associated with 
accumulation in the lung. Once bound to integrins, exosomes can deliver genetic information and 




Thus, exosomes have a large impact in both early and late stage tumour development. As well as 
the roles discussed here, exosomes are also involved in immune suppression, angiogenesis and 
tumour chemoresistance (Guo et al., 2019).  
1.4 Breast Cancer Extracellular Matrix  
1.4.1 The Cancerous Extracellular Matrix   
The ECM is an important regulator of breast cancer and part of the non-cellular aspect of the TME. 
The ECM is formed in part, from the combined secretomes of stromal cells (predominantly non-
neoplastic cells, immune cells and CAF) (Bhowmick et al., 2004). The local composition of the ECM 
creates a niche environment for growth of a tumour and impacts on all stages of cancer development. 
Connective ECM acts as an extracellular network scaffold for stromal cells and directs many 
biochemical and biomechanical signals. Basement membrane ECM provides support below 
epithelial cells and acts as a barrier to malignant cell migration.  The proteinaceous composition of 
breast ECM is very diverse and changes during cell proliferation or differentiation. A cancerous ECM 
is physiologically very different from a normal ECM. The characteristics of breast cancer ECM closely 
resemble breast ECM during mammary gland involution post-pregnancy or an ECM involved in 
wound healing (Bissell and Hines, 2011; Muschler and Streuli, 2010). The similarities to wound 
healing are because there is excessive ECM deposition, proliferation and recruitment of fibroblasts, 
and increased expression of ECM remodelling enzymes, albeit without the regulatory mechanisms 
that maintain long-term ECM homeostasis in the normal breast. The results of these changes tend 
to support breast cancer metastasis (Bissell and Hines, 2011).  
Normally, physical attachment of epithelial cells to the ECM and to each other prevents cell 
migration. Loss or change of cell-cell, cell-basement membrane or cell-ECM adhesions are features 
that enable an EMT and subsequent mesenchymal-type cell migration. The normal adhesions also 
sustain distinct apical-basal polarity, a fundamental aspect of the epithelial phenotype. Tight and 
adherens junctions form cell-cell attachments at the apex of in the epithelial layer, hemidesmosomes 
link the base of cells to the basement membrane (BM) and other integrins link  cells to ECM via focal 
adhesions (Lee and Streuli, 2014). Integrin expression can change according to malignancy status 
and cell positioning in the ECM. Through these adhesions, biomechanical cues from the ECM are 
transmitted to the cells and throughout the epithelial cell layer. ECM binding to integrins initiates 
downstream signalling pathways and affects the transcription of ECM-dependent genes (Figure 
1.4). These functions can bolster cancer progression (Desgrosellier and Cheresh, 2010).  
If normal epithelial cells are detached from their ECM they undergo anoikis, a form of programmed 
cell death (Paoli et al., 2013). With alterations in integrin expression, breast cancer cells can subvert 
these normal controls and survive in non-native ECM environments. Thus, resistance to apoptosis 





Figure 1.4. The extracellular matrix can affect transcription in target cells. Depiction of how a 
cancerous ECM can modulate biological functions in cancer progression. Modified from ‘The 












compared to normal ECM. Components of the ECM that contribute to this include fibrillar collagens 
(I, III, V), fibronectin and adhesive extracellular glycoproteins such as thrombospondin-1 (Egeblad 
et al., 2010). ECM stiffness also is partly due to the abundance of collagen cross-linking enzymes of 
the lysyl-oxidsase (LOX) family; cross-linking results in highly aligned collagen fibres (Rodriguez-
Pascual 2016). It is thought the aligned collagen fibres act like ‘train tracks’ to facilitate and direct 
cancer cell migration (Figure 1.4). Increased ECM stiffness aids cancer progression by enhancing 
the ability of cancer cells to extend actin rich protrusions whilst migrating (Berger et al., 2019). A 
stiffer ECM also promotes the development of blood vessels and thus supply of nutrients to a tumour, 
and increases the risk of extravasion (Broders-Bondon et al., 2018). 
The ECM of tumours also contains increased levels of active MMPs (Radisky and Radisky, 2015). 
This can lead to remodelling of ECM in abnormal places, affecting stromal biochemical and 
biomechanical signalling pathways, cell proliferation and making accessible pathways for tumour cell 
migration (Benson et al., 2013).  
1.4.1 Roles of ECM Glycoproteins in EMT and Cancer Progression 
1.4.1.1 Collagen  
Collagen is the most abundant protein in the ECM. There are 28 different types of collagens in 
humans with different roles in the ECM. Fibrillar collagens (I, III, V), form the largest structural fibrils 
of connective ECM and act as scaffolds for stromal cells. Non-fibrous collagen IV is a central part of 
the BM that is assembled as a flat network (Lochter and Bissell, 1995).  
The abnormal breast cancer ECM included increased adjacently aligned, collagen fibres (Insua-
Rodríguez and Oskarsson, 2016). The high degree of collagen alignment increases ECM stiffness, 
which impacts on malignant cells as discussed in 1.4.1. In the clinic, ECM stiffness correlates with 
poor breast cancer prognosis  and  resistance to breast cancer therapy (Hayashi et al., 2012). 
Increased mechanical tension in the ECM induces changes in cancer cell behaviour by activating 
intracellular signalling pathways through integrins. For example, activation of phosphoinositide 3-
kinase and mitogen-activated protein kinase (MAPK) signalling pathways regulates mammary cells 
invasive behaviour or proliferation (Levental et al., 2009; Klein et al., 2009). Stiffness of the ECM 
also has a role in cell plasticity. Mammary epithelial cell differentiation is induced by ECM tension by 
affecting Rho-associated protein kinase levels and by changing cellular transcriptional activity, in 
particular promoting transcriptional coactivator with PDZ-binding motif (TAZ) to form an active 
transcriptional complex with yes-associated protein (YAP) which induces stem-cell like properties 
(Dupont et al., 2011; Wozniak et al., 2003).  
1.4.1.2 Fibronectin 
Fibronectin is an ECM glycoprotein. Fibronectin is largely secreted by fibroblasts, but other stromal 




membrane. As the concentration of fibronectin dimers increase, they are assembled by tissue-
transglutaminase 2 to form a mesh-like network surrounding cells (Singh et al., 2010). 
Fibronectin binding has regulatory effects on cell behaviour: it relays biomechanical cues from the 
ECM through binding integrins and syndecan-4, which affect downstream intracellular signalling 
pathways (Bass et al., 2007). For example, fibronectin modulates the intracellular signal transducer 
and activator of transcription 3 (STAT3) signalling pathway that promotes EMT and induce 
invasiveness in breast cancer (Balanis et al., 2013).  
Fibronectin in the ECM also influences cancer progression through effects on the biochemical 
signalling of other proteins. For example, insulin growth factor binding protein 3 (IGFBP3) in the 
presence of fibronectin increases breast cancer proliferation (McIntosh et al., 2010). Fibronectin 
abundance has been associated with  mesenchymal phenotype and promotes EMT through TGF 
signalling(Park and Schwarzbauer, 2014). Fibronectin contributes to a pre-metastatic niche in 
secondary organs by increasing the recruitment of cancer stem cells (Kaplan et al., 2005). It is also 
a cargo of exosomes (Sung and Weaver, 2017). Therefore, fibronectin abundance has been 
associated with a poor prognosis in breast cancer (Bae et al., 2013).  
1.4.1.3 Lysyl oxidase and Lysyl-oxidase-like Family 
Lysyl oxidase (LOX) is a member of a family of extracellular, copper-dependent enzymes, that 
function in collagen fibril assembly. LOX oxidises peptidyl lysine on fibrillar collagen to mediate 
molecular crosslinking. LOX has an essential role in vascular homeostasis (Cox et al., 2016).  
There are five members of the LOX family, LOX and lysyl-oxide-like 1-4 (LOXL1-4). All members 
share a highly conserved C-terminal domain that contains the catalytic domain, a Cu2+ binding site, 
a cytokine-like receptor domain and cofactor residues, lysyl tyrosyl quinine (LTQ). They differ in the 
N-terminal region. LOXL1 has a proline rich domain and LOXL2-4 have four scavenger receptor 
domains. The N-terminus is thought to be involved in protein-protein interactions. LOX is synthesised 
as a zymogen and cleaved outside cells by bone morphogenetic protein 1 to produce mature LOX 
and pro-protein LOX fragment (Wang et al., 2016).  
LOX production is induced by the transcription factor hypoxia-inducible factor 1 (HIF-1) under 
hypoxic conditions. A hypoxic core is a feature of all tumours and therefore it is likely that LOX is in 
high abundance in the tumour core (Pez et al., 2011). Furthermore, FoxM1b, a transcription factor 
globally upregulated in cancer that is correlated with metastasis, also induces LOX and LOXL2 
expression (Park et al., 2011). The abundance of LOX is increased in invasive basal breast cancer 
but not in non-invasive breast cancer, suggesting that LOX may contribute to EMT (Chu et al., 2012).  
Mature LOX that has been cleaved in the ECM can become intracellular. LOX can be shuttled into 
the nucleus of cells and affects cancer progression by directly modulating transcriptional activity. 




chromatin structure regulation. Intracellular LOX also effects transcriptional activity by interaction 
with other intracellular proteins that themselves have roles in the transcription regulation (Iturbide et 
al., 2015). 
LOX has been shown to affect cancer progression through transcriptional modulators, or platelet 
derived growth factor receptor -β, as well as basic fibroblast growth factor (Xiao and Ge, 2012). 
LOXL2 is thought to increase cancer aggression by cooperating with the transcription factor SNAIL 
to downregulate an epithelial phenotype (Cuevas et al., 2017).  
 
1.5 Breast Cancer Cells in vitro  
1.5.1 MDA-MB-231 cells 
Currently there are 27 TNBC cell lines (Chavez, Garimella, Lipkowitz 2010). One of the most 
well characterised TNBC cell lines was derived nearly 50 years ago from a 51-year old woman. This 
woman had IDC that had metastasized to the lungs and the pericardial effusion after having a radical 
double mastectomy four years previously.  The malignant cells established the MDA-MB-231 (A231) 
cell line (R.Cailleau 1974).  A231 cells have a basal, TNBC phenotype, are highly metastatic and 
poorly differentiated and have migratory activity in vitro (Bigagli et al., 2019). This cell line is important 
for understanding breast cancer metastasis in vitro (Chavez et al., 2010). 
1.5.2 2-Dimensional Cell Culture 
A231 cells in 2-dimensional (2D) cell culture have a distinctive ‘kite-shaped’ appearance with F-actin-
rich leading edges that provide tensile force to push the cell forward (Ohashi et al., 2017). Actin-rich 
protrusions such as lamellipodia at the leading edge or invadopodia under the cell body aid 
migration. Lamellipodia form cell-matrix adhesions (focal adhesions (FA)) via integrins, which exert 
new sites of traction for migration, whereas mature invadopodia secrete MMPs (2, 9 and 14) that 
digest ECM and help create a loose ECM for migration (Izdebska et al., 2018; Harris et al., 2018). 
At the rear ‘trailing edge’ of the cell, the F-actin cytoskeleton is contracted to allow forward movement 
(Kalluri and Weinberg, 2009).  
The migratory ability of A231 cells can be characterised by assessment of cell phenotype by 
fluorescence microscopy. In fixed cells, fluorescently labelled antibodies for cytoskeletal proteins 
such as actin and tubulin can give an overall impression of cell shape or disruptions of the 
cytoskeleton. Fluorescent-phalloidin provides a one-step reagent to visualise filamentous actin (F-
actin) structures (Chazotte, 2010).  Larger cell area and dense meshwork of F-actin at leading edges 
are associated with greater migratory capacity (Lyons et al., 2016; Rottner et al., 2017). Indirect 
immunofluorescence can also show the number and location of FA, by staining for proteins such as 
vinculin. FA are the intracellular protein complexes associated with integrin cytoplasmic domains 
and include adhesion molecules that enable mechanotransduction from the ECM to F-actin. FA are 




characteristic of the distinctive mesenchymal phenotype (Khalili and Ahmad, 2015). Another method 
to analyse cell migratory ability is to grow cells to confluence and introduce a ‘scratch’ wound. Time-
lapse imaging can be used to analyse the ability of cells to migrate and resolve the wound (Cory, 
2011).  
1.5.3 3-Dimensional Cell Culture  
Molecular therapies for breast cancer often fail pre-clinical drug trails. One reason this may be is 
that, traditionally, the understanding of cancer cell mechanisms has been based on 2D cell culture 
models. These  are increasingly being shown to be a far cry from in vivo tumours (Friedrich et al., 
2009). Culturing cancer cells as 3-dimensional (3D) structures (spheroids) better recapitulates cell 
organisation in a tumour and is more physiologically relevant. Cells in 3D form cell-cell and cell-
matrix adhesions and organise as a ball-like structures (Rodday et al., 2011). These 3D structures 
also provide a gradient for pH, hypoxia and cell waste products. The collective term for the adhered 
cells in 3D is a spheroid. Large spheroids (>500m) are more representative of a tumour with the 
presence of a necrotic core. Spheroids can also form as co-cultures with different cell types, for 
example breast cancer cells and fibroblasts (Kim et al., 2015). These features make spheroids better 
models to understand the molecular mechanisms of EMT or tumour progression (Nath and Devi, 
2016).  
 
Spheroids can be cultured with or without a synthetic scaffold. Scaffolds in 3D culture are used to 
create a synthetic ECM that recapitulates an in vivo TME, as cell-matrix adhesions can have a large 
impact on cell adhesion, proliferation and migration (Gkretsi 2018). Examples of scaffold methods 
include Matrix Encapsulation, Spinner Flasks and Micropatterned Plates (Tan et al., 2001; Justice et 
al., 2009; Lee et al., 2007). A synthetic matrix can help hydration, passage of oxygen and nutrient 
flow. The limitations of scaffolds are that they introduce a large amount of manufacturing variability: 
scaffold batch variability could have a large unknown impact on cancer cell phenotypes and limit 
reproducibility. Scaffold-free culture relies on cancer cells self-aggregating to form spheroids.  
Methods to achieve this include Ultra-low attachment plates, Hanging Drop and Magnetic Levitation 
(Nath and Devi, 2016).  
 
Spheroids can be characterised by microscopy, biochemical assays or flow cytometry.  3D image 
analysis can be done using a confocal microscope. The 3D nature of the spheroids requires 
consideration of the X, Y and Z axis. For smaller spheroids, immunofluorescence can be used to 
visualise cytoskeletal and extracellular proteins. Larger spheroids  (>150μm) are more difficult to 
visually analyse by confocal microscopy. Large spheroids are more fragile, and the usual 
immunofluorescent methodology can damage the spheroid. A large diameter also makes antibody 
penetration more challenging (Weiswald et al., 2010). However, different microscopy techniques 




al., 2017). Small spheroids tend to form within 48 hours whilst larger spheroids and spheroid culture 
with scaffolds can take 4-5 days to form spheroids. In some cases, spheroids can be kept growing 
long-term for weeks through media changes, which gives the ability for spheroid analysis over time 
(Cohen et al., 2015).  Breast cancer spheroids are enriched with cancer stem cells which suggests 
that spheroids have the propensity to change over time (Ishiguro et al., 2017).  
1.5.4 Conditioned Media  
In vivo, extracellular fluids contain the combined secretomes of stromal cells (e.g. neoplastic cells, 
CAF and immune cells) and regulates autocrine and paracrine signalling and ECM remodelling (Dai 
et al., 2016). In vitro, the secreted products of a cell type or co-culture enter the conditioned media 
(CM), which will then contain proteins such as cytokines, growth factors, ECM components and 
enzymes (e.g. MMPs), lipids, and extracellular vesicles such as exosomes. Precise measurements 
of the CM proteome can be carried out using proteomics, helping to gain a greater understanding of 
the mechanisms that sustain malignancy. This is particularly effective for identifying pathological 
protein markers that could be targeted for disease treatment or as biomarkers of cancer progression 
or relapse (Brandi et al., 2018).  
Although less physiologically relevant than body fluids, CM is advantageous for studying cancer cell 
secreted products since it simpler in composition, meaning that low abundance secreted proteins, 
that may pass unrecognised in proteomics analysis from biological fluids, can be identified (Méndez 
and Villanueva, 2015).  
 
1.6 Protein Disulphide-Isomerase A3  
Protein disulphide-isomerase A3 (PDIA3) is an ER-resident protein of relative molecular mass 
~57kDa. It is also known as Erp57, Grp58, 125D3MARR and Grp60. PDIA3 is a multi-functional 
isomerase and oxidoreductase that catalyses a series of redox reactions that ultimately break or 
make disulphide bonds in target proteins. Disulphide bonds are often important for proteins’ final 
tertiary structure. PDIA3 is in part responsible to ensure that newly synthesised glycoproteins, 
destined for secretion, reach their native folded state. PDIA3’s role in protein folding and quality 
control is well documented (Turano et al., 2011).  
The enzymatic chaperone activity of PDIA3 is mediated in conjunction with homologous lectin 
chaperones calreticulin and calnexin as part of the ER machinery for new protein folding and the 
unfolded protein response (UPR). As an important regulator of ER homeostasis, PDIA3 is 
upregulated during the UPR and helps to disassemble protein aggregates (Ellgaard and Frickel, 
2003). PDIA3 is important in the assembly of MHCI (Raghavan et al., 2008). Its oxidoreductase 
activity folds MHCI, in addition to PDIA3 being a component of the MHCI complex itself along with 
calreticulin, ER antigen peptide transporter 1 (TAP), and tapasin (Stepensky et al., 2007).  PDIA3 




reports that PDIA3 may also locate elsewhere, including the cytoplasm, plasma membrane and in 
the ECM (Raykhel et al., 2007). It is not clear how PDIA3 reaches these locations from within the 
secretory pathway, although TGF1 was reported to increase PDIA3 extracellularly in renal fibrosis 
(Dihazi et al., 2013). Due to the fundamental nature of PDIA3 its dysregulation has been attributed 
in  many disease aetiologies (Hatahet and Ruddock, 2009). 
1.6.1 Structure and Mechanism  
PDIA3 is made up of four thioredoxin domain: each thioredoxin domain is characterised by a 
βαβαβαββα fold. Two of the thioredoxin domains are catalytically active and possess a catalytic 
cysteine residue within a CXXC motif (Figure 1.5). The catalytic domains, or the a/a’ domains, flank 
the two redox inactive b/b’ domains. The a/a’ domains are more similar to each other than to the b/b’ 
domains (Kozlov et al.). Nuclear magnetic resonance has shown that these domains form a “U-like” 
structure, with the b/b’ domains at the base and the a/a’ domains at the ‘ears’ parallel to one another 
(Pollock et al., 2004). The b’/a’ domains are joined by a 19 amino acid linker sequence and are a 
component of prolyl-4 hydroxylase (important for a post-translation modification that stabilises the 
collagen triple helix) (Pirneskoski et al., 2001).  
The main site for substrate binding is the b’ domain. PDIA3’s substrate binding pocket is very 
shallow. Coupled with high hydrophobicity in this pocket, substrate selection is promiscuous. During 
catalysis the two independent catalytic domains a/a’ rotate out of the starting plane, whereas the b/b’ 
domains remain stationary throughout the reaction. This movement positions a catalytic cysteine of 
the CXXC motif in the a/a’ domains to attack a thiol bond in the substrate. After the reaction PDIA3 
becomes reduced and must be re-oxidised to be ready to perform another round of reduction.  
PDIA3 then undergoes a series of redox reactions facilitated by oxidising agents, peroxiredoxin, 
glutathione peroxidase 7 or 8 and ER-oxidoreductin 1 (Ero1). The reaction terminates with the 
reduction of molecular oxygen to hydrogen peroxide. The catalytic cysteine must be maintained at 
low pH (4.4 - 6.7) to keep the reduction potential high and the kinetics efficient to be favourable for 
thiol-disulphide exchange (Hawkins and Freedman, 1991). Alone, PDIA3 has a much slower rate of 
isomerase and oxidoreductase activity than other members of the PDI family (Hatahet and Ruddock, 
2009).  
PDIA3 is unique amongst the PDI family in that it uses cofactors, calnexin and calreticulin, to 
enhance substrate binding (Oliver et al., 1999). PDIA3 binds calnexin and calreticulin on its acidic 
C-terminal. The b’ domain on a proline-rich arm and one lysine residue of the b domain contribute to 
this interaction (Frickel et al., 2002) (Figure 1.5). Both of these proteins are important in the quality 
control cycle that involves PDIA3 in the UPR (Hatahet & Ruddock, 2009).   
1.6.2 Known Targets of PDIA3  
It is well established that PDIA3 interacts with calnexin and calreticulin to form a complex that helps 




naïve disulphide bonds. This reaction only occurs on mono-glycosylated protein substrates (Oliver 
et al., 1999).  
Experimental identification of proteins that are targeted by PDIA3 has been done by mass 
spectroscopy and use of substrate trapping mutants of PDIA3. 25 proteins have been found to be 
targets of PDIA3. Of these proteins many contain small, disulphide rich domains (such as EGF 
domain, IgG domain and Kunitz domain) and many have a low level of secondary structure. All 
proteins identified to date are glycoproteins and have an array of cellular locations. However, 
secreted proteins or cell-surface proteins appear to be particularly targeted as substrates. Examples 
include agrin, clusterin, integrin α3 and laminin β3 (Jessop et al. 2007).  
Some of the 25 proteins identified as PDIA3 substrates are known components of breast cancer 
ECM. For example, over-expression of LOXL2 and collagen (VI) chain promote breast cancer 
metastasis (Salvador et al., 2017; Karousou et al., 2014). Agrin is upregulated in some breast cancer 
cell lines and has roles in stimulating focal adhesions (Chakraborty et al., 2015). Laminins are the 
major component of the basement membrane and fundamental for the epithelial phenotype (Holler, 
2005).  
Identification of these proteins showed that although PDIA3 is resident in the ER, it has a role in the 
secretory pathway of many glycoproteins. Therefore, through proteins that it targets PDIA3 has a 















Figure 1.5 The Structure of PDIA3. (A) Structural Schematic of PDIA3 Showing Four Domains. (B) 





1.6.3 PDIA3 and Breast Cancer  
In general, PDIA3 expression is correlated with more aggressive breast cancer. Proteomic analysis 
taking samples from Korean women has revealed that PDIA3 is upregulated in human DCIS and 
IDC tissue compared to normal tissue. This study also found a comparative increase in calreticulin 
in breast cancer tissue (Song et al., 2012). At the transcript level, PDIA3 is upregulated in aggressive 
primary ductal breast cancer and also has increased abundance in metastatic lymph-node tumours 
(Ramos et al., 2015). Because PDIA3 is multifunctional, it is hypothesised to affect breast cancer 
progression in many ways, as discussed in the following sections.  
1.6.3.1 Cell Proliferation  
PDIA3 has been implicated in cancer cell proliferation. In general, this is because PDIA3 is involved 
in the assembly process of the serine threonine kinase, mammalian target of rapamycin 1 (mTOR1), 
a key mediator in cell growth, proliferation, autophagy and protein synthesis. The analysis of mTOR1 
and PDIA3 interaction was done by a yeast two-hybrid screen. Confirmation was performed by 
expression of recombinant proteins for mTOR1 and PDIA3 in HEK293T cells, cell lysates were then 
purified on an affinity column and proteins identified by immunoblot. It has been suggested that 
overexpression of PDIA3 helps to stabilize the mTOR complex and promote tumour progression 
(Hussmann et al., 2015). 
However, the specific role of PDIA3 in breast cancer proliferation is unclear. This is largely because 
of the multi-functional role of PDIA3 in cellular mechanisms. Many breast cancers overexpress 
epidermal growth factor receptor (EGFR) and as a result have sustained proliferative signals. PDIA3 
inhibits the degradation of EGFR by decreasing its cycling from the plasma membrane and inhibits 
dephosphorylation of EGFR. This results in copious active EGFR at the cell-surface and unchecked 
breast cancer cell proliferation (Gaucci et al., 2013). Conversely, PDIA3 expression in the MCF-7 
breast cancer cell line was shown to modulate vitamin D signalling. This was achieved with a 
ribozyme construct for PDIA3 mRNA knockdown and levels of 1,25 dihydroxyvitamin D3 expression 
were measured by real time PCR and western blotting. Vitamin D signalling is often anti-tumorigenic 
and protective against cancer progression (Richard et al., 2010).  
1.6.3.2 Chemoresistance  
Increased activity of PDIA3 may help cancerous cells survive adverse tissue conditions and promote 
chemoresistance. One aspect of this is that an increased abundance of PDIA3 correlated with 
reduction of MHCI receptors, which may help cancer cells to escape immune surveillance (Antoniou 
et al., 2002). In addition, PDIA3 may assist cancer survival under conditions of cell stress, reducing 
the impact of hypoxia, high pH or depletion of nutrients by inducing UPR. Overexpression of PDIA3 




1.6.3.3 Bone Metastasis of Breast Cancer 
Transcriptomic and proteomic profiling of breast cancer cells (MDA-MB-231 and its osteotropic BO2 
subclone (BO2)) was used to identify the functional characteristics that promote breast cancer 
metastasis to the bones. This study revealed that PDIA3 functions as a ‘hub’ that mediates a range 
of cancer-associated cellular phenotypes. The study suggested that PDIA3 regulates human MHCI 
expression in BO2 and A231 cells, and in BO2 cells PDIA3 has an inverse relationship with MHCI 
expression at the plasma membrane. The study also suggested that there is an inverse relationship 
between vimentin (an intermediate filament mainly found in mesenchymal cells) and PDIA3 
abundance, suggesting that PDIA3 may have substrates with roles in breast cancer cell MET. 
Subcellular location analysis and abundance of proteins of interest (MHCI, PDIA3 or cytoskeletal 
proteins) was done by immunofluorescence and RT-PCR, knock-down of proteins was done with 
small interfering RNA. There is also a suggestion that PDIA3 interacts with cytoskeletal proteins like 
galnetin-1, cytokeratin-19 and stathmin-1 from online curated databases that include databases on 
disease-gene associations (Guney and Oliva, 2012). Finally, PDIA3 knockdown by short hairpin RNA 
reduced bone-specific metastasis in the BO2 breast cancer subclone variant in mice, as measured 
by mouse whole body analysis of tumour formation with non-invasive bioluminescence imaging 
(Santana-Codina et al., 2013). Taken together, these results support that PDIA3 contributes 
functionally by unknown mechanisms in breast cancer metastasis.  
1.6.4 Chemical Inhibition of PDIA3  
One commercially available small molecule inhibitor of PDIA3 is 16F16. Like all PDI-targeted 
inhibitors, 16F16 functions to inhibit PDIA3’s catalytic cysteine. The chloroacetyl moiety of 16F16 
covalently and irreversibly binds to the catalytic cysteine of the CXXC motif in the active thioredoxin 
domain of PDIA3 (Figure 1.6) (Hatahet and Ruddock, 2009). However, because of the high degree 
of conservation of the thioredoxin domains of the PDI family, specific inhibition of PDI family 
members is hard to achieve (Hoffstrom et al., 2010). The efficacy of intracellular 16F16 has been 
debated;16F16 was originally described as a PDIA1 inhibitor, yet recent studies comparing 16F16 
to PACMA31 (a known PDIA1 inhibitor with no off-target binding) on breast cancer cell spreading, 
attachment and migration assays proved to elicit very different outcomes (Xu et al., 2012; Young, 
unpublished, 2018; Chen et al., 2018). These data suggest that 16F16 is probably an inhibitor of 
PDIA3. With lack of truly specific, commercially available pharmacological inhibitors and the recent 
evidence in Adams laboratory for the action of 16F16 on breast cancer cells, 16F16 was chosen as 









Figure 1.6 Structure of 16F16. Skelton diagram retrieved from the Sigma-Aldrich website: catalogue 





1.7 The PDIA3-Dependent Secretome of Mouse Embryonic Fibroblasts  
As discussed, PDIA3 is up-regulated in metastatic forms of breast cancer (Santana-Codina et al., 
2013). Because PDIA3 could have effects on the TME by directing the folding of secreted 
glycoproteins (Jessop et al., 2007, Halperin 2014), Professor Adams’ laboratory has begun to 
investigate a potential role of the PDIA3-dependent secretome in the TME.  Research carried out by 
Dr. Hellewell (under Medical Research Council- K018043) showed that Pdia3-/- mouse embryonic 
fibroblasts (MEF) had a reduced migratory phenotype compared to wild type (WT) MEF, as assessed 
by cell area, F-actin organisation and number of FA. It was also found that a normal migratory 
phenotype could be restored in Pdia3-/- MEFs by plating with CM from WT-MEF. Tandem mass tag 
(TMT)-based quantitative proteomics on the CM from Pdia3-/- and WT-MEF revealed a set of proteins 
that were decreased in the Pdia3-/- secretome. These proteins included cytokines, growth factors 
and ECM proteins (unpublished data).  A subsequent M.Res project carried out by Harry Young 
examined the effects of PDIA3 inhibition by 16F16 on several breast cancer cell lines. Cell spreading 
and migration was decreased upon PDIA3 inhibition and this effect depended on the conditioned 
medium.  The stronger phenotypic changes were obtained with A231 cells. The data indicated that 
PDIA3 activity affects cell morphology of these breast cancer cell lines through secreted products 




1.8 Aims of this M.Res Project  
The central objective of this project is the identification of the PDIA3-dependent secretome in A231 
breast cancer cells.  
Specific goals are:  
1. To characterise the effect of secreted PDIA3-dependent proteins on F-actin, cell spreading 
and focal adhesions in naïve A231 cells and to identify if these effects depend on heparin-
binding secreted proteins.  
 
2. To identify the PDIA3-dependent, heparin-binding proteins in A231 breast cancer cells by 
quantitative TMT-based proteomics and to analyse the dataset and validate selected 
proteins. 
 
3. To examine the effect of pharmacological inhibition of PDIA3 on spheroid formation by A231 














2.1 Cell Culture  
2.1.1 MDA-MB-231 Cells  
The entirety of this project has used MDA-MB-231 cells (described originally by Caileau et al.1973) 
that were purchased from American Type Culture Collection.  
2.1.2 Cell Culture Media  
DMEM containing 44.5µM of phenol red was used throughout the project to sustain and grow cells 
and was supplemented with 10% foetal bovine serum (FBS). Some experiments used Fibroblast 
Growth Medium (FGM) (Table 2.1) which is a complete medium that contains 3.3M of phenol red.  
2.1.3 Recovery and Expansion of Cells  
Cells were removed from long term storage in liquid nitrogen (-196oC), then rapidly warmed in their 
cryovial in a 37oC water bath, to avoid dimethyl sulfoxide (DMSO)-induced toxicity. Cells were then 
diluted 1:10 in Dulbecco’s Modified Eagle Medium high glucose (DMEM) (Table 2.1), which had 
been warmed to 37oC and supplemented with 10% foetal bovine serum (FBS) (Table 2.1). Cells 
were then centrifuged at 1000rpm for 5 minutes, resuspended in DMEM with 10% FBS, and placed 
in a T25 flask for culture (Table 2.4). at 37oC in a sterile, humidified, copper-lined incubator gassed 
with 5% CO2. Medium was changed every Monday, Wednesday and Friday: depending on 
confluence (≥80%) and experimental requirements, cells were either passaged or used in 
experiments.   
2.1.4 Passaging of Cells  
As required, cells were rinsed briefly with 0.05% trypsin/EDTA (1x) (Table 2.1) to remove dead cells 
and cell debris. Cells were then incubated at 37oC with a small volume of 0.05% trypsin/EDTA for 
2/3 minutes to detach adherent cells from plastic. Trypsin was collected and then inactivated by 
resuspending the cells in DMEM containing 10% FBS to be re-plated according to requirements or 












2.2 Chemicals and Inhibitors 
Table 2.1 and Table 2.2 list all the chemicals and inhibitors used in this project.  
Table 2.1. Chemicals used in project 
Name   Supplier   Catalogue Number   
Acrylamide (40%)   Bio-Rad  1610140  
Ammonium Persulfate powder (APS)  BDH (now VWR life science)  BDH9214-500G  
Bromophenol Blue Sigma B0126 
Bis-acrylamide(2%)  Solution  Bio-Rad  161-0142  
Dimethyl sulphoxide (DMSO)  GPR™  282164K  
DL-dithiothreitol (DTT)  Sigma   D9779  
Dulbecco’s Modified Eagle’s Medium  Sigma- Aldrich  D6429  
Enhanced Chemiluminescence (ECL) ™ WB 
detection agent   
Amersham   RPN2209  
Ethanol (100%)  Sigma-Aldrich  32221  
Ethylenediaminetetracetic acid (EDTA)  Sigma   ED2SS  
Foetal Bovine Serum  Sigma-Aldrich  F7524  
Fibroblast Growth Medium   Promocell   C-23010  
Glycerol   Sigma   G5516  
Glycine  Sigma  G8898 
Heparin−Agarose in aqueous ethanol 
suspension 
Sigma-Aldrich   H0402  
Hydrocholoric acid   Sigma   H1758  
L-Ascorbic Acid   Sigma  A4544  
Methanol  Sigma   322415  
Milk Powder  Sainsbury’s  7742528 
N,N,N′,N′-
Tetramethylethylenediamine (TEMED)   
Sigma   T9281  
Paraformaldehyde (PFA) 16% (w/v)  Alfa Aesar  43368  
Phalloidin–Atto 565 Sigma   94072 
Pierce™ Control Agarose Resin Thermo Scientific   26150  
Ponceau S Stain  Sigma   P71701  
Precision Plus Protein ™ 
Dual Colour Standards   
BIO-RAD  #1610374  
Sodium Dodecyl Sulphate (SDS)   Fischer Scientific   28906  
Triton X-100 Sigma  T6066  




Trypsin-EDTA  Sigma- Aldrich  T3924  
Tween-20 Sigma   P2287   
VectaMount   Vector   H5000  
VectaShield with 4’,6-diamidino-2-phenylindole 
(DAPI)  
Vector  H1200  
 
Table 2.2. Inhibitors used in project 
Inhibitor   Mechanism of action  Supplier   Catalogue 
Number   
CAS  
16F16  Irreversible inhibitor of 
PDIA3 and PDIA1  
Sigma  SML-0021  922507-80-0  
 3-
Aminopropionitrile 
fumarate salt (- 
APN)  
Irreversible inhibitor of 
LOX and LOXL2  
Sigma  A3134 2079-89-2  
Pierce™ Protease 
inhibitor tablets-
mini   
Broad spectrum 
inhibitors of cellular 
proteases  




















Buffers were prepared in the laboratory using the solutions detailed in Table 2.3. 
Table 2.3. Solutions used in project. Key: WB= Western Blot 
Buffer  Abbr.   Working Composition   Experiment   




80g NaCl, 25g KCl, 30g Tris base, 5M HCl 
made up with 800ml dH2O  
 General Use 
1X Tris buffered 
saline  
1X TBS  900mL dH2O; 100mL 10x TBS  Proteomics; 
Staining, fixing  








PBS containing 2% (w/v) semi-skimmed 
dried milk and 0.2% (v/v) Tween 20  
WB   
Phosphate buffered 
Saline   




WB; proteomics   
Phosphate buffered 




PBS containing 0.2% (v/v) Tween 20  WB  
Resolving Gel 10% 
acrylamide Final   
  5ml of 40% Acrylamide, 1.5ml of 2% Bis 
solution, 7.4ml of 1M Tris base pH 8.7, 6.55 
ml of H2O, 190µl of APS (w/v in dH2O), 90µl 
20% SDS, 72µl of TEMED  
WB  
10X SDS-PAGE 
Running Buffer  
  151g Trizma base; 720g glycine; 5ml 20% 
SDS, made up to 1l in dH2O 
WB   
SDS-PAGE Sample 
Buffer   
SDS-
SB  
100mM Tris pH 6.8, 4% SDS, 0.2% 
bromophenol blue, 20% glycerol  
WB   
Stacking Gel 4% 
acrylamide Final   
  1.28 ml of 40% Acrylamide, 0.65 ml of 2% 
Bis solution, 1.25 ml of 1M Tris base pH 6.8, 
6.77ml of dH2O, 150µl of 10% APS, 20 µl of 
TEMED  
WB  
Transfer Buffer  TB  100ml 10X SDS-PAGE Running Buffer; 
200ml Methanol, made up to 1l in dH2O  











2.4 Plasticware  
Table 2.4. The plasticware used in this project. Key: PVDF= Polyvinylidene Difluoride, TC= Tissue 
Culture 
Supplier   Type   Abbreviation   Catalogue 
Number   
 Falcon ® 50mL polypropylene conical tube   - 352070  
 Falcon ®   Tissue Culture Treated Flasks 
250ml  
T75   35316 
Greiner Bio-one Cell culture microplate, 96 well, F-
bottom (chimney well), black, 
CellStar® TC 
- 655079 
Alpha Laboratories  Transfer Pipettes  -  LW4141  
Amersham   PVDF (0.2µM) membrane   -  10600021  
Anachem  20-200µl sterile filter tips     ABA2005  
ATTO Corporation  Slab Gel Casting Stand -  AE6200  
Corning®  96-well Clear Round Bottom Ultra-





Falcon ®  Cell scraper   -  35386  
Falcon ®  100mm TC-treated cell culture 
dishes  
P90  353003  
Falcon ®  60mm TC-treated cell culture 
dishes  
P60  353002  
Falcon ®  6-well Cell Clear Flat Bottom TC-
treated Multiwell Culture Plate  
6-well plate 353934  
Millex  Syringe Filter Unit, 0.22 
µm, polyethersulfone, 33 mm, 
gamma sterilized  
 - SLGP033RB  
Millipore  Stericup and Steritop 0.45µm  -  SCHV U01 RE  
SARSTEDT  15ml centrifuge tube   -  62.554.002  
Thermo Scientific™  Nunc™ Cell Culture Treated Flasks 
with Filter Caps 
T25   136196  
 
2.5 Centrifuges  
Table 2.5.Centrifuges used in this project. 
Name  Model Number  Rotator Volumes  
Eppendorf Centrifuge  5804 R FA-45-6-30 2.5 -50ml  




2.6 Antibodies  
The primary and secondary antibodies used are shown in Table 2.6 and Table 2.7.  
Key: IF: Immunofluorescence, IgG: Immunoglobulin G, RT: Room temperature, WB: Western blot, HRP: Horseradish Peroxidase 
Table 2 6. Primary Antibodies 




WB  IF  
Binding 
immunoglobulin 
protein (BiP)  
Rabbit 
Polyclonal IgG  
abcam  Ab21685  1:2000  -  Overnight/-  4oC/-  
Fibronectin (FN)  Rabbit 
Polyclonal IgG  







IgG   
abcam  Ab9484  1:600  -  Overnight/-  4oC/-  




Polyclonal IgG  




Polyclonal IgG  







abcam  Ab13506  1:2000  -  Overnight/-  4oC/-  
Vinculin   Mouse 
monoclonal  IgG 





Table 2.7.Secondary Antibodies 
Antigen  Antibody  Supplier  Cat. Num.  Dilution  
WB  IF  
Mouse IgG  Alexafluor®488 
conjugated polyclonal 
goat IgG  
Life Technologies  A11001  -  1:200  
Mouse IgG, IgA, IgM  HRP-conjugated goat 
IgG  
LI-COR  926-80010  1:50000  -  
Rabbit IgG, IgA, IgM   HRP-conjugated goat 
IgG   




2.7 Cell Culture: Experimental Setup of Cells  
2.7.1 Experimental Setup of Cells with 16F16 Inhibitor 
MDA-MB-231 cells were trypsinised as described in 2.1.4.  Cells were collected into a 15ml 
centrifuge tube (Table 2.4) containing 8ml of DMEM and 10% FBS  (Table 2.1). If experiments 
used more than one dish of cells, all cells were collected into one 15ml centrifuge tube (Table 
2.4). The cell suspension was centrifuged at 1000rpm for five minutes to pellet the cells. Spent 
medium was discarded, and cells were resuspended in 8ml of FGM (Table 2.1) and mixed 
very thoroughly before being centrifuged again at 1000rpm. According to the experimental 
design, p90 dishes were set up with a total volume of 8ml of FGM and 1.5x106 cells.  L-
Ascorbic acid was diluted from 10mg/ml stock (Table 2.1) and added to give a final 
concentration of 50µg/mL to promote collagen synthesis. Ascorbic acid is a cofactor for prolyl-
4-hyroxylase, a key enzyme for collagen hydroxylation and is essential for collagen to reach 
its tertiary structure (Pihlajaniemi et al., 1991). Plates were incubated at 37oC 2-3 hours to 
allow cells to attach, then 5M of 16F16 (Table 2.2) was added or an equivalent volume of 
DMSO as solvent-only control, and cells incubated for 48 hours at 37oC.  
2.7.2 Preparation of Conditioned Media (Small Scale) 
After 48 hours of incubation of cells with either DMSO or 16F16, medium was removed from 
each p90 dish using a transfer pipet and put in a 50ml polypropylene conical tube (Table 2.4). 
Cell lysates were collected according to 2.7.3. The medium was centrifuged at 1000rpm for 5 
minutes to pellet any cell debris, and the supernatant then passed through a 0.22m pore  
Syringe Filter Unit (Table 2.4) to sterilize and remove particles larger than 0.22µm, and then 
collected into a fresh 50ml polypropylene conical tube. 
2.7.3 Preparation of Cellular Samples for Western Blotting  
After conditioned medium was removed from p90 dishes as described in 2.7.2, cells were 
gently rinsed three times in PBS to remove any detached cells or residual medium. Then 200l 
of SDS-PAGE sample buffer containing 100mM of DTT was added and the cell lysate scraped 
into a 1.5mL Eppendorf tube (Table 2.4) and stored at -20oC.  
2.8 SDS-PAGE and Immunoblotting   
All samples were stored at -20oC in SDS-PAGE-SB containing 100mM DTT. Prior to gel 
loading, samples were heated at 95oC for 5 minutes. Samples that contained heparin-agarose 
or control-agarose beads were centrifuged at 1000rpm for 1 minute to pellet beads and the 
supernatant loaded onto the gel. Precision Plus Protein™Dual Colour Standards (Table 2.1) 
was diluted 2:5 with SDS-PAGE-SB containing 100mM DTT and provided molecular weight 
references on the gel. Gels were cast as 10% SDS-polyacrylamide resolving gels overlain with 




separated in the resolving gel at 140V for 4 hours.  For immunoblotting, proteins were 
transferred onto 0.2µm pore PVDF membrane at 15V for 1.5 hour using a Trans-
Blot®SD Semi-Dry Transfer Cell (Biorad). The membrane was stained with Ponceau S (Table 
2.1) to visualise transferred proteins. The membrane was then washed three times in dH2O to 
increase band clarity and a digital image was taken using a Syngene G:BOX Chemi XRQ. The 
membrane was then cut into segments according to the experimental design and blocked for 
30 minutes in immunoblot blocking buffer (Table 2.3). Proteins of interest were probed for with 
specific primary antibodies (Table 2 6). Primary antibody dilutions were made in blocking 
buffer and incubated at 4oC overnight with rotation to bind to antigen. The membrane was then 
washed three times (10 minutes each) in blocking buffer to remove non-specific bound 
antibody and then incubated with the appropriate diluted secondary antibody (Table 2.7) for 
one hour at room temperature with rotation.  The membrane was washed in blocking buffer 
as described above, with two additional 10-minute washes in PBS. Bound antibodies were 
visualised by adding equal volumes of Amersham ECL Western Blot detection reagent (Table 
2.1) to provide chemiluminescence at the band location and imaged in 
a Syngene G:BOX Chemi XRQ. A digital image was taken with the GeneSys software and the 
file exported to GeneTools for quantitative band analysis and normalisation to loading 
control.    
2.9 3-Dimensional Spheroid Cell Culture  
2.9.1 Experimental Setup and Quantification 
Breast cancer spheroids were grown in 96-well Clear Round Bottom Ultra-Low Attachment 
Microplates (Table 2.4). Each well contained 100l of DMEM with 10% FBS. To minimise the 
time cells were not at 37oC, the total volume in the wells was made up in halves: the first half 
containing 50 l of DMEM with 20% FBS and double the final concentration of 16F16; the 
second half containing 50 l of DMEM with the correct number of cells to be seeded. To begin, 
a stock solution of 20mM 16F16 which had been dissolved in deionised water was thawed 
from storage at -20oC and the correct volume diluted in 8ml of DMEM with 20% FBS to make 
final concentrations of either 1, 2.5, 5, 10, 12.5, 17.5, 25 or 50M (depending on experimental 
design/requirements) in a 15ml centrifuge tube. A further 8ml DMEM with 20% FBS was made 
up individually with DMSO at an equivalent total volume to the highest volume used for 16F16. 
A stock of DMEM with 20% FBS only was made up for control wells. Once made up and mixed 
well, 50l aliquots were put into the allocated wells. The 96-well plate was then left in the 
humidified 37oC incubator until the cells had been prepared. One T75 of stock cells was 
trypsinised as described in 2.1.4 and cells collected into a 15ml centrifuge tube and counted 
in a haemocytometer. A volume of cell suspension was then taken into an Eppendorf tube 




well plates this included 400, 200, 1000, 2500, 5000, 7500 and 10000 cells/100µl. For 
experiments with varying concentrations of 16F16 there were 6 replicate wells per condition, 
except the third experiment which has 2 replicate wells. For experiments investigating seeding 
cell number there were 6 replicate wells for the 50µM 16F16 and 0µM 16F16 conditions, and 
3 replicate wells for the control. This volume was further diluted as needed with DMEM such 
that the desired number of cells was present in a 50l volume. After remixing, 50l of cell 
suspension was then added to allocated wells containing 50l DMEM, 20%FBS and 16F16 
and mixed well. The 96-well plate was then placed in a humidified chamber at 37oC 5% CO2, 
and within a maximum of 15 minutes taken to the Wolfson Bioimaging Facility to be put in the 
EssenBiosciences IncuCyte® ZOOM Live-Cell Analysis System.  Here, cells were incubated 
in a humidified chamber at 37oC with 5% CO2 whilst being live-imaged. A phase contrast digital 
image of each well was taken every 2 hours for 72 hours under control of the IncuCyte 
Software. After images had been collected, the 96-well plate was removed from the IncuCyte® 
ZOOM incubator and the spheroids were fixed for further inspection of 3D character. Control 
wells or wells with DMSO seeded at 10000 cells/100µl were chosen since spheroids could be 
seen by eye in these wells and under a light microscope appeared to have 3D quality. Being 
careful not the damage the spheroid and drawing liquid from the edges of wells, 70l of spent 
media was discarded, and wells washed gently in 70l of PBS. The spheroids were then 
submersed in freshly made 4% PFA in PBS (Table 2.1) for 30 minutes for fixation. The 4% 
PFA was removed and the spheroids left in 100l of PBS. The 96-well plate was wrapped in 
parafilm and stored at 4oC until staining (2.10.5).  
Spheroid formation was quantified using the IncuCyte ® ZOOM System Software. A phase-
contrast image of every well, for every timepoint was exported as a TIFF file. Spheroid area 
was then defined using ImageJ tools (https://imagej.net/Welcome), (threshold > binary> 
measure particles (particles size above 10000m)). The spheroid area was analysed and 
recorded by region-of-Interest (ROI) manager on ImageJ. The TIFF files were processed by 
ImageJ by a batch macro; once all the spheroid areas had been collected for a plate, they 
were exported from the ROI into Microsoft Excel. The processed spheroid TIFF files that 
showed the threshold images of quantified area were also saved in a separate folder and were 
checked visually that the batch ImageJ macro had worked correctly on all images.  If the macro 
had incorrectly measured a spheroid, the phase-contrast TIFF was loaded into ImageJ and 
the spheroid area measured by freehand outline. The average spheroid area for each time-
course, reciprocal data and ratios were calculated in Microsoft Excel and then exported to 




2.9.2 Experimental Setup of Cells with β-aminopropionitrile Inhibitor  
A T75 flask of cells was treated with 500µM of β-aminopropionitrile (βAPN) (Table 2.2) and 
incubated at 37oC for 72 hours. Then, 1M βAPN dissolved in deionised water was diluted to 
5mM in DMEM containing 20% FBS under sterile conditions. This concentration was chosen 
because βAPN has been shown to be most effective at inhibiting LOXL2 around 300µM, 1M 
was prepared for a βAPN serial dilution (Rodriguez et al., 2010). Breast cancer cells were 
setup for spheroid formation in a 96-well plate as described in 2.9.1. The media was again set 
up in two parts to minimise cell-handling time. First, fresh 5mM βAPN was diluted to 10, 100, 
200, 500, 1000 or 2000M in DMEM 20%FBS and 50l of each was added to its allocated 
wells. Secondly, the prepared cells were trypinised as described in 2.1.4 and an aliquot of cell 
suspension at 400cells/µl was diluted in DMEM to give either 5000 or 10000 cells/50µl. Next, 
50µl of either cell suspension was added to 50µl DMEM/ 20% FBS/ βAPN in the 96-well plate 
making final concentrations of βAPN of 5, 50, 100, 250, 500 or 1000M, with 6 replicate wells 
per condition. The plate was then imaged as described in 2.9.1.  
2.10 Fluorescence Microscopy 
2.10.1 Effect of the PDIA3-Dependent Secretome on Cell Spreading  
Cells for experiments were trypsinised as described in 2.1.4 from a T75 flask. The cell 
suspension was centrifuged at 1000rpm for 5 minutes to pellet cells, and cells resuspended 
and washed three times in FGM. Conditioned media were prepared as in 2.7.2. In the laminar 
flow tissue culture cabinet 4 sterile glass coverslips (VWR- 631-0149) were added per well in 
wells of a 6-well plate containing either 3ml FGM or 3ml conditioned media (2.7.2) and 
incubated with 16F16 or DMSO for 48 hours. A total of 1.5 x105 cells (in 100µl) was added per 
well, mixed and incubated at 37oC for 4 hours or 20 hours to allow cells to attach and spread 
on the glass coverslips. At end of either incubation, medium was gently removed from each 
well and the cells gently washed three times in PBS to remove non-adherent cells. Freshly 
made 4% PFA in PBS was added to wells to completely cover the coverslips and left for 10 
minutes to fix the cells. Wells were then washed three times in PBS and, if necessary, stored 
for a maximum 3 days before permeabilization and staining according to the experimental 
procedures described in 2.10.2 or 2.10.4. 
2.10.2 Quantification of Cell Attachment and Vinculin Staining  
Cells were seeded at 1.5x106 in a p90 dish containing glass coverslips and then treated and 
fixed after 4 or 20 hours as detailed in 2.10.1, then permeabilised with 0.5% Triton X100 as 
described in 2.10.4.  Cells were blocked in 1% Bovine Serum Albumin (BSA) in PBS for 30 
minutes, washed three times in a PBS bath, and then incubated with anti-vinculin primary 
antibody (Table 2 6) in PBS containing 1% BSA for 90 minutes. All incubations/ blocking was 




coverslips were incubated with Alexafluor® 488 secondary antibody (Table 2.7) in 1% BSA in 
PBS for 45 minutes.  Finally, coverslips were washed thrice in PBS followed by deionised 
water before mounting on slides in VectorShield® with DAPI. Slides were examined as 
described in 2.10.4, with a 100mW 488nm Argon laser to detect the Alexafluor® 488 
secondary antibody. Images were saved as TIFF files and the Z-stack merged to give 
MaxIntensity in ImageJ as described in 2.10.4, then converted to red-green-blue (RGB) TIFF 
images for display.  
2.10.3 Role of Secreted Heparin-Binding Proteins in Cell Spreading  
First, heparin-agarose affinity beads or agarose-beads (Table 2.1) were prepared. Keeping 
the beads on ice as much as possible, a total volume of beads corresponding to 20µl of 
heparin-agarose or control-agarose beads, per p90 dish of cells, was resuspended as 1:1 (v/v) 
suspensions in chilled 1x TBS (Table 2.3) and centrifuged for 30 seconds at 7500rpm. Beads 
were washed twice more in large volumes of TBS, finally leaving the beads in TBS as a 1:1 
(v/v) suspension.  After 48 hours culture of cells prepared as described in 2.7.1, the 
conditioned medium was collected and prepared as described in 2.7.2. 16ml of conditioned 
media was put into a 50mL polypropylene conical tube for each condition. 90l of either 
heparin-agarose beads or 90l of control-agarose beads (each 1:1 v/v in TBS) was added, 
respectively, to a tube, and incubated on a rotatory wheel at 4oC for 1.5 hours, to allow binding 
of proteins from the media. Each medium was then centrifuged at 1000rpm for 5 minutes to 
pellet the beads. Each supernatant conditioned medium was transferred to a fresh tube. Beads 
were discarded.  In the laminar flow cabinet, a 6-well plate was prepared with glass coverslips 
as in 2.10.1. Cells were prepared as in 2.1.4 and added at 1.5 x105 cells per well along with 
either fresh FGM, control conditioned media (after incubation with control-agarose beads) or 
conditioned media depleted of heparin-binding proteins (after incubation with heparin-
agarose) to a final volume of 3ml. The attachment assays then proceeded in accordance with 
2.10.1. 
2.10.4 Quantification of Cell Area  
After fixation on glass coverslips (as in 2.10.1 or 2.10.3), cells were permeabilised with 0.5% 
Triton- X100 in PBS for 10 minutes, then re-immersed in PBS. Coverslips were drained and 
placed cell-side up in a humidified chamber. Cells were stained with Phalloidin-Atto565 
fluorescent compound (Table 2.1) diluted 1:100 in PBS, for 50 minutes at room temperature. 
Then the coverslip was passed three times through a bath of PBS and then deionised water 
to remove salts. Coverslips were mounted cell-side down on slides using VectaShield with 
DAPI (Table 2.1) and left overnight at room temperature to harden before being examined by 
microscopy. All slides were examined under a Lecia SP5-AOBS confocal laser scanning 




PL APO lambda blue 63x 1.4NA oil objective. Using Lecia Application Suite AF software 
2.7.3.9723, Z-stack images were taken with approx. 0.50m z-slice thickness, over 2.5-3m 
total Z-stack thickness from the base of the cells upwards. Two lasers were used to detect 
immunofluorescence, 20mW solid state yellow laser (561nm) was used to detect Phalloidin- 
Atto565 and a 50mW 405nm diode laser for 4′,6-diamidino-2-phenylindole (DAPI) (Table 2.1). 
Three coverslips were imaged per condition per experiment and enough Z-stack-stack images 
collected so that at least 50 cells could be scored. All files were saved as TIFF files and were 
loaded into ImageJ as composite images (DAPI and Phalloidin stain) and all Z-stacks were 
merged using Image> Stacks> Z-Project (Max Projection). Stacked images were processed 
using Image> Adjust> Threshold following Process>Binary> Make Binary. Cell area was 
measured using Analyse> Analyse Particles. These steps were combined into an automated 
macro in which most cell areas were extracted and added to the Region of Interest (ROI) 
manager. Occasionally cell area was determined using ImageJ freehand outline tool if the 
macro failed to quantify cell area correctly.  
2.10.5 Phalloidin Staining of Breast Cancer Spheroids  
After spheroid fixation as described in 2.9.1, PBS was removed and 100l of 0.5% Triton X100 
added to each well with a fixed spheroid and permeabilised for 15 minutes. After washing in 
PBS, 100l of Phalloidin-Atto565 fluorescent compound (Table 2.1), (diluted 1:60 in PBS) was 
added and spheroids incubated at room temperature for 1.5 hours. After washing three times 
in PBS and storing in 100l of PBS, each spheroid was delicately transferred to a flat-bottomed 
96-well plate with copious PBS and left overnight before imaging. The plate transfer was 
necessary because the confocal microscope can only focus correctly with flat-bottomed 
plates. Images were taken using a Lecia SP5-AOBS confocal laser scanning microscope 
attached to a Lecia DM I6000 inverted epifluorescence microscope with an HCX PL APO 
lambda blue with a 10x HCX PL Fluotar lens. Using Lecia Application Suite AF software 
2.7.3.9723, Z-stack images were taken with approx. 1m z-slice thickness. The total Z-stack 
thickness from the base of the spheroid upwards was 80-100m. A 20mW solid state yellow 
laser (561nm) was used to detect Phalloidin-Atto565 fluorescence. Images were saved as 
TIFF files using Volocity® 3D Analysis Software. 3D reconstruction of the Z-stack images was 
made using the default settings. A total of seven spheroids were imaged.  
2.11 Preparation for Tandem Mass Tag-Based Quantitative Proteomics 
2.11.1 Experimental Setup  
Confluent cells in four T75 flasks were trypsinised as described in 2.1.4 and cells prepared as 
in 2.7.1, except for some minor changes to decrease serum proteins from the medium.  Cells 




10% FBS). This was repeated for a further 4x T75 flasks, so collecting all the cells into one 
tube. The cell suspension was then centrifuged at 1000rpm for five minutes in 10mL of FGM 
and the pellet resuspended in FGM. This was repeated twice more to remove all traces of 
DMEM. Then eight p90 dishes were set up with a total volume of 8ml of FGM and 
1.5x106 cells per plate. The rest of cellular setup was the same as described in 2.7.1.  
2.11.2 Heparin Affinity Pull-Down from Conditioned Media (Large Scale) 
Heparin-affinity pulldown from conditioned media was carried out as described in 2.7.2, but 
with some alterations to increase purity for TMT-proteomics. Since 8x p90 dishes were 
prepared in total (four per condition), in total 160µl of Heparin-agarose beads and 230µl 
control-agarose beads were prepared for this experiment. In the laminar flow cabinet cell, each 
conditioned medium (+DMSO or +5M 16F16; 32ml each) was filtered through a 
150mL Stericup filtration unit (Table 2.4) with a 0.45µm filter made of  Durapore (PVDF) low-
protein-binding membrane. This removed particulate material and ensured sterility. Each 
filtered medium was added to a fresh 50ml polypropylene conical tube and 3 tablets 
of Pierce™ Protease inhibitor tablets-mini (Table 2.2) added. Next, 100µl of 1:1 (v/v) control 
agarose-bead suspension was added to each tube, to absorb any non-specific agarose-
binding proteins from the medium. Each tube was rotated on a rotatory wheel for 1 hour at 
4OC. The tube was then centrifuged at 1000rpm for 5 minutes to pellet the control beads. Each 
supernatant medium was then placed in a fresh 50mL tube and 80µl of heparin-beads/TBS 
suspension added. The two tubes were rotated on the rotatory wheel at 4OC for 1.5 hours, this 
time to allow heparin-binding proteins to attach to the heparin-beads.  The suspensions were 
then centrifuged at 1000rpm for 5 minutes to pellet the heparin-agarose beads. The beads 
were washed three times in TBS and then each moved into a 1.5mL Eppendorf tube and 
washed once more, with all liquid removed from the final pellets. 50l of SDS-PAGE SB 
containing 100mM DTT was added to the heparin-beads to dissociate bound proteins, 
heparin-beads then centrifuged at 10,000rpm for 30 seconds and stored at -20oC before being 
taken to the Proteomics Facility. Four independent experiments were carried out.   
2.11.3 Tandem Mass Tag-Based Quantitative Proteomics  
This method was conducted at Bristol University’s Proteomics Facility by Dr. Kate Heesom. 
The samples prepared in 2.11.2 were resolved on a 1D SDS-PAGE gel to facilitate removal 
of buffer components which would interfere with downstream LCMS analysis. Electrophoresis 
was carried out until the dye front had moved approximately 1cm into the separating gel. Each 
gel lane was then excised and the proteins in one gel slice were digested with trypsin (which 
cleaves C-terminal to lysine and arginine residues) using a DigestPro automated digestion 
unit. Resulting peptides were then extracted and labelled with Thermo Fisher Scientific TMT 




hydroxylamine and then all labelled peptide samples were pooled. The pooled sample was 
analysed by LCMS using an Orbitrap Fusion Tribrid mass spectrometer with data analysis 
performed using Thermo Scientific™ Proteome Discoverer™ Software. All proteins with a 
Unique Peptide Score over one was included in analysis. Data were exported to Microsoft 
Excel and underwent statistical analysis by Dr. Phil Lewis, Research Associate, School of 
Cellular and Molecular Medicine (2.14). Proteins were picked for statistical analysis if they 
were present with a fold difference in all four independent experiments. Of these proteins, only 
those with a 2-fold-change and statistical significance p<0.05 between the +DMSO and 
+16F16 conditions were taken for further bioinformatics analysis.   
2.12 Bioinformatic Tools: Computational Analysis of the PDIA3 Dependent 
Secretome  
All proteins found to be significantly (p≤0.05) different across 4 independent repeats by 
statistical analysis of the control and 16F16 samples in the TMT-Based Quantitative 
Proteomics (2.11.3) were taken forward for further investigation. Each accession number was 
converted to gene-name using https://www.uniprot.org/uploadlists/. If the gene-name could 
not be found automatically, it was found manually using Uniprot. The final list of gene-names 
was analysed manually and then split by known intracellular or extracellular location of the 
proteins. Table 2.8 shows the bioinformatic tools used. The outputs from STRING (Szklarczyk 
et al., 2019) and GOrilla (Eden et al., 2009) tools were saved as JPEG files for visual 
interpretation. For Gorilla, the background protein list used was the entire list of proteins not 
significantly altered (341) from the TMT-based quantitative proteomics. FASTA sequences 
(retrieved from the National Centre for Biotechnology Information, 
https://www.ncbi.nlm.nih.gov/protein/) for each protein were analysed in InterProScan 
(Mitchell et al., 2019) using default settings. Protein domains with disulphide bonds or 
cysteine-rich regions were identified and results presented as mosaic plots made in R. This 
plot was also used to display the top 10 enriched molecular signatures from the GSEA 
database (Subramanian et al., 2005). Enrichment in gene sets from GSEA was displayed 
using GraphPad Prism 7.0. GOBO (Ringnér et al., 2011) was used to analyse the extracellular 
gene set in relation to breast cancer cell lines and Reactome (Fabregat et al., 2018) was used 






Table 2.8. The bioinformatic tools used in this project 































et al., 2005 
http://software.broadinstitute.org/gsea/msigdb/index.jsp 
InterProScan - Mitchell et al., 
2019 
https://www.ebi.ac.uk/interpro/ 
Reactome  - Fabregat et 
al., 2018 
https://reactome.org/ 







2.13 Replication of Experiments  
Three independent experiments were carried unless otherwise stated. This included the control and 
technical repeats.  
2.14 Statistical Analysis   
All statistical significance tests were performed in GraphPad Prism 7.0 except for the proteomics 
experiments.  
Immunoblots involving two conditions were analysed by unpaired Student’s t.test. 
For cell area plots and final spheroid area (at 50 hours) plots, data were analysed by two-way 
ANOVA with Tukey’s multiple comparison post-hoc test.  
For the rate of spheroid formation, reciprocal plots (Time vs. 1/Area) were prepared for the time 
period 20 to 50 hours. Multiple linear regression was performed to find the gradient of the line of best 
fit for each condition and the goodness of fit (R2). This analysis was decided after consultation with 
Professor Green, a statistician at the University of Bristol.  
Each protein abundance was normalised by log(2) transformation and a log(2)Mean and a 
log(2)Median was calculated. It was decided that because of the similarity between the  log(2)Mean 
and the log(2)Median, and the high number of independent repeats (n=4), the statistical significance 
between protein abundance in the two experimental conditions could be calculated using a paired 
Student’s t-test (paired because the control and 16F16 samples were pooled in the mass 
spectrometer). Analysis was only performed on proteins identified in all four repeats. Statistical 
testing and consultation was carried out by Dr. Phillip Lewis from Bioinformatics Support at the 

































3.1 The Role of PDIA3 in Promoting a Pro-Metastatic Phenotype  
3.1.1 PDIA3 is present in MDA-MB-231 Cells  
Before starting the investigations, it was confirmed whether PDIA3 is present in MDA-MB-231 cells 
(referred to hereafter as A231 cells) by use of immunoblot. Cell lysates and CM were prepared as 
described in the Methods 2.7. Cells were grown for 48 hours in serum-free media with the addition 
of either DMSO or 5µM 16F16 at 0 hours. Previous experiments in this laboratory have shown that 
5µM 16F16 induces phenotype changes in A231 cells without causing toxicity (H.S.Young, 
unpublished, 2018). All cells were grown in the presence of 50µM ascorbic acid. Ascorbic acid is an 
antioxidant and acts as a cofactor of prolyl-4-hyroxylase, an enzyme that catalyses the hydroxylation 
of proline in collagen’s GXY triple helical sequence (Gly-Pro-Y is frequent) (Pihlajaniemi et al., 1991). 
Thus, addition of ascorbic acid promotes assembly of collagen molecules and thus collagen 
secretion and ECM assembly. A 48-hour timepoint was chosen to give time for global biochemical 
effects of PDIA3 inhibition to take place before collecting cell lysates or CM.  
Immunoblots revealed a band at apparently 57kDa (Figure 3.1A), the expected molecular weight for 
PDIA3, in cell lysates of both control and 16F16-treated cells. PDIA3 protein abundance was lower 
in the 16F16 condition relative to DMSO-treatment, when PDIA3 abundance was normalised against 
GAPDH (35kDa) (Figure 3.1B). The graph may also give some insight into 16F16 induced toxicity 
showing less protein in 16F16 treated samples, but this would need to be tested with replicate 
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Figure 3.1. Presence of PDIA3 in MDA-MB-231 cells. (A) Proteins were separated on a 10% 
polyacrylamide gel under reducing conditions, transferred to a PVDF membrane and probed with 
antibodies to PDIA3 or GAPDH. n=1 experiment.  Key: CL: Cell Lysate, CM: Conditioned Media. (B) 
Automated quantification using Synegene GeneTools© of bands for PDIA3 normalised against 














3.1.2 Fibronectin is a Target of PDIA3 and Present in MDA-MB-231 Conditioned Media  
Some of PDIA3’s known substrate glycoproteins are destined for secretion to the ECM, including 
important structural glycoproteins such as fibronectin and collagen VI (Jessop et al., 2007b). We 
hypothesised that a change in PDIA3’s redox activity would alter the ECM of A231 cells by affecting 
secretion of some of these proteins. To validate that the concentration of 16F16 used was effective 
against the known substrate fibronectin in A231 cells, PDIA3 was inhibited by 16F16 and fibronectin 
protein abundance in the CM was analysed by immunoblot.  
The immunoblot showed a band at around 220kDa for fibronectin in the control condition (treated 
with DMSO) and no band in the CM treated with 16F16 (Figure 3.2). This result was reproduced in 
two experiments (Figure 2A, experiments 1 and 2), but not in a third experiment (Figure 2A, 
experiment 3) where CM treated with 16F16 showed a small band at 220kDa for fibronectin. In every 
sample the fibronectin band was diffuse which is typical as fibronectin is heavily glycosylated. A 
limitation of the blots of CM is that an internal normalisation control could not be used as the protein 
concentration of the samples were too low to produce clear bands by Ponceau S stain. Therefore, 
for quantitation, fibronectin abundance in CM was compared between control and 16F16 conditions. 
The means of each condition were compared using an unpaired Student’s t-test and this showed 
that the abundance of fibronectin was not significantly different between the CM treated with DMSO 
and the CM treated with 16F16. Bands were not normalised using GAPDH, since GAPDH was only 
present in cell lysates it cannot be assumed that its protein abundance would be proportionate to 
fibronectin in the CM. The results showed that 5µM of 16F16 decreased secretion of a known PDIA3 
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Figure 3.2. Effect of PDIA3 Inhibition on Fibronectin (FN) Abundance in the CM of MDA-MB-
231 Cells. (A) Immunoblot of cell lysates and conditioned media after treatment with 5M 16F16 or 
equivalent volume of DMSO. Samples were resolved on a 10% polyacrylamide gel under reducing 
conditions, transferred to PVDF membrane and blotted for the indicated proteins. Automated 
quantification using Synegene GeneTools© bands for fibronectin for (B) all three independent 










3.1.3 Assessment of Cell Spreading and F-Actin Organisation   
It has been reported that in culture highly metastatic cells have a larger area that their counterparts 
(Shen et al., 2012). Previous research in the Adams laboratory (Hellewell.et.al., manuscript in 
preparation & Young, unpublished, 2018) has shown that pharmacological inhibition of PDIA3 in 
breast cancer cells (including A231 cells) and in fibroblasts, leads to an altered cell morphology and 
reduced cell spreading. This effect has been shown to depend on secreted proteins (Introduction 
1.7).   
In this project, the effects of a PDIA3-dependent secreteome on the morphology and attachment of 
A231 cells was analysed by fluorescence microscopy methods. The CM was prepared by from A231 
cells by incubating 1.5x106 cells in serum-free media (FGM) for 48 hours after treatment with either 
5µM 16F16 or equivalent volume of DMSO at 0 hours. All 2-dimensional cell-based assays were 
performed in FGM because as well as being a well-defined serum-free medium, it has been 
consistently used for inhibitor-based experiments involving breast cancer cells and fibroblasts in 
Professor Adams’ Laboratory. Serum-free medium was also used to avoid including serum proteins 
in the CM. It was hypothesised that 48 hours was enough time for global effects of 16F16 in view of 
the result with fibronectin. Also, in 48 hours nutrients would not become too depleted or possible 
effects on cell toxicity high. To examine the impact that CM alone may have on A231 cells, a third 
condition was included using only fresh FGM. Next, 2.5x105 naïve recipient cells were plated onto 
glass coverslips and exposed separately to each of the three different serum-free CM conditions. 
The cells were left for 4 or 20 hours to attach and spread. Two time points were used to give an 
indication of whether the secreted products of the naïve A231 cells could overcome the effects of an 
PDIA3-inhibited CM at 20 hours. At each time point, cells were fixed and stained with phalloidin to 
visualise the F-actin cytoskeleton or with antibody to vinculin to visualise focal adhesions (Methods 
2.9). The different outputs of these experiments are detailed in the separate following sections.  
3.1.3.1 The Effect of a PDIA3-dependent Secretome on F-actin Organisation 
Naïve A231 cells plated in fresh-FGM for both 4 and 20 hours showed a typical migratory A231 
breast cancer cell phenotype with bright F-actin at the leading edges of the cells. Also visible were 
mesh-like lamellipodia and F-actin stress-fibers extending throughout the cells (Figure 3.3 & Figure 
3.4). The A231 cells plated in CM from cells that had been treated with DMSO had also strong F-
actin arrays at leading edges and phenotypic features consistent with a migratory phenotype at both 






Figure 3.3 F-actin localisation in MDA-MB-231 Cells Plated in CM from Cells Treated with 5M 
16F16 or DMSO for 48 hours. Cells were fixed 4 hours after plating with respective media and 
stained with Phalloidin-Atto565 to visualize F-actin. Top Row displays higher magnification of the 
boxed area from Second Row (63x frame), to show details. Confocal Images are displayed as 





Figure 3.4. F-actin Localisation in MDA-MB-231 Cells Plated in CM from Cells Treated with 5µM 
16F16 or DMSO for 48 hours. Cells were fixed 20 hours after plating with respective media and 
stained with Phalloidin-Atto565 to show F-actin organisation. Top Row displays higher magnification 
of the boxed area from Second Row (63x frame). Confocal Images are displayed as Maximum 





However, cells plated in CM from 16F16-treated cells did not display F-actin stress fibers and overall 
appeared to have smaller areas. After 4 hours of incubation with CM from cells treated with 16F16, 
cells did not display the distinct networks of bright F-actin that indicate lamellipodia (Figure 3.3).  
After 20 hours of incubation, the A231 cells showed lamellipodia but these were not as extensive or 
as numerous as in the A231 cells plated in fresh-FGM or CM from cells treated with DMSO (Figure 
3.4).  
3.1.3.2 The Effect of a PDIA3-Dependent Secretome on Area of MDA-MB-231 Cells 
To quantify cell areas, the images of phalloidin-stained cells were imported to ImageJ and cell areas 
measured.  As many cells were measured as possible in each experiment; within the image frames 
collected, the only reasons a cell was not measured was because it overlapped so heavily with 
another cell its boundaries were hard to identify, or it was undergoing cell division. The plot of cell 
areas is shown in Figure 3.5. 
At the 4 hour timepoint, the mean cell area of naïve A231 cells plated in CM from cells treated with 
DMSO was not statistically difference from the mean area of cells plated in fresh FGM. However, 
after 20 hours of adhesion, the mean cell area in these conditions was significantly different (Figure 
3.5).  
At 4 hours and at 20 hours, the mean cell area of cells plated in CM from 16F16-treated cells was 
significantly different from either cells plated in fresh FGM or cells in CM from DMSO-treated cells 
(Figure 3.5).  
Thus, A231 cells plated in CM from cells treated with 16F16 had a reduced ability to spread. Analysis 
by immunofluorescence (3.1.3.1) revealed that these cells had a reduced number of F-actin stress 
fibers, lamellipodia, or other features of a migratory breast cancer phenotype. Collectively, these 
results suggest that PDIA3-dependent proteins secreted to the medium support the cell spreading 









Figure 3.5. Quantified Comparison of MDA-MB-231 Cell Areas after Plating in CM of Cells 
Treated with 5M 16F16 or Equivalent Volume of DMSO for 48 hours. Cells were fixed after 4 
hours (A) or 20 hours (B) adhesion. Dot plots show the cell areas; mean value (black line). Areas 
were measured from confocal Maximum Intensity Z-Projections of phalloidin-stained cells. Cell areas 




















3.1.4 Assessment of Focal Adhesions  
Another aspect of a migratory phenotype is the localisation of proteins that link the actin cytoskeleton 
via integrins to the ECM. Focal adhesions include assemblies of proteins that are mechanosensory, 
they transduce force from either side of the plasma membrane to elicit movement (Introduction 
1.5.2). An important protein of focal adhesions is vinculin (Harris et al., 2018). Vinculin was stained 
for by immunofluorescence as another indicator of the adhesive status of the cells. A231 cells and 
images were prepared as described in Methods 2.7 & 2.10. The images presented are from a single 
experiment due to time constraints.  
Naïve A231 cells plated in fresh FGM for 4 or 20 hours showed vinculin faintly distributed throughout 
the cytoplasm and more concentrated at the leading edges of cells. In A231 cells plated with CM 
from cells treated with DMSO, vinculin was found throughout the cells but not clearly concentrated 
at the leading edges after 4 hours. After 20 hours vinculin was strongest around the leading edges 
(Figure 3.7). In A231 cells plated in CM from cells treated with 16F16, vinculin staining was very low 
throughout cells at the 4-hour timepoint with no concentration of staining at cell edges. At 20 hours 
there was little vinculin localised to focal adhesions (Figure 3.6 & Figure 3.7). Thus, the A231 cells 
plated in CM from cells treated with 16F16 showed less vinculin localised to focal adhesions. This 
suggests that cells plated in CM from cells treated with 16F16 have limited capacity to assemble 







Figure 3.6. Vinculin Localisation in MDA-MB-231 Cells Plated in CM from Cells Treated with 
5M 16F16 or Equivalent Volume of DMSO for 48 hours. Cells were fixed 4 hours after plating 
with respective media and stained for vinculin. Top Row displays higher magnification of the boxed 
area from Second Row (63x frame). Confocal images are displayed as Maximum Intensity Z-





Figure 3.7. Vinculin Localisation in MDA-MB-231 Cells Plated in CM from Cells Treated with 
5M 16F16 or Equivalent Volume of DMSO for 48 hours. Cells were fixed 20 hours after plating 
with respective media and stained for vinculin. Top Row displays higher magnification of the boxed 
area from Second Row (63x frame). Confocal Images are displayed as Maximum Intensity Z-




3.2 Examination of the Effect of 16F16 on Endoplasmic Reticulum Stress in MDA-MB-231 
Cells 
It is well established that if misfolded proteins accumulate in the endoplasmic reticulium (ER) an 
unfolded protein response (UPR) is triggered (Ojha and Amaravadi, 2017). Misfolded proteins can 
build up during adverse conditions in pH, temperature, oxygen and nutrience levels. The UPR affects 
global translation and protein abundance: proteins that are particularly upregulated during UPR are 
those involved in protein folding or chaperone function because PDIA3 is an ER-resident 
oxidoreductase that adds disulphide bonds into proteins. Inhibiting PDIA3 with 16F16 might increase 
missfolded proteins in the ER and cause an UPR (Rellmann and Dreier, 2018; Yoo et al., 2019). If 
this is the case, phenoptypic changes seen when using 16F16 could be due to an elevated UPR. 
Therefore, immunoblotting was used to analyse A231 cells that had been pre-treated with 5µM 
16F16 or DMSO for 48hours as described in 3.1.1. Binding immunoglobulin protein (BiP) was used 
as a proxy for UPR. BiP is a molecular chaperone residing in the ER that is upregulated during an 
UPR (Sano and Reed, 2013). Three independent repeats were carried out and BiP bands were 
normalised against GAPDH to quantify protein abundance (Figure 3.8). BiP was detected in control 
cells and no significant difference in BiP abundance was found between the lysates from DMSO or 
16F16-treated A231 cells (p=0.8479). The equal abundances of BiP suggest that UPR is not 
activated by these conditions of 16F16 treatment. This shows that the observed phenotypic 







Figure 3.8. Assessment of ER Stress in MDA-MB-231 Cells. (A) Immunoblots of A231 cell lysates 
and conditioned media after treatment with 5M 16F16 or equivalent volume of DMSO. Samples 
were resolved on a 10% polyacrylamide gel under reducing conditions, transferred to a PVDF 
membrane and blotted for the indicated proteins. Key: CL: Cell Lysate, CM: Conditioned Media.  (B) 
Automated quantification of BiP band intensities normalised against GAPDH loading control. Black 













3.3  The Role of Heparin-Binding Secreted Proteins in MDA-MB-231 Cell Adhesion 
3.3.1 Assessment of Cell Spreading and F-Actin Organisation   
Previous experiments in the laboratory with mouse embryonic fibroblasts (MEF) have identified 
secreted, PDIA3-dependent, heparin-binding proteins (HBP) to be functionally important for 
adhesion and spreading (Hellewell et.al., manuscript in preparation). Because many ECM proteins 
or cytokines contain heparin-binding domains, heparin-affinity binding is a convenient way to isolate 
these proteins from CM. The experiments described in 3.1.2 and 3.1.3 showed that PDIA3-
dependent secreted proteins have a role in promoting the spreading and F-actin organisation of 
A231 cells. To examine the contribution of secreted HBP, CM from A231 cells was examined on 
naïve A231 cells. 2.5x105 A231 cells were plated in fresh FGM or CM prepared as in 3.1.2, but this 
time the control CM was compared with CM depleted for HBP. HBP were depleted from the CM by 
an hour-long pre-incubation with high affinity heparin-agarose beads. At the end, CM was centrifuged 
to pellet the heparin-agarose beads with associated HBP. Evidence that this procedure results in 
effective binding of proteins to the heparin-agarose beads will be provided in the proteomics section 
of the results (3.4). The HBP-depleted CM were then added to naïve A231 cells, whilst the pellet that 
contained the HBP was discarded. Control CM was prepared by pre-incubation with plain-agarose 
beads, to control for proteins in the CM that may bind non-specifically to agarose-beads and 
processed in the same way as for the CM without HBP. The fresh A231 cells were plated under the 
various conditions for either 4 or 20 hours, and cell morphologies examined by staining for F-actin. 
A231 cell phenotypes were analysed as described in 3.1.3. The experiments are described below.  
 
3.3.2 The Role of Secreted Heparin-Binding Proteins in F-actin Organisation  
From the fluorescent images, the A231 cells plated in fresh FGM for 4 hours displayed classic ‘kite’ 
shaped morphologies of migratory cells. The cells displayed F-actin-rich leading edges with a dense 
mesh-network of actin-like lamellipodia. Clear F-actin bundles were seen that spanned the cells; 
these are typical of F-actin stress fibres. Naïve A231 cells plated for 20 hours in fresh FGM displayed 
the same F-actin phenotypes (Figure 3.10). Likewise, the naïve A231 cells plated in control CM for 
4 hours showed strong F-actin leading edges and an abundance of F-actin stress fibers and 
lamellipodial actin networks (Figure 3.9). These F-actin phenotypes were also seen in naïve A231 
cells plated in control CM for 20 hours. Overall, these results suggest that in fresh-FGM and control 
CM, naïve A231 cells display a typical migratory phenotype, as seen in the previous experiment 
(3.1.2).  
In general, A231 cells plated for 4 hours in CM depleted of HBP displayed fewer of the F-actin 
structures associated with a migratory phenotype. The A231 cells appeared much smaller. As shown 
in detail in the Insert Panel, F-actin appeared mostly more diffuse throughout the cells with little 




actin stress fibers (Figure 3.9). At the 20 hour timepoint, A231 cells plated in CM depleted for HBP 
appeared more spread. The F-actin generally appeared more diffuse than in cells plated in the 
control conditions. A231 cells plated in CM without HBP also had fewer F-actin stress fibres spanning 
the cells and limited evidence of lamellipodia network on the edges of the cells (Figure 3.10).  
Thus, the depletion of HBP from CM of A231 cells appeared to reduce A231 cell spreading and the 
organisation of F-actin. This effect on F-actin was most clear at the 4-hour timepoint and was less 









Figure 3.9. F-actin Localisation in MDA-MB-231 Cells Plated in Control CM, CM without 
Heparin-Binding Proteins (w/o HBP) or Fresh FGM for 4 hours. Cells were fixed after 4 hours 
stained with Phalloidin-Atto565 to show F-actin organisation. Top Row displays higher magnification 
of the boxed area from Second Row (63x frame). Confocal Images are displayed as Maximum 





Figure 3.10. F-actin Localisation in MDA-MB-231 Cells Plated in Control CM, CM without 
Heparin-Binding Proteins (w/o HBP) or Fresh FGM for 20 hours. Cells were fixed after 20 
hours and stained with Phalloidin-Atto565 to show F-actin organization. Top Row displays 
higher magnification of the boxed area from Second Row (63x frame). Confocal Images are 





3.3.3 The Effect of Depletion of Heparin-Binding Proteins on MDA-MB-231 Cell Area 
Images from the above experiments were also used to quantify effects of depleting HBP on cell 
areas, as in 3.1.3. The quantification of cell areas for each condition is presented in Figure 3.11.  
The data showed that the mean cell areas of A231 cells were not significantly different when plated 
in fresh FGM or control CM, either at 4 hours or 20 hours. In contrast, the A231 cells plated in CM 
depleted of HBP had reduced cell areas and this reduction in cell area was significantly different 
from that of cells plated in control CM or fresh FGM. This difference was consistent at 4 and 20 hour 
plating times.  
Overall, the results show that when CM is depleted of HBP it has reduced activity to stimulate cell 


















Figure 3.11. Quantified Comparison of MDA-MB-231 Cell Areas After Plating for 4 hours (A) or 
20 hours (B) in CM Depleted for HBP. Dot plots shows the cell areas; black line the mean values. 
Areas were quantified from confocal Maximum Intensity Z-Projection images. Cell areas are taken 



















3.4 Analysis of the PDIA3-Dependent Secretome of MDA-MB-231 Cells by TMT-Based 
Quantitative Proteomic 
As shown in section 3.1 and 3.3, analysis by immunofluorescence after treatment of naïve A231 
cells with A231 CM, showed that secreted PDIA3-dependent proteins or secreted heparin-binding 
proteins each had activity to promote cell spreading and pro-migratory organisation of F-actin. The 
next line of investigation sought to identify what heparin-binding proteins are in the PDIA3-dependent 
secretome.  
Identification of proteins was carried out by TMT-based quantitative proteomics on serum-free 
conditioned media (CM) from A231 cells. However, TMT-proteomics requires a more concentrated 
protein sample than CM itself can provide. To concentrate the secreted proteins, only the heparin-
binding fractions of the CM was used in TMT-proteomics. As explained in 3.3, the heparin-binding 
proteins (HBP) from the CM of A231 cells was shown to have activity to promote spreading and F-
actin organisation in naïve recipient cells. Based on previous experiments on fibroblasts (Hellewell 
et.al., manuscript in preparation), it is likely that proteins in the PDIA3-dependent secretome include 
heparin-binding proteins and so the heparin-binding fraction of the A231 CM would be enriched for 
the PDIA3-dependent proteins that can promote cell spreading and a migratory phenotype. The 
heparin-binding fraction of CM was used in TMT-proteomics, by binding proteins to high affinity 
heparin-agarose beads as in section 3.3. 
CM was prepared as described as in Methods 2.7.2, but at larger scale to produce 32ml of each CM. 
The use of serum-free media was to avoid the complexity of having heparin-binding proteins from 
foetal calf serum included in the analysis, as stated in 3.1.1. In addition, non-specific agarose-binding 
proteins were removed from CM by a first incubation with plain (unconjugated) agarose beads. Extra 
precaution was taken to very thoroughly wash cells in serum-free medium after trypsinisation to 
remove FBS and any other contaminants. Each CM was also filtered through a 0.45µm Stericup-HV 
Sterile Vacuum Filtration System to remove all cell debris that had not been removed during washing 
of cells. The full protocol is given in Methods 2.11.2. The final heparin-bead affinity sample were 
resuspended in SDS-PAGE sample buffer with 100mM DTT and then prepared for TMT-proteomics 
(Methods 2.11.3). Four independent repeated experiments were carried out. Each pair of control and 
test samples were run as a pair in the LCMS using an Orbitrap Fusion Tribrid mass spectrometer 
(Methods 2.11.3).  
From the lists of proteins identified (by at least 1 unique peptide per protein) in each experiment, the 
proteins identified in all four biological repeats were pooled and a paired Student’s t.test was used 
to compare each protein’s abundance in the DMSO and 16F16 conditions (Appendix I) and then 
the significance was normalised (-log10p.value) around zero. Change in protein abundance was 
considered significant for ±2-fold difference. A total of 345 proteins were identified to be PDIA3-




inhibited condition (p≤0.05 and at least 2-fold decrease in abundance). There were no proteins that 
increased significantly in the CM of cells treated with 16F16 (Figure 3.12). 
The proteins were then filtered to those with a significant false discovery rate of under 0.05 (q≤0.05). 
It was important to remove proteins that could be false positives to improve reproducibility. This left 
80 proteins that were decreased by at least 2-fold in the CM of cells treated with 16F16, here 
collectively termed the PDIA3-dependent, heparin-binding secretome. The names of genes 
encoding the 80 proteins are displayed in Figure 3.13.   
The 80 reproducible and significantly decreased proteins (filtered protein dataset) were then split by 
their subcellular location according to UniProt’s curated database. In total there were 48 extracellular 
proteins, 30 intracellular proteins and two proteins that are both intracellular and extracellular (Figure 
3.14). The proteins found in both subcellular locations were treated for further analysis as 
intracellular proteins.  
It was also examined whether any of the 80 proteins are known HBP or known PDIA3 substrates. 
12 of the proteins were known to be heparin-binding and 4 are known substrates of PDIA3 (Table 
3.1). The 48 extracellular proteins were then split by function according to UniProt. They covered a 





Figure 3.12. PDIA3-Dependent, Heparin-Binding Secreted Proteins of MDA-MB-231 Breast 
Cancer Cells. Cells were treated with either 5µM 16F16 or equivalent volume of DMSO and the 
heparin-binding fractions of the CMs collected for TMT-Base Quantitative Proteomic Analysis. 
Dashed vertical lines represent ±2-fold change, vertical green line represents P=0.05 and vertical 
black line marks 0-fold change. White points represent the 107 proteins with a p-value significance 
over p≤0.05. Results pooled from four independent repeats.  Gene names are given for the most 







Figure 3.13. Zoom in of Volcano Plot: The 80 Proteins Significantly Decreased in the PDIA3-
Dependent, Heparin-Binding Secretome. Enlarged area of Figure 3.12 to show gene name for 
all the proteins decreased significantly (p≤0.05) by at least 2-fold. Results compiled from four 





Figure 3.14 Venn Diagram of the Subcellular Locations of the 80 Filtered PDIA3-Dependent, 
Heparin-Binding Proteins from TMT-based Quantitative Proteomics. Analysis performed 













Table 3.1. Known Heparin-binding and PDIA3 Substrates within the 48 Extracellular Proteins in the 
Filtered TMT-Proteomics dataset. These proteins were identified with p≤0.05 and ±2-fold change. 
Information from (Jessop et al., 2007b; Carbon et al., 2009). 
Gene Name  Log2FoldChange Adjusted p.Value  Heparin Binding  Known PDIA3 Substrate  
AGRN -1.740031244 0.020564834 
 
X 
ANOS1  -1.328769116 0.039878104 
  
APLP2 -1.7325747 0.042460678 X 
 
APOB -1.503851602 0.047603722 X 
 
APOM -1.410774935 0.003684174 
  
APP -1.921346147 0.029152123 X 
 
AREG -1.622976813 0.041399566 
  
CLSTN1 -1.816571703 0.04049051 
  
CLSTN3  -1.819656719 0.034326707 
  
COL12A1 -2.440656945 0.015074592 
  
COL14A1 -1.518770853 0.026510089 
  
COL2A1 -1.721441198 0.037981018 
  
COL5A1 -2.714191378 0.009684439 X 
 
CTGF -1.798645462 0.023037412 X 
 
CYR61 -1.331412956 0.043869839 X 
 
DKK1 -2.273822434 0.022797747 
  
ECM1 -1.926160999 0.028414135 
  
EEF2 -1.370068307 0.031692122 
  
F13A1 -1.394352844 0.048796574 
  
FBN1 -1.710491537 0.008340685 X 
 
FN1 -2.154812212 0.038767829 X 
 
FST -1.716793348 0.004366334 
  
HSPG2 -1.650667918 0.012861 
  
IGFBP4 -1.818854668 0.034951891 
  
IGFBP7 -1.88504472 0.039242523 
  
ITIH2 -1.698212016 0.018107777 
  
LAMA5 -2.135670205 0.002123124 
  
LAMB1 -2.286367447 0.01352354 
 
X 
LAMC1 -2.037300052 0.012577036 
  
LOXL2 -2.525054697 0.003104902 
 
X 
MARS -1.389855912 0.025437063 
  
MST1 -2.101881659 0.00771543 
  
NOG -2.103324073 0.012112559 
  
NRP1 -1.555604049 0.028277882 X 
 
PLAT -2.233689247 0.020869607 
  
PLAU -3.023536975 0.004244137 
  
PRSS23 -2.416079339 0.013401314 
  
PTPRS -1.755153917 0.007818062 X 
 
QSOX1 -1.596009923 0.012145822 
  
RARRES2 -1.861788834 0.018172451 
  
SERPINE1 -2.020721715 0.031316122 
  
SOD3 -1.439321413 0.016155273 X 
 
SPON1 -1.484953201 0.016398411 
  
SRPX -2.921942411 0.003772864 
  
TGFB2 -1.782004114 0.011589291 
  
TGM2 -1.763084349 0.017637331 
 
X 
THBS1 -2.346490206 0.011240091 X 
 
TIMP1 -1.618457234 0.025661055 
  
TIMP2 -1.641731253 0.032189028 
  
TMEM132A -2.378741874 0.005597112 







Figure 3.15. Pie Chart of the Functions of the 48 Extracellular Proteins in the PDIA3-
Dependent, Heparin-binding Filtered Dataset identified by TMT-Proteomics. Analysis was 









3.4.1 Analysis of the Filtered Protein Dataset by Gene Ontology and Other 
Bioinformatics Tools  
The PDIA3-dependent, heparin-binding secretome was then analysed by online curated 
databases. PDIA3 is an oxidoreductase and its substrate glycoproteins are likely to contain 
disulphide bonds in their tertiary structure. The domains in the 80 protein, filtered protein dataset 
were investigated by InterProScan. The domains were recorded if they were cysteine-rich or 
contained a critical disulphide bond; the results were then displayed as a mosaic plot (Figure 
3.16). Nearly all the extracellular proteins from the TMT-proteomics dataset contained at least 
one domain that fulfilled the criteria stated above, with 6 exceptions (quiescin sulfhydryl oxidase 
1 (QSOX1), retinoic acid receptor responder 2 (RARRE2), serpin family E member 1 
(SERPINE1), superoxide dismutase 3 (SOD3), spondin-1 (SPON1) and transmembrane protein 
123 (TMEM123A)). The most common domain was an EGF-like domain. Only one of the 
intracellular proteins from the TMT-proteomics dataset (ribonuclease A family member 4 




Extracellular Set (48 Proteins) 
 
Figure 3.16. Mosaic Plot Displaying Extracellular, PDIA3-Dependent, Heparin-Binding Proteins with Cysteine-Rich Domains. 
Domains were identified using InterProScan and those displayed are either cysteine-rich or contain a critical disulphide bond 
(https://www.ebi.ac.uk/interpro/search/sequence-search). Tiles in dark purple show which proteins have the respective domain. The 





Intracellular Set (32 Proteins) 
 
Figure 3.17. Mosaic Plot Displaying Intracellular PDIA3-Dependent, Heparin-binding Proteins with Cysteine-Rich Domains. 
Domains were identified using InterProScan and those displayed are either cysteine-rich or contain a critical disulphide bond 
(https://www.ebi.ac.uk/interpro/search/sequence-search). Tiles in pink show which proteins have the respective domain. The Mosaic 




3.4.2 Gene Ontology  
To understand the cellular relevance of the identified PDIA3-dependent, heparin-binding proteins, 
the 80-protein filtered dataset was further analysed by Gene Ontology (GO). GO gives reliable 
cellular attributes of genes and proteins (Subramanian et al., 2005). The Gene Set Enrichment 
Analysis (GSEA) database was used to find the top 10 GO terms of the three main GO domains 
(Biological Process, Cellular Component and Molecular Function) that were significantly enriched 
in the protein dataset (Figure 3.18, Figure 3.19 & Figure 3.20). GO can also analyze the 
enrichment of one or more genes for a GO term.   
A second independent GO tool was used to confirm the findings from the GSEA database. This 
was done with Gene Ontology Enrichment Analysis and Visualization Tool (GOrilla) (Eden et al., 
2009). This tool reports on significance through shade coding and was used to investigate the 
main GO domains: GO Biological Process, GO Cellular Component and GO Molecular Function 
for the extracellular and intracellular proteins.  
First the 48 extracellular proteins were analysed at both portals and many GO terms that relate 
to cancer metastasis were found. At GSEA, the extracellular proteins were enriched for terms 
Extracellular Space, Receptor Binding, Regulation of Multicellular Organismal Development and 
Locomotion (Figure 3.18 & Figure 3.19). The GOrilla analysis of the extracellular proteins found 
many of the same GO terms for all three major GO domains. Only the most significant GO 
Biological Process terms from GOrilla are shown in Figure 3.21. These include Extracellular 
Matrix, Endoplasmic Reticulum Lumen, Locomotion, Integrin Binding and Extracellular Matrix 
Structural Constituent. Likewise, GO Cellular Component showed many significantly-enriched GO 
terms, particularly significant was Collagen-Containing Extracellular Matrix (Figure 3.21 & Figure 
3.22).  
The 32 intracellular proteins were analyzed by the same procedures. There was no overlap in any 
of the top 10 significantly enriched GO terms between the extracellular and intracellular proteins 
using the GSEA curated database. Most of the enriched GO terms were associated with 
ribosomal proteins (Figure 3.23, Figure 3.24 & Figure 3.25). The GO terms identified by GOrilla 
were very similar to the GO terms found enriched in GSEA, such as Ribosomal Subunit and DNA 
Packing Complex. Overall, the intracellular proteins were associated with fewer GO terms and 







Figure 3.18. Mosaic Plot: Gene Set Enrichment Analysis of the Extracellular Proteins in the 80-protein dataset. Analysis of the 
Molecular Signature Database (http://software.broadinstitute.org/gsea/index.jsp) showing the top 10 terms identified as significant for 





Figure 3.19. Mosaic Plot: Gene Set Enrichment Analysis of the Extracellular Proteins in the 80 protein dataset. Analysis of the 
Molecular Signature Database (http://software.broadinstitute.org/gsea/index.jsp) showing the top 10 terms identified as significant for 





Figure 3.20. Mosaic Plot: Gene Set Enrichment Analysis of the Extracellular Proteins in the 80 protein dataset. Analysis of the 
Molecular Signature Database (http://software.broadinstitute.org/gsea/index.jsp) showing the top 10 terms identified as significant  for 








Figure 3.21. Gene Ontology Enrichment Analysis and Visualization Tool Analysis (GOrilla) 
on the Extracellular Proteins for the GO Domain Biological Process. http://cbl-
gorilla.cs.technion.ac.il/. 48 extracellular proteins from TMT-Proteomics 80 protein dataset. 
Colour key: White p>10-3; Yellow 10-3< p>10-5; Light Orange 10-5< p>10-7; Dark Orange 10-7<p>10-






Figure 3.22. Gene Ontology Enrichment Analysis and Visualization Tool (GOrilla) on the   
Extracellular Proteins for the GO domain Cellular Component (Top) and Molecular 
Function (Bottom). http://cbl-gorilla.cs.technion.ac.il/. 48 extracellular proteins from TMT-
Proteomics 80 protein dataset. Colour key: White p>10-3; Yellow 10-3< p>10-5; Light Orange 10-5< 






Figure 3.23 Mosaic Plot: Gene Set Enrichment Analysis of the Intracellular Proteins from the 80 protein dataset. Analysis of the 
Molecular Signature Database (http://software.broadinstitute.org/gsea/index.jsp) showing the top 10 terms identified as significant for 






Figure 3.24. Mosaic Plot: Gene Set Enrichment Analysis of the Intracellular Proteins in the 80 protein dataset. Analysis of the 
Molecular Signature Database (http://software.broadinstitute.org/gsea/index.jsp) showing the top 10 terms identified as significant for 







Figure 3.25 Mosaic Plot: Gene Set Enrichment Analysis of the Intracellular Proteins in the 80 protein dataset. Analysis of the 
Molecular Signature Database (http://software.broadinstitute.org/gsea/index.jsp) showing the top 10 terms identified as significant for 









Figure 3.26. Gene Ontology Enrichment Analysis and Visualisation Tool (GOrilla) on the 
Intracellular Proteins from the 80 protein dataset.  GO domains Biological Process (Top), 
Cellular Component (Bottom Left) and Molecular Function (Bottom Right)( http://cbl-
gorilla.cs.technion.ac.il/). 32 intracellular proteins were included from the TMT-Proteomics 
dataset. Colour key: White p>10-3; Yellow 10-3< p>10-5; Light Orange 10-5< p>10-7; Dark Orange 




In GSEA, every identified GO term was very significantly enriched, enrichment scores are 
summarised displayed in Figure 3.27 and enrichment significance (p.values) are displayed in 
Figure 3.28. For the extracellular proteins, every GO term for Biological Process, Cellular 
Component and Molecular Function was very significant, with the least significant GO term having 
a p.value of <2.31 x10-9 (GO Molecular Function: Peptidase Inhibitor Activity). The most significant 
GO term was Extracellular Space (p= 1.01 x10-41). The GO Cellular Component domain had the 
highest enrichment score, especially for the terms Platelet Alpha Granule Lumen and Basement 
membrane (Figure 3.27). The GO domain Molecular Function showed 11 proteins known to be 
heparin-binding proteins, validating the enrichment of the CM by heparin-binding affinity. 
The intracellular proteins had less enrichment and less significant GO correlations than the 
extracellular proteins. The most highly enriched GO terms for the intracellular proteins were 
Protein Complex Binding and Cytosolic Part (Figure 3.27). The intracellular GO Molecular 
Function had less significant p values; the least significant being Kinase Binding (p= 5.02 x10-5) 
(Figure 3.28). 
In GSEA, the GO domains “Hallmarks” and “Cancer Modules” were also investigated for the 
extracellular protein set. These domains were not investigated for the intracellular proteins 
because there was no significant association of the intracellular proteins with GO terms in these 
categories. The Hallmarks domain revealed enrichment of 18 proteins involved in Epithelial-
Mesenchymal Transition (EMT) (Figure 3.29 & Figure 3.31A), with p value of 8.79x10-29 (Figure 
3.31B). Many of the proteins were also associated with Cancer Modules (Figure 3.30). The GO 
Hallmarks associations were less significant: the least significant was TGFβ signaling with p.value 
=2.4x10-5 (Figure 3.31 3.31B).  
Thus, two separate GO-based tools (GSEA and GOrilla) produced very similar outputs for 
analysis of the intracellular and extracellular proteins of the TMT dataset. The extracellular 
proteins had a high correlation with an array of GO terms relating to cancer, but in this set no 








Figure 3.27. Gene Set Enrichment Analysis of Extracellular and Intracellular Proteins. Bar 
charts of the top 10 terms from the analysis of the Molecular Signature Database 
(http://software.broadinstitute.org/gsea/index.jsp) with the 48 extracellular (top row) or 32 
intracellular proteins (bottom row) of the 80 protein dataset, according to enrichment of GO terms  
within the 3 categories of GO classification. In each chart, the GO terms are plotted in order of 







Figure 3.28. Enrichment p.values for Gene Set Enrichment Analysis of Extracellular and 
Intracellular Proteins. Table of the top 10 terms from the Molecular Signature Database 
(http://software.broadinstitute.org/gsea/index.jsp) with the 48 extracellular or 32 intracellular 







Figure 3.29. Mosaic Plot: Gene Set Enrichment Analysis of the Extracellular Proteins in the 80 Protein Dataset. Analysis of the 
Molecular Signature Database (http://software.broadinstitute.org/gsea/index.jsp) showing the top 10 terms identified as significant for 






Figure 3.30. Mosaic Plot: Gene Set Enrichment Analysis of the Extracellular Proteins in the 80 Protein Dataset. Analysis of the 
Molecular Signature Database (http://software.broadinstitute.org/gsea/index.jsp) showing the top 10 terms identified as significant for 








Figure 3.31. Gene Set Enrichment Analysis of Extracellular Proteins. (A) Bar charts of the top 
10 terms enriched from the Molecular Signature Database analysis  
(http://software.broadinstitute.org/gsea/index.jsp) of the indicated categories with the 48 
extracellular proteins from TMT-Proteomics dataset. In each chart, the GO terms are plotted in 
order of significance (considering p.value, false-discovery rate and enrichment); on the left is the 
most significant GO term and on the right is least significant GO term. (B) Enrichment p.values 







3.4.3 Analysis of the Extracellular, PDIA3-Dependent, Heparin-binding Proteins by 
Protein Association Networks  
It was also important to consider how the proteins in the PDIA3-dependent 80 protein dataset 
might be interacting. This was investigated using Search Tool for the Retrieval of Interacting. 
Genes/Proteins (STRING) (Szklarczyk et al., 2019). STRING uses a curated database of protein 
interactions such as co-expression and protein homology. STRING extracts protein database 
associations from either Biocarta, BioCyc, GO, KEGG or Reactome. A STRING analysis was first 
done on all 80 proteins in the filtered dataset and carried out at medium confidence (0.40 
interaction score). The interaction map appeared to have three focal networks: an extracellular 
protein cluster, a histone protein cluster and a ribosomal protein cluster, that was linked by a few 
proteins from the curated database (cyan line). Only 11 of the 80 proteins had no interactions 
(Figure 3.32).   
The STRING analysis was repeated on either the 32 intracellular or the 48 extracellular proteins, 
again using medium confidence, with no text or database interactions included. The extracellular 
interaction map showed three distinct networks. The plasminogen activator, tissue type(PLAT)/ 
plasminogen activator, urokinase(PLAU)/SERPINE1 network included the proteins that account 
for the enrichment in the Platelet Alpha Granule Lumen GO term and the laminin subunit alpha-5 
(LAMA5)/ laminin subunit gamma-1(LAMAC1)/ laminin subunit beta-1(LAMB1) were the proteins 
involved in GO terms relating to the basement membrane (Figure 3.33). The largest network 
included 15 proteins, 9 of which were associated with the GO term Epithelial-Mesenchymal 
Transition. LAMA5 and LAMAC1 were also included in the GO EMT but were not linked to the 
extensive protein network (Figure 3.33).  
The intracellular proteins split into two main interaction groups, one representing ribosomal 
proteins and the other histone interactions, these groups did not link together (Figure 3.33). There 
was only one mapped protein interaction between the intracellular proteins and an extracellular 
protein: staphylococcal nuclease and tudor domain containing 1 (SND1) had an experimentally 
determined and a curated database interaction with fibronectin (FN1) (Figure 3.33) (Humphries 






Figure 3.32. Output of Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) for the 80  Protein Dataset 
(https://string-db.org/). All the proteins are identified by gene name. Line Colour Key:  Black: Co-expression, Cyan: Curated from 








Figure 3.33. Output of separate STRING analyses for the Extracellular or Intracellular 
Proteins Identified from the 80 Protein TMT-Proteomics Dataset (https://string-db.org/). Line 
Colour Key:  Black: Co-expression, Green: Gene Neighborhood, Lilac: Protein Homology, Pink: 




Overall the analysis by GO and other bioinformatics showed evidence that the extracellular proteins 
in the PDIA3-dependent, heparin-binding secretome are involved in many biological, cellular and 
molecular processes associated with cancer metastasis, such as Locomotion, Integrin Binding and 
Structural Extracellular Matrix. GO analysis also validated the CM experimental protocol, showing 
that many of the identified proteins were known heparin-binding proteins found in the ECM or the 
ER lumen. Also, many of the extracellular proteins contained disulphide bonds. The analysis by 
STRING highlighted that the major interaction network associated with these proteins included 
proteins associated with the process of EMT. 
3.4.4 Validation of Selected PDIA3-Dependent, Heparin-binding Proteins in the CM of A231 
Cells by Immunoblotting  
The proteins identified in the TMT-proteomics dataset were identified with a range of protein 
abundance changes and significances (p.value) (Figure 3.13). Insulin Growth Factor Binding Protein 
7 (IGFBP7) (p=0.0392) was an extracellular protein close to the p=0.05 significance cut-off. Lysyl-
Oxidase Like 2 (LOXL2, p=0.0031), also an extracellular protein, was amongst the most significant 
identifications with the greatest fold change. To confirm results from the TMT-based quantitative 
proteomics, immunoblotting experiments were carried out on these selected proteins, IGFBP7 and 
LOXL2. 
Cell lysates and CM were prepared as described in Methods 2.7. The CM preparation was identical 
to the TMT-quantitative proteomics workflow. The immunoblots were repeated on three independent 
samples.  
The immunoblots for IGFBP7 (30kDa) revealed a band at 30kDa across all three repeats, with a 
much stronger band in the CM from cells treated with DMSO (Figure 3.34). Repeat one also showed 
the presence of IGFBP7 in the cell lysates. Quantification of the bands in the CM showed that 
IGFBP7 abundance was significantly different between the CM from cells treated with DMSO or 
16F16, albeit that a loading control was not available to normalise the CM loading. This result was 
consistent with the TMT-proteomics identification that IGFBP7 is a PDIA3-dependent, heparin-
binding protein in the A231 secretome.  
All blots for LOXL2 (87kDa) showed a band at just under 100kDa and a second band around 75kDa 
in the CM but no band in the cell lysates (Figure 3.34). Extracellular LOXL2 can be cleaved by serine 
proteases into a 65kDa protein (Okada et al., 2018) and cleaved LOXL2 is very likely the second 
band at around 75kDa. Only one blot showed a clear reduction of LOXL2 in the CM after treatment 
of 16F16. Two blots showed an equally visible band for LOXL2 in the CM treated with 16F16. When 
quantified there was no statistically significant difference between the abundance of LOXL2 in the 












Figure 3.34. Assessment of IGFBP7 and LOXL2 in the CM of A231 Cells. (A) Proteins were 
separated on a 10% polyacrylamide gel under reducing conditions, transferred to PVDF membrane 
and probed with antibodies to IGFBP7 or LOXL2. Images shown from 3 experimental repeats for 
each protein.  Key: CL: Cell Lysate, CM: Conditioned Media. (B) Band quantification using Synegene 





3.5 Impact of PDIA3 inhibition on MDA-MB-231 Tumor Cell Spheroid Formation  
Culturing cancer cells in 3-dimensions better reflects in vivo tumours (Nath and Devi, 2016). To 
obtain 3D cultures, cells can be grown on non-adherent surfaces, meaning that cells will adhere to 
each other, rather than the plastic surface, and therefore form a spheroid. To address whether PDIA3 
also has a role in A231 phenotype in a 3D culture, A231 cells were cultured in scaffold-free 3D 
conditions (Methods 2.9) and the rate of spheroid formation was investigated by live-cell imaging 
under control conditions or after addition of 16F16 to inhibit PDIA3. 
3.5.1 Cell Seeding Density and Spheroid Formation 
It was first important to consider the plating density of cells suitable to form a spheroid and how long 
a spheroid would take to form. Based on prior publications, A231 cells were seeded at 40, 200, 1000, 
5000 or 10000 cells per well in a scaffold-free, 96-well round bottom ultra-low attachment plate. 
These are coated with an inert substrate that prevents cell adhesion to the surface and forces the 
cells to adhere to each other. This plate was imaged over 3 days in an IncuCyte Microscope which 
has integral heating, gassing and humidity (Methods 2.9.1). At each cell density, the effect of DMSO 
(0µM 16F16 control), 50µM 16F16, or medium with supplement only (general control) on the rate of 
spheroid formation was measured. A digital phase contrast image of each well was taken by the 
IncuCyte® System every 2 hours for at least 66 hours.  
The images of cells at the end of the 66-hour incubation are displayed in Figure 3.35. At cell densities 
of 5000 and 10000 cells/well, the control and DMSO-only conditions showed a grey ‘haze’ in the 
centre of the cell cluster. This is because the cells in the centre are above the plane of focus of the 
image and so appear out of focus. In these conditions, one spheroid was formed per well. There was 
no indication of spheroid formation at other seeding densities. There was no evidence of spheroid 
formation at any cell density for cells treated with 50µM 16F16, yet the cell sheet appeared healthy 
in the images.  
The area occupied by cells was then quantified using ImageJ software. As a spheroid forms the area 
of the visible “patch” of cells decreases (Elliott and Yuan, 2011; Härmä et al., 2014; Sodek et al., 
2012). Change in area with time is displayed in Figure 3.36. For conditions of 40 and 200 cells/well 
there was no decrease in area over 66 hours incubation, in agreement that these cells did not form 
visible spheroids. Cell densities above 1000 cells/well all showed a decrease in “patch” area. For 
1000 cells/well the decrease occurred in the first 20 hours, for 5000 cells/well over the first 40 hours, 
and for 10000cells/well, “patch” area decreased between 20 and 50 hours. In general, adding DMSO 
alone seemed to reduce spheroid compaction compared to the general control. More strikingly, cells 
treated with 50µM 16F16 did not form spheroids: all seeding cell-densities maintained a high area 
throughout the 66-hour incubation. This supports the endpoint phase contrast images, which showed 





Figure 3.35. End Point Phase Contrast Images of A231 Cell Spheroid Formation. Defined 
number of cells were plated in wells of a scaffold-free 96-well round bottom ultra-low attachment 
plate in media supplemented with serum and either 50 µM 16F16 or DMSO only. Images were taken 







Figure 3.36. Rate of Spheroid Formation at Different Seeding Densities. MDA-MB-231 cells were 
seeded as shown in wells of a scaffold-free 96-well round bottom ultra-low attachment plate and 
incubated for 66 hours with an image taken every 2 hours. Each line shows the mean area of cells 

















The phase contrast images did not provide enough detail to demonstrate clearly that spheroids had 
formed as 3D objects. When analysing cells in 3D culture it is important to consider the Z-axis. 
Therefore, spheroids were stained for F-actin and imaged by a confocal laser scanning microscope. 
Six spheroids grown from 10000 cells/well, under control conditions, were fixed after 66 hours of 
incubation, transferred to a flat-bottomed 96-well plate using a pipette and then permeabilised and 
stained with Phalloidin. The spheroids were moved to a 96-well flat bottom plate since the confocal 
microscope cannot focus accurately on structures in round-bottomed wells. Z-stack images were 
taken through the depth of each spheroid and 3D image reconstructions were made in Volocity®. 
The Z-axis of the spheroids was around 80-100m. The spheroids looked slightly disrupted, this 
could be because cells on the exterior were damaged during washing and transfer steps (Figure 
3.37). The image reconstructions confirmed that the spheroids were 3D objects.  
3.5.2 Effect of Inhibition of PDIA3 on Rate of Spheroid Formation 
The seeding densities of 5000 and 10000 cells/well were taken forward to investigate the effect of 
PDIA3 inhibition on spheroid formation in more depth. The 96-well spheroid plate was set up for 
spheroid analysis as described in 3.5.1, but this time including a range of concentrations of 16F16. 
Cells were incubated and imaged as before, and spheroid area quantified using ImageJ. At both cell 
densities, cells treated with DMSO-only decreased in area, in agreement with results from 3.5.1 that 
spheroids have formed (Figure 3.38 A&B). However, at 10000 cells/well, there was a clear 
separation of areas between cultures treated with 10, 17.5 or 25 µM 16F16, which did not decrease 
in area with time, and the other concentrations tested (Figure 3.38 B). However, 16F16 
concentration did not have a linear relationship to area decrease. At 5000 cells/well, 5µM and 12.5µM 
16F16 resulted in similar final areas, and 10µM- and 25µM-treated cells had closer final areas than 
cells treated with 25µM or 17.5µM 16F16 (Figure 3.38 A). Overall, above a threshold of about 10µM 
16F16, PDIA3 inhibition blocked spheroid formation.  
The decrease in area of cells (i.e. compaction of cells) was most pronounced most between 20 and 
50 hours (Figure 3.38 A&B). Figure 3.39 shows phase contrast images of the cells over this period.  
Between 20 and 50 hours after plating, cultures treated with DMSO only showed a clear reduction 
in “patch” area, gain of a circular form and an out of focus centre, indicating 3D-spheroid formation. 
With increasing concentration of 16F16, this phenotype was not apparent at 50-hours, with cells 






Figure 3.37. Fluorescence Microscopy Images of MDA-MB-231 Cell Spheroids. 10000 cells/well 
were plated in a scaffold-free 96-well round bottom ultra-low attachment plate and incubated for 72 
hours. Cells were then fixed, permeabilized and stained with Phalloidin. 6 spheroids represent 6-
replicates from one experiment. Images were taken on a confocal laser scanning microscope (10x 
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 16F16 (µM) 
Cells 0 1 2.5 5 10 25 
R2 
5000 0.2247 0.9057 0.8397 0.9737 0.9964 0.9316 
10000 0.6044 0.3938 0.9972 0.991 0.9801 0.9778 
        
 
Figure 3.38. The Effect of PDIA3 Inhibition on the Rate of Spheroid Formation by MDA-MB-231 
cells. Defined number of cells were plated in wells of a scaffold-free 96-well round bottom ultra-low 
attachment plate in DMEM media supplemented with serum and either 1, 2.5, 5. 10 or 25 µM 16F16, 
or DMSO only. Images were taken using a IncuCyte® S3 Live-Cell Analysis System from 0 hours 
when cells were seeded and then every 2hours until 66 hours. (A&B) Spheroid formation with 
increasing 16F16 concentration. (C&D) Reciprocal plots of spheroid area against time with Line of 
Best Fit and slope gradient (m). The line of best fit was calculated by Linear Regression. (E) Table 
of goodness of fit (R2). n=3 experiments, one spheroid per well over 6 replicate wells per experiment 





Figure 3.39. Phase Contrast Images of A231 Cell Spheroid Formation at 20 and 50 hours. 
Defined number of cells were plated in wells of a scaffold-free 96-well round bottom ultra-low 
attachment plate in media supplemented with serum and either 1, 2.5, 5. 10 or 25 µM 16F16, or 
DMSO only. Images were taken using a IncuCyte® S3 Live-Cell Analysis System from 0 hours when 






To better understand the rate of area change, i.e rate of spheroid formation, a reciprocal plot of cell 
area against time was plotted (Figure 3.38 C&D). To capture the initial rate of change, these plots 
were made for the period 20 hours to 50 hours only. The slopes of the lines were then calculated (m 
= (y2 − y1)/ (x2 − x1)). At both seeding densities, cells treated with DMSO only had the steepest 
gradient, i.e., the fastest rate of change (5000 cells/well: m= 5.641x10-8, 10000 cells/well: m= 
7.227x10-8). As 16F16 concentration increased, the rate of spheroid formation decreased (shown by 
a smaller gradient). This agrees with observations from the phase-contrast images that spheroid 
formation was reduced at high concentrations of 16F16.   
The line of best fit was calculated using Linear Regression. The goodness of fit (R2) shows how well 
the line of best fit matches the data and is most accurate when R2=1. Higher concentrations of 16F16 
(5µM, 10µM, 25µM) had R2 values closer to 1 (R2>0.80) for both cell seeding densities. This shows 
that the line of best fit is likely to be representative of the data. At 1µm 16F16, the line of best fit for 
5000 cells/well fit the data well (R2>0.90) but for 10,000 cells/well the fit was very low. This was also 
true for the line of best fit representing the DMSO condition, R2 values were 0.2247 and 0.6044 for 
5000 or 10000 cells/well (Figure 3.38 E). These results may indicate variability in cell plating steps 
or inaccuracies in the image processing.  
The final cell area at 50 hours was also compared between each condition (Figure 3.40 A&B). 
Statistical analysis was performed with two-way ANOVA with Tukey’s multiple comparison post-hoc 
test, this showed that 16F16 concentrations of 5µM and above had a statistically significant effect 
on the final spheroid cell area compared to the DMSO condition. Combining this result with 
information from the phase contrast images suggests that 5 µM is the threshold concentration of 
16F16 to inhibit spheroid formation.  
3.5.3 Effect of LOX Inhibition on MDA-MB-231 Spheroid Formation  
The TMT-proteomics experiments (3.4) revealed that Lysyl-Oxidase Like 2 (LOXL2) was one of the 
most significantly decreased proteins in the heparin-binding, PDIA3-dependent secretome dataset 
(Figure 3.12). LOXL2 is also a known substrate of PDIA3 (Jessop et al., 2007b) and in GO LOXL2 
is part of an Epithelial-to-Mesenchymal Transition signature. Its abundance is also highly associated 
with metastatic breast cancer ECM (Salvador et al., 2017). To investigate the possible contribution 
of LOXL2 to spheroid formation by A231 cells, LOXL2 was inhibited using β-aminopropionitrile 
(βAPN). βAPN is not LOXL2-specific but is an irreversible inhibitor of the LOX and LOX-like family 
of enzymes (Hutchinson et al., 2017).  
To attempt substantial LOXL2 inhibition, cells were pre-treated with 500M APN for 3 days before 
being plated into the 96-well spheroid plate. This time and βAPN concentration were used for prior 
experiments with fibroblasts (Rosini et al., 2018).  Spheroids were then grown as described in 3.5.1 
with the addition of either 0, 5, 50, 250, 500 or 1000M APN to wells seeded with 5000 or 10000 




Spheroids were formed in all conditions regardless of the APN concentration (Figure 3.42). The 
phase contrast images of the spheroids display the change in phenotype indicating a spheroid: an 
out-of-focus centre and circular, compacted arrangement of cells (Figure 3.41). 
The rate of area change was the same in all wells at both 5000 and 10000 cells/well, with the greatest 
area change between 20 and 50 hours (Figure 3.42). Thus, every well formed a spheroid regardless 


















0 vs. 1 0.7634 0.995 
0 vs. 2.5 0.3624 0.2378 
0 vs. 5 <0.0001 0.0007 
0 vs. 10 <0.0001 <0.0001 
0 vs. 25 <0.0001 <0.0001 








1 vs. 2.5 0.9872 0.5138 
1 vs. 5 0.0008 0.0031 
1 vs. 10 <0.0001 <0.0001 
1 vs. 25 <0.0001 <0.0001 
2.5 vs. 5 0.0071 0.2851 
2.5 vs. 10 <0.0001 <0.0001 
2.5 vs. 25 <0.0001 <0.0001 
5 vs. 10 0.0378 0.0004 
5 vs. 25 0.0029 <0.0001 
10 vs. 25 0.9562 0.8714 
 
Figure 3.40. Analysis of Final Spheroid Area from MDA-MB-231 Cells Grown in Different 
Concentrations of 16F16. (A&B) Defined number of cells were plated in wells of a scaffold-free 96-
well round bottom ultra-low attachment plate in DMEM media supplemented with serum and either 
1, 2.5, 5. 10 or 25 µM 16F16, or DMSO only. Images were taken using the IncuCyte® System and 
area quantified using ImageJ. Results show spheroid area at 50 hours. Plotted significance 
compares spheroid area to DMSO only spheroid area at 50hours. (C) Tables shows Tukey’s Multiple 
Comparison test of ANOVA results. Adjusted p.values highlighted (yellow) compare the spheroid 
area at 50 hours against the spheroid area treated with DMSO only. Non-highlighted (white) shows 








Figure 3.41. Phase Contrast Images of MDA-MB-A231 Cell Spheroids after βAPN Treatment. 
Cells were plated in 96-well round bottom ultra-low attachment plate with different βAPN 






Figure 3.42. The Effect of βAPN on the Rate of Spheroid Formation by MDA-MB-231 cells. Cells 
were seeded at either 5000 or 10000 cells/well in the presence of the indicated concentration of 
βAPN or DMSO-only control. Spheroid area was analyzed by the IncuCyte® System and quantified 













The main goal of this project was to identify the PDIA3-dependent secretome of A231 human breast 
cancer cells. The effect of PDIA3 on A231 breast cancer cells was investigated with a combination 
of 2D and 3D cell-based assays. Identification of the heparin-binding fraction of the PDIA3-
dependent secretome was then carried out by TMT-proteomics and validated by immunoblots. In-
depth bioinformatic analysis then suggested that the heparin-binding fraction of the PDIA3-
dependent secretome was associated with many Gene Ontology (GO) terms related to cancer 
metastasis such as cell-adhesion, EMT, ECM, locomotion and integrin binding (Subramanian et al., 
2005; Eden et al., 2009). 
Limitations of the research are that in each experiment PDIA3 was inhibited pharmacologically only 
with 16F16. 16F16 has not been proven to specifically target PDIA3 and potentially targets PDIA1 
and other proteins in the thioredoxin superfamily (Hoffstrom et al., 2010). It would be advantageous 
for further analysis of the PDIA3-dependent secretome to be achieved with a CRISPR-mediated 
PDIA3 gene editing or with siRNA to PDIA3, or other specific pharmacological inhibitors as they 
become available (Altieri et al., 2019).  
Furthermore, analysis of the PDIA3-dependent secretome has only been performed using one cell 
line (A231). There are a total of 26 basal breast cancer cell lines that can be divided into into basal 
A or basal B phenotypes depending on transcriptional profile: A231 represents only 1/14 of basal B 
breast cancer cell lines (Dai et al., 2017). Future analysis should analyse the PDIA3-dependent 
secretome in other basal cell lines (such as MDA-MB-157, BT549 and MCF10A). It may also be 
important to assess the impact of PDIA3 in explant cultures, as these organotypically cultured cells 
better represent in vivo conditions and present a more accurate ECM model (Marino et al., 2016). 
Specific outcomes of the research are discussed below.  
 
4.1 Cell-Based Experiments  
 2D Cell Culture  
The results from all the 2D cell-based experiments are summarised in Table 4.1A.  
Generally, the results from the 2D cell-based experiments suggest that the activity of PDIA3 
promotes phenotypes in A231 cells that are associated with in vitro metastatic behaviour-cell 
spreading and pro-migratory F-actin structures. Immunofluorescence was used to observe cell 
features that indicate pro-migratory capacity. Naïve A231 cells incubated with conditioned media 
(CM) from cells that had been pre-treated with 16F16 had fewer lamellipodia and stress fibres 
compared to cells grown in fibroblast growth medium (FGM) or CM from cells that had been pre-
treated with DMSO only. Average cell area and the apparent number of focal adhesions, both at 4 
and 20 hours of adhesion, was also significantly lower than for the two control conditions. The results 









Table 4.1. Summary of Data from the Cell-Based Experiments. Each feature is compared to the 
Fresh FGM Only condition. Key: HBP- Heparin Binding Proteins, L- lamellipodia, N/A- experiment 





The latter experiment was only performed once, and results would become clearer upon repetition. 
The naïve A231 cells incubated in CM that had been pre-treated with DMSO seemed to have less 
focal adhesions that when grown in fresh FGM. This shows that incubation with CM alone may have 
affected focal adhesions. It is also noteworthy that naïve A231 cells incubated for 20 hours in CM 
pre-treated with DMSO showed a significant decrease in cell spreading compared cells grown for 20 
hours in FGM. Perhaps the reason for the disparity is because the CM contains cellular waste 
products and apoptotic bodies that could be stressful or toxic to naïve cells, whilst the FGM is fresh 
and engineered for optimal cell growth. Efforts to remove cell debris were done by passing CM 
through a 0.22M syringe filter, allowing only proteins and small vesicles to pass through (Moussay 
et al., 2011). Despite this limitation, the CM of cells treated with 16F16 had a significantly different 
effect on cell behaviour, implicating PDIA3 activity in promoting phenotypic features characteristic of 
a pro-metastatic phenotype. 
The same type of 2D cell adhesion experiment was used to access the contribution of heparin-
binding proteins in the cell secretome. Although assessment of focal adhesions is a good parameter 
for measuring contractile migration, this was not carried out due to project time constraints. A231 
cells incubated with CM depleted of HBP showed a decrease in the number of lamellipodia but not 
of actin stress fibres. These cells also showed a significant decrease in cell area at both 4 and 20 
hours compared to A231 cells incubated with fresh FGM or CM depleted of non-specific, agarose 
bead-binding proteins.  
At this stage of the project it was unknown whether the heparin-agarose beads were effectively 
removing heparin-binding proteins from the CM. Validation on a small scale could be achieved by 
collecting the heparin-agarose beads (post incubation with the CM), dissociating proteins from 
heparin-agarose beads and separating the proteins on SDS-PAGE and then carrying out a western 
blot. Proteins could then be identified by probing with antibodies against common heparin-binding 
proteins in the CM e.g. thrombospondin-1 (TSP1) or fibronectin (FN) (Carbon et al., 2009). However, 
in the timeline of the project, validations were made through identification of proteins by TMT-
proteomics.   
 3D Cell Culture  
Cell culture in 3-dimensions better represents in vivo conditions and makes results more 
physiologically relevant. The results in these experiments showed an inverse correlation between 
the rate of spheroid formation and the concentration of 16F16 applied to A231 cells, when cells were 
seeded into low-attachment wells at 5000 or 10000 cells per well (Table 4.1B).   
Although the phase contrast images of spheroids showed evidence of being 3D (Figure 3.39), the 
Z-axis of the spheroids was not measured. The ‘flattened’ phase contrast digital images of spheroid 
areas could be misleading because these do not show spheroid height. Therefore results from a 2D 




to resolve this issue would include measuring the spheroid Z-axis using high content screening, for 
example, Perkin Elmer Opera LX System (Opera System) attached to a confocal microscope, 
allowing high resolution for 3D phase contrast imaging (Foitzik et al., 2016). This would allow 3D 
image analysis of all 96 spheroids to be measured in one experiment. However, the Opera System 
is incompatible with the round bottomed wells of the 96-well plate used in the spheroid experiments. 
Therefore, the 3D nature of the spheroids was assessed by transfer of 6 spheroids grown in control 
conditions to wells of a flat-bottomed 96-well plate, staining for F-actin, and collection of 3D images 
of these spheroids via confocal microscopy Z stacks.  
Considering the 2D spheroid measurements from the phase contrast images, PDIA3 seemed to 
have a contribution in the rate of spheroid formation. A line of best fit was calculated for the rate of 
spheroid formation at each concentration of 16F16 applied to the A231 cells. Coefficient of 
determination (R2) was used to measure how well the data fitted the line of best fit; an R2 closer to 1 
is a good fit. Most of the lines of best fits for the different 16F16 concentrations were over 0.90. 
Conditions with an R2 much lower than 1 were with DMSO-only at both cell seeding densities and 
1M 16F16 at 10000 cells seeded. It is clear from Figure 3.36 C, D & E that the data do not fit the 
line of best fit well. The results were presented with one axis (area) plotted as a reciprocal; this was 
done to make the data more linear. Possible reasons for less correlation to a linear trend at lower 
concentrations of 16F16 could be that the rate of spheroid formation is more non-linear under these 
conditions than spheroid formation at high 16F16 concentrations (as shown in Figure 3.36 C & D). 
The deviance in R2 may just be a reflection that these are the most non-linear rates of spheroid 
formation. Other reasons for variations in R2 could include inaccuracies in cell plating or inaccuracies 
in thresholding the digital image in ImageJ.  
All concentrations of 16F16 caused a significant change in the final spheroid areas at 50 hours 
compared to the DMSO-only condition, apart from 0M vs. 1M and 0M vs. 2.5M 16F16 which 
were not significantly different. There was also no significant difference in final spheroid area 
between 1M and 2.5M 16F16. The incremental rise in increase in final spheroid area with 16F16 
concentration may suggest that PDIA3 inhibition has a proportional effect on spheroid formation. 
However, 16F16 is toxic at high concentrations (10µM and 25µM) and perhaps spheroid formation 
is inhibited because normal cellular activities are being affected by 16F16 induced-toxicity making 
the cells more stressed (Hoffstrom et al., 2010).   
Formation of a 3D spheroid involves the coordinated compaction of many cells and is accompanied 
by a change in phenotype, for example, cells in 3D form different cell-cell and cell-matrix adhesions 
that make a different ECM environment (Costa et al., 2016). With concentrations of 16F16 above 
12.5M A231 cells were unable to form a spheroid, which suggests that PDIA3 has some role in cell 




actin, vimentin and vinculin) in a spheroid to see if they are more epithelial or mesenchymal and test 
for E- and N-cadherin expression (Konstantinovsky et al., 2012; Iglesias et al., 2013). 
Spheroid formation seemed unaffected by lysyl-oxidase like 2 (LOXL2) inhibition, LOXL2 will be 
discussed in 4.3. 
4.2 The PDIA3-Dependent Secretome  
To relate the results from inhibition with 16F16 to the similar effects of depletion of heparin-binding 
proteins, the heparin-binding fraction of the PDIA3-depdendent secretome was identified by TMT-
based proteomics. This experiment identified 80 heparin-binding proteins reproducibly decreased in 
CM after inhibition with 16F16. 48 of these are extracellular proteins.  The majority of bioinformatic 
analysis focused on the extracellular protein subset. Primarily, this was because extracellular 
proteins would be expected to be found in the CM. Analysis by Gene Ontology (GO) was performed 
on two bioinformatic platforms to increase confidence of association.  
The first investigations began with Gene Set Enrichment Analysis (GSEA) and showed that only the 
extracellular proteins were significantly related to GO cancer terms; these included Biological 
Adhesion, EMT and Extracellular Structure Organisation (Subramanian et al., 2005). Related GO 
terms were identified when analysed with a second GO tool - Gene Ontology Enrichment Analysis 
and Visualisation (Gorilla) (Eden et al., 2009).  
The extracellular proteins were also related to significant GO Cancer Module terms, whilst the 
intracellular proteins were not. The most significant GO term that described the extracellular proteins 
in the PDIA3-dependent secretome was EMT (p= 8.79x10-29) which involved 18 of the extracellular 
proteins. Protein association network analysis with STRNG showed that many of the extracellular 
proteins were associated in a large network of 15 proteins, mainly by experimental determination or 
co-expression (Szklarczyk et al., 2019). Six of the proteins in this network were classified in EMT. 
There were 32 significantly decreased intracellular proteins found in the heparin-binding fraction of 
the PDIA3-dependent secretome, which included many ribosomal and histone proteins. These were 
significantly related to GO terms in Protein Localisation to ER, Ribsome and RNA binding. It is 
interesting to speculate why intracellular proteins were found in the heparin-binding fraction of the 
PDIA3-dependent secretome. Intracellular proteins could arise in the CM after cell necrosis or cell 
damage that might result as part of experimental protocol, however both test and control conditions 
were treated in the same manner and so this doesn’t explain the difference in intracellular protein 
composition. It is more likely that cell damage may arise from slight 16F16 induced toxicity, however, 
analysis of BiP protein did not provide evidence that 16F16 increased UPR (Hoffstrom et al., 2010). 
Also, the cell images did not show evidence of nuclear fragmentation.   
The CM for proteomics was filtered through a 0.45µm pore size membrane and would exclude large 




exosomes. Exosomes are from endosomal origin and carry intracellular proteins, they are small, 
typically 100nm in diameter and would pass through the 0.45µm pore size membrane into the CM. 
The occurrence of proteins with transmembrane domains in the dataset could also be explained by 
exosomes- amyloid-like protein 2 (APLP2) and receptor-type tyrosine-protein phosphatase S 
(PTPRS) are both transmembrane proteins known to be present in exosomes (Keerthikumar et al., 
2016; Mathivanan 2009).  
The intracellular proteins showed no significant associations with GO terms related to an unfolded 
protein response (UPR). This is in agreement with immunoblot of binding immunoglobulin protein 
(BiP) on A231 cell lysates. After inhibition of PDIA3 with 16F16 the abundance of BiP was unchanged 
which suggests no induction of UPR with PDIA3 inhibition.  
Further investigations into the PDIA3-dependent secretome may consider enriching the CM by other 
methods such as immunodepletion (selecting the top six most abundant proteins in the CM to be 
removed) or by ligand-based enrichment, instead of enrichment with heparin-beads (Severino et al., 
2013; Paulus et al., 2009).  
4.3 Validation of the PDIA3-Dependent Secretome  
The results from TMT-based proteomics revealed that proteins from the CM were successfully 
captured by the heparin-beads and that a heparin-binding fraction of the PDIA3-dependent 
secretome had been identified. GO revealed that the extracellular proteins were significantly related 
to Heparin Binding (11 proteins) using GSEA analysis (Figure 3.20). However, not all proteins in the 
heparin-binding fraction of the PDIA3-dependent secretome may be direct targets of PDIA3. Indeed, 
none of the intracellular proteins (except RNASE4) contained disulphide bonds or cysteine-rich 
domains and therefore seem unlikely to be targets of PDIA3. Validation that a protein is a target of 
PDIA3 could have been achieved by adding a fluorescent mass-tag PDIA3 and treating cells with N-
Ethylmaleimide (NEM) to prevents thiol exchange (Jessop et al., 2007). This results in a fluorescently 
labelled mass-tagged PDIA3 becoming irreversibly, covalently linked to a target protein during 
oxidoreductase exchange. PDIA3 can then be purified from cell lysates with an affinity isolation 
column of agarose beads conjugated to an antibody complementary to the mass-tag that was added 
to PDIA3. PDIA3 and associated target proteins can be eluted out the column, separated by SDS-
PAGE and visualised by immunoblot. Precise PDIA3 targets identification can be achieved by taking 
protein bands from the gel and analysing the protein content by mass spectroscopy.  
Validation of selected proteins found by TMT-based proteomics in this study was done by 
immunoblotting. Two proteins were selected; insulin growth factor binding protein 7 (IGFBP7) 
because TMT-based proteomics suggested that it had a high p.value near to the significance cut-off 
threshold (p=0.392), and LOXL2 because it had a very low p.value (p=0.003). On blots, IGFBP7 was 
significantly reduced in the CM from cells treated with 16F16 but LOXL2 was not. The TMT-




be worth repeating LOXL2 immunoblot a fourth time since there is a large disparity between the 
results from experiments one and two and experiment three. Alternatively, the LOXL2 antibody 
specificity was not validated. It is possible that the antibody recognises other LOX family members 
that are not PDIA3-dependent.   
LOXL2 is a known target of PDIA3 (Jessop et al., 2007) and was amongst the most significant and 
most greatly changed (Log2FoldChange = -2.525) proteins in the heparin-binding fraction of the 
PDIA3-depedent secretome. It has roles in cross-linking collagens and associations with cancer 
(Salvador et al., 2017; Cuevas et al., 2017; Wang et al., 2019a). For these reasons, LOXL2 was 
inhibited with beta-aminopropionitrile (APN) and the effect on 3D spheroid formation by A231 cells 
was analysed. Inhibition of LOXL2 did not reproduce the results of 16F16 treatment on 3D spheroid 
formation. At all APN concentrations tested, A231 cells were able to form spheroids (Figure 3.40). 
This may give some indication that a network of proteins in the heparin-binding fraction of the PDIA3-
dependent secretome is necessary for spheroid compaction. However, APN is a general LOX-
family inhibitor and might not effectively inhibit LOXL2 (Chang et al., 2017). Few specific inhibitors 
of LOXL2 exist. Recently 2-chloropyridin-4-yl)methanamine was shown to be selective and effective 
for irreversible LOXL2 inhibition over LOX and could be a candidate inhibitor for future investigation 
(Hutchinson et al., 2017). LOXL2 could also be diminished by using antibodies against LOXL2 to 
block or deplete it in the CM of A231 cells, or by CRISPR-mediated LOXL2 gene-editing (Ikenaga et 
al., 2019). These methods might yield a more profound impact on 3D spheroid formation, and as 
mentioned in 4.1.2, consideration of the Z-axis should be taken into account in future measurements 
(Friedrich et al., 2009).  
4.4 Implications for Future Research on PDIA3 and Breast Cancer Metastasis  
The heparin-binding fraction of the PDIA3-dependent secretome was identified from 2D-based cell 
culture assays and therefore may only be representative of in vitro 2D cell culture. Future 
experiments could focus on identifying the PDIA3-dependent secretome from 3D culture, this would 
be more physiologically relevant and may lead to successful identification of cancer biomarkers 
(Brandi et al., 2018b). Future experiments could involve CM that better represents the tumour 
microenvironment by analysis of the PDIA3-dependent secretome from in vitro co-cultures of A231 
cells with fibroblasts (Arrigoni et al., 2016).   
Bioinformatic analysis of the heparin-binding fraction of the PDIA3-dependent secretome revealed 
three protein association networks in the extracellular protein subset (Figure 3.32). All three are 
linked with aspects of breast cancer metastasis. The first large network represents EMT as described 
in 4.2. The second network consists of three laminin chains (LAMA5, LAMB1 and LAMC1) and 
represents components of the basement membrane (BM). BM was the second most enriched GO 
term in the heparin-binding fraction of the PDIA3-dependent secretome. The BM has a complex role 




becomes invasive, however, there are some reports that some types of laminin can promote 
anchorage-independent proliferation by influencing autocrine signalling in the TME by other cancer 
cells, acting through integrins (Chang et al., 2017; Zahir et al., 2003; Carpenter et al., 2009). Some 
laminins have also been linked to EMT (Kim et al., 2011). The precise role of PDIA3 in maintaining 
the BM and the effect of laminins on breast cancer progression is unclear, but laminin β1, β3, γ1 and 
γ2 have been identified as PDIA3 substrates (Jessop et al., 2007). 
The third network displayed on Figure 3.32 represents proteins that were enriched in the GO term 
Platelet Alpha Granule Lumen. This GO term was the most enriched of all the GO terms found for 
the heparin-binding fraction of the PDIA3-dependent secretome and contains urokinase (PLAU) 
which had the highest fold change (Log2FoldChange= -3.024). Upon further inspection of the 
extracellular proteins with Reactome (https://reactome.org/PathwayBrowser/#TOOL=AT) it became 
clear that Fibrin Clot Dissolution was very highly enriched (Figure 4.1). A protein found in this 
pathway, SERPINE1, is a poor prognosis marker for breast cancer (Duffy, 2002; Janicke et al., 
2001). This pathway includes the urokinase plasminogen activator system (uPAR). Activation of this 
pathway is thought to be an essential part of breast cancer metastasis. Cascading activation of 
serine proteases (including PLAU) catalyses the conversion of plasminogen to plasmin. Active 
plasmin is able to degrade and remodel ECM, enhancing cell migration and invasiveness (Tang and 
Han, 2013). It is a novel finding that PDIA3 is related to the uPAR system and future work may seek 
to investigate this relationship. 
Previous research on PDIA3 in the Adams laboratory suggested that basal breast cancer cell lines 
may be more dependent of PDIA3 for 2D migration (H.S.Young, unpublished data, 2018). My own 
analysis of gene expression in breast cancer cell lines and tumours from clinical datasets suggests 
that the many of the transcripts encoding proteins of the heparin-binding fraction of the PDIA3-
dependent secretome are more highly expressed in basal B breast tumours and cell lines (Figure 
4.2) (Ringnér et al., 2011). In future, perhaps some of these proteins may be valid biomarkers for 
early detection of aggressive breast cancer. However, research on PDIA3 in breast cancer 






Figure 4.1. Dissolution of Fibrin Clot Markers Identified by Reactome 
(https://reactome.org/PathwayBrowser/#TOOL=AT). The 48 extracellular proteins from the heparin-
binding fraction of the PDIA3-dependent secretome were analysed. Colour Key: Blue Box; Protein 
Complex, Green Box; Protein, Green Circle; Small Molecule, Orange; Cell Compartment, White; 
Extracellular Space, Yellow; Enrichment in Pathway. Line Key: Arrow end; Positive Regulation, 














Figure 4.2. Conditions of mRNAs Encoding Extracellular Proteins of the Heparin-Binding 
Fraction of the PDIA3-Dependent Secretome of A231 Cells (48 proteins). Breast Cancer 
Tumours (left) or Cell Lines (right). Results identified from Gene expression-based Outcome for 








4.5 Contribution to Knowledge  
 
The novel research contributions of this research are:  
 
1. Analysis in A231 cells of effects of the PDIA3-dependent secretome and the heparin-binding 
fraction of the secretome on cell spreading, focal adhesions and F-actin organisation.  
 
2. Assessment of the role of PDIA3 in scaffold-free 3D spheroid formation.  
 
3. Identification of proteins of the heparin-binding fraction of the PDIA3-dependent secretome 
in A231 breast cancer cells and a strong suggestion for roles in aspects of cancer biology 
(migration, adhesion, extracellular matrix) from Gene Ontology and other bioinformatic tools.  
 
 
Overall the results suggest a role for the PDIA3-dependent secretome in promoting a pro-metastatic 
phenotype in A231 cells. 
 
These investigations into the role of the PDIA3-dependent secretome of MDA-MB-231 breast cancer 













Figure 4.3 Summary Figure. Figure summarises the achievements of the project and contribution 









Table 5.1. Global Protein Changes identified from Four TMT-Proteomics Experiments. Ranked by t-test value. Colour Gradient Key (for 
Log(2)Mean and Log(2)Median)): Red: More negative in +16F16 condition. Blue: Increased in +16F16 condition. Key: AAs, Amino Acids; AR, 
Abundance Ratio; MW, Molecular Weight. 
 
 
Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
LAMA5 0.148 0.278 0.276 0.236 -2.75 -1.849 -1.856 -2.082 -2.1356702 -1.9693897 0.427 0.002123 0 15.88633 45 81 45 3695 399.5
LOXL2 0.114 0.145 0.192 0.287 -3.14 -2.786 -2.377 -1.8 -2.5250547 -2.5816899 0.575 0.003105 0 37.4677 27 68 27 774 86.7
APOM 0.284 0.484 0.342 0.427 -1.81 -1.047 -1.553 -1.229 -1.4107749 -1.3913348 0.341 0.003684 0.006 7.978723 2 3 2 188 21.2
SRPX 0.142 0.179 0.066 0.186 -2.81 -2.486 -3.958 -2.431 -2.9219424 -2.6491495 0.711 0.003773 0 17.4569 7 9 7 464 51.5
PLAU 0.061 0.218 0.144 0.119 -4.04 -2.195 -2.797 -3.066 -3.023537 -2.9316466 0.766 0.004244 0 44.2029 19 38 19 414 46.9
RPL35 0.323 0.47 0.389 0.534 -1.63 -1.088 -1.363 -0.906 -1.2472808 -1.2255956 0.318 0.004316 0.001 9.467456 2 5 2 169 17.8
FST 0.215 0.419 0.363 0.262 -2.22 -1.254 -1.46 -1.934 -1.7167933 -1.6969326 0.44 0.004366 0 55.23256 16 26 16 344 38
TMEM132A 0.109 0.176 0.331 0.215 -3.2 -2.508 -1.596 -2.215 -2.3787419 -2.3617713 0.664 0.005597 0 11.82796 9 16 9 1023 110
EBNA-2 0.168 0.309 0.402 0.301 -2.57 -1.696 -1.313 -1.731 -1.8275192 -1.7136018 0.53 0.006235 0 26.86722 23 37 23 964 107.4
MST1 0.204 0.447 0.155 0.208 -2.29 -1.161 -2.689 -2.267 -2.1018817 -2.2788487 0.656 0.007715 0 7.310345 5 7 5 725 81.9
PAFAH1B1 0.296 0.473 0.508 0.282 -1.75 -1.079 -0.983 -1.827 -1.4109131 -1.4168677 0.441 0.007755 0 7.073171 3 5 3 410 46.6
PTPRS 0.188 0.327 0.469 0.267 -2.41 -1.614 -1.091 -1.907 -1.7551539 -1.7606185 0.551 0.007818 0 10.83162 14 22 14 1948 216.9
FBN1 0.173 0.362 0.375 0.371 -2.53 -1.464 -1.414 -1.43 -1.7104915 -1.447239 0.549 0.008341 0 6.443748 17 19 17 2871 312
COL5A1 0.06 0.18 0.239 0.21 -4.07 -2.471 -2.064 -2.252 -2.7141914 -2.3614838 0.919 0.009684 0 7.834603 12 20 12 1838 183.4
TLN1 0.337 0.378 0.56 0.582 -1.57 -1.405 -0.839 -0.78 -1.1479049 -1.1219334 0.398 0.010323 0 3.010164 8 10 8 2558 271.3
THBS1 0.088 0.192 0.263 0.335 -3.5 -2.38 -1.928 -1.576 -2.3464902 -2.1536795 0.838 0.01124 0 63.93162 71 294 53 1170 129.3
TGFB2 0.162 0.47 0.339 0.277 -2.62 -1.09 -1.561 -1.853 -1.7820041 -1.7073757 0.643 0.011589 0 23.91304 11 21 10 414 47.7
HSP90AB1 0.315 0.447 0.52 0.608 -1.67 -1.16 -0.944 -0.718 -1.1219743 -1.0520877 0.405 0.011615 0 41.98895 36 75 17 724 83.2
NOG 0.11 0.355 0.228 0.329 -3.18 -1.495 -2.134 -1.603 -2.1033241 -1.8683305 0.771 0.012113 0 11.2069 2 5 2 232 25.7
QSOX1 0.195 0.435 0.473 0.299 -2.36 -1.202 -1.079 -1.741 -1.5960099 -1.4714309 0.586 0.012146 0 22.22222 14 23 14 747 82.5
LAMC1 0.127 0.225 0.455 0.27 -2.97 -2.151 -1.135 -1.891 -2.0373001 -2.020967 0.757 0.012577 0 25.48167 34 60 34 1609 177.5






Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
RAB15 0.338 0.489 0.66 0.496 -1.57 -1.032 -0.601 -1.01 -1.0527681 -1.0213837 0.396 0.012998 0.001 8.943089 2 3 1 246 27.9
PRSS23 0.087 0.283 0.143 0.35 -3.52 -1.821 -2.809 -1.516 -2.4160793 -2.3150395 0.919 0.013401 0 30.28721 9 14 9 383 43
PSMC2 0.467 0.77 0.553 0.565 -1.1 -0.376 -0.866 -0.824 -0.7911196 -0.8451277 0.302 0.013479 0.001 7.621247 3 3 3 433 48.6
LAMB1 0.097 0.165 0.38 0.289 -3.36 -2.597 -1.396 -1.793 -2.2863674 -2.1947993 0.873 0.013524 0 11.98895 22 34 22 1810 200.3
HSP90 0.211 0.305 0.526 0.442 -2.25 -1.715 -0.927 -1.18 -1.5170403 -1.4473228 0.587 0.014045 0 20.67248 16 21 14 803 92.4
COL12A1 0.112 0.095 0.347 0.311 -3.16 -3.388 -1.528 -1.686 -2.4406569 -2.4229085 0.969 0.015075 0 32.02742 84 154 84 3063 332.9
PRDX6 0.488 0.663 0.771 0.601 -1.04 -0.593 -0.375 -0.735 -0.6844709 -0.663697 0.277 0.015858 0 20.08929 4 7 4 224 25
HIST1H3A 0.07 0.379 0.167 0.221 -3.83 -1.398 -2.582 -2.177 -2.4970574 -2.3798074 1.016 0.016109 0 28.67647 5 12 5 136 15.4
SOD3 0.238 0.611 0.305 0.416 -2.07 -0.712 -1.713 -1.264 -1.4393214 -1.4887592 0.586 0.016155 0 42.91667 8 18 8 240 25.8
SPON1 0.201 0.345 0.441 0.533 -2.31 -1.534 -1.184 -0.909 -1.4849532 -1.3594091 0.608 0.016398 0 6.69145 5 7 5 807 90.9
CAPG 0.219 0.462 0.528 0.241 -2.19 -1.114 -0.921 -2.055 -1.5695783 -1.5845247 0.645 0.016559 0 11.49425 4 5 4 348 38.5
TAGLN2 0.232 0.365 0.531 0.525 -2.11 -1.455 -0.914 -0.93 -1.3523447 -1.1929173 0.564 0.017233 0.001 9.547739 2 2 2 199 22.4
TGM2 0.142 0.325 0.475 0.343 -2.81 -1.619 -1.074 -1.544 -1.7630843 -1.5817583 0.741 0.017637 0 28.52984 17 29 17 687 77.3
ITIH2 0.176 0.234 0.5 0.439 -2.51 -2.098 -0.999 -1.189 -1.698212 -1.6438549 0.721 0.018108 0 6.969377 7 21 7 947 106.5
RARRES2 0.18 0.28 0.191 0.593 -2.47 -1.834 -2.387 -0.753 -1.8617888 -2.1104577 0.791 0.018172 0 25.76687 4 7 4 163 18.6
RPL23A 0.176 0.294 0.493 0.476 -2.5 -1.768 -1.021 -1.071 -1.5905264 -1.4191983 0.697 0.019757 0 26.28866 5 8 5 194 21.9
RPS25 0.246 0.521 0.584 0.404 -2.03 -0.942 -0.774 -1.308 -1.2623533 -1.124691 0.556 0.019985 0 21.6 4 6 4 125 13.7
TKT 0.254 0.453 0.595 0.514 -1.98 -1.142 -0.757 -0.96 -1.2092816 -1.0510047 0.536 0.020349 0.001 4.333868 2 2 2 623 67.8
RPS17 0.211 0.383 0.462 0.57 -2.24 -1.385 -1.113 -0.812 -1.3879816 -1.2486368 0.616 0.020404 0 10.10274 6 9 6 584 64.5
AGRN 0.161 0.278 0.598 0.299 -2.63 -1.846 -0.743 -1.741 -1.7400312 -1.7935973 0.774 0.020565 0 7.398453 14 18 14 2068 217.2
BQ8482_100073 0.283 0.647 0.525 0.346 -1.82 -0.629 -0.924 -1.53 -1.2261558 -1.2272878 0.546 0.020581 0.028 1.827676 1 2 1 383 41
GGH 0.142 0.407 0.354 0.44 -2.82 -1.298 -1.5 -1.186 -1.7007781 -1.3987747 0.757 0.020587 0 32.38994 11 24 11 318 36
RPL27 0.189 0.432 0.493 0.453 -2.41 -1.211 -1.02 -1.143 -1.445244 -1.1770752 0.646 0.020782 0 41.17647 5 7 5 136 15.8
PLAT 0.1 0.168 0.52 0.235 -3.33 -2.578 -0.944 -2.086 -2.2336892 -2.3319686 1 0.02087 0 29.89324 13 23 13 562 62.9
HIST1H2BJ 0.074 0.396 0.252 0.231 -3.76 -1.337 -1.988 -2.114 -2.2989619 -2.0508764 1.03 0.020922 0 57.93651 9 26 2 126 13.9
HIST1H1C 0.146 0.54 0.274 0.364 -2.78 -0.889 -1.865 -1.457 -1.7465709 -1.6608583 0.794 0.021771 0 23.47418 6 12 1 213 21.4
HIST1H2BA 0.077 0.462 0.194 0.223 -3.7 -1.113 -2.368 -2.162 -2.335328 -2.264785 1.062 0.021812 0 43.9759 9 27 2 166 18
RPS16 0.176 0.517 0.462 0.344 -2.51 -0.953 -1.113 -1.541 -1.5291117 -1.3266751 0.7 0.022139 0 45.20548 9 14 9 146 16.4
LOXL4 0.386 0.613 0.617 0.294 -1.37 -0.705 -0.702 -1.766 -1.1366365 -1.0389833 0.525 0.022728 0 5.15873 3 5 3 756 84.4
DKK1 0.073 0.351 0.211 0.336 -3.77 -1.51 -2.24 -1.574 -2.2738224 -1.9068098 1.052 0.022798 0 32.33083 9 21 9 266 28.7
CTGF 0.138 0.553 0.264 0.34 -2.86 -0.856 -1.922 -1.556 -1.7986455 -1.7386296 0.835 0.023037 0 51.86246 15 31 15 349 38
DARS 0.239 0.599 0.251 0.51 -2.06 -0.739 -2.012 -0.97 -1.4465135 -1.4911632 0.691 0.024792 0 11.57685 4 6 4 501 57.1
RAC1 0.074 0.124 0.548 0.167 -3.76 -3.01 -0.874 -2.582 -2.5559649 -2.7959034 1.222 0.024881 0.001 14.74359 1 2 1 156 17.6






Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
TIMP1 0.147 0.497 0.387 0.399 -2.77 -1.01 -1.37 -1.326 -1.6184572 -1.3480533 0.783 0.025661 0 32.36715 5 14 5 207 23.2
CLTC 0.24 0.408 0.708 0.304 -2.06 -1.294 -0.496 -1.716 -1.3916507 -1.5052237 0.674 0.025798 0 3.871352 6 7 6 1679 191.9
CKAP5 0.205 0.268 0.6 0.49 -2.28 -1.9 -0.74 -1.027 -1.487524 -1.4635032 0.724 0.026117 0.001 2.214567 4 4 4 2032 225.4
RPS20 0.25 0.438 0.629 0.538 -2 -1.191 -0.67 -0.895 -1.1894264 -1.0431419 0.582 0.026484 0 19.32773 2 5 2 119 13.4
COL14A1 0.162 0.433 0.495 0.427 -2.62 -1.208 -1.014 -1.228 -1.5187709 -1.21815 0.744 0.02651 0 2.951002 6 12 6 1796 193.4
MYL6 0.195 0.403 0.537 0.522 -2.36 -1.311 -0.888 -0.938 -1.3739248 -1.1243688 0.683 0.027613 0.001 8.823529 2 3 2 238 26.7
TFPI 0.359 0.782 0.553 0.435 -1.48 -0.355 -0.856 -1.202 -0.9724703 -1.0287297 0.484 0.027672 0 11.18421 3 5 3 304 35
HIST1H4L 0.085 0.48 0.324 0.192 -3.56 -1.06 -1.628 -2.377 -2.1553382 -2.0024541 1.079 0.028094 0 52.42718 7 24 7 103 11.4
NRP1 0.162 0.328 0.555 0.455 -2.63 -1.609 -0.849 -1.136 -1.555604 -1.3723724 0.781 0.028278 0 17.6598 11 18 11 923 103.1
ECM1 0.107 0.26 0.324 0.533 -3.23 -1.944 -1.627 -0.908 -1.926161 -1.7856141 0.968 0.028414 0 25 12 22 12 540 60.6
APP 0.146 0.148 0.495 0.454 -2.78 -2.754 -1.016 -1.14 -1.9213461 -1.9470212 0.976 0.029152 0 34.67532 25 78 24 770 86.9
YWHAQ 0.229 0.687 0.469 0.307 -2.13 -0.541 -1.091 -1.705 -1.3660859 -1.3980099 0.696 0.029384 0 16.73469 3 8 2 245 27.7
RPL17 0.189 0.544 0.553 0.342 -2.4 -0.878 -0.855 -1.546 -1.4196243 -1.2119873 0.728 0.029903 0 25 5 7 5 228 26.4
PLK4 0.253 0.528 0.564 0.597 -1.98 -0.921 -0.826 -0.745 -1.1184735 -0.8736185 0.58 0.030773 0.002 1.237113 1 3 1 970 108.9
SERPINE1 0.1 0.602 0.25 0.244 -3.32 -0.733 -2.002 -2.032 -2.0207217 -2.017128 1.055 0.031316 0 49.25373 16 43 16 402 45
EEF2 0.201 0.493 0.637 0.354 -2.31 -1.02 -0.65 -1.496 -1.3700683 -1.2579805 0.718 0.031692 0 11.18881 8 12 8 858 95.3
TIMP2 0.132 0.383 0.431 0.484 -2.92 -1.384 -1.213 -1.046 -1.6417313 -1.2986287 0.866 0.032189 0 27.27273 10 21 10 220 24.4
RARS 0.202 0.547 0.502 0.509 -2.3 -0.871 -1 -0.972 -1.2868402 -0.986047 0.681 0.032406 0.001 4.393939 3 3 3 660 75.3
LECT2 0.233 0.596 0.542 0.506 -2.1 -0.746 -0.882 -0.983 -1.1784994 -0.9327118 0.624 0.032473 0.001 11.25828 2 4 2 151 16.4
RPL7 0.178 0.585 0.512 0.344 -2.49 -0.773 -0.965 -1.54 -1.441263 -1.2526984 0.769 0.033177 0 35.90734 10 14 10 259 30.4
RPL9 0.273 0.676 0.343 0.15 -1.88 -0.565 -1.546 -2.74 -1.681409 -1.7105966 0.899 0.03331 0.001 7.272727 2 3 2 220 25
RPS7 0.213 0.547 0.401 0.617 -2.23 -0.87 -1.32 -0.695 -1.2796285 -1.0947965 0.689 0.033881 0 23.71134 5 8 5 194 22.1
eEF1a1 0.485 0.708 0.818 0.48 -1.04 -0.498 -0.29 -1.059 -0.7230816 -0.7714625 0.389 0.033945 0 37.01299 15 30 15 462 50.1
CHID1 0.251 0.635 0.472 0.586 -2 -0.656 -1.079 -0.771 -1.1258617 -0.9251193 0.608 0.034144 0 10.57269 5 8 5 454 51
CLSTN3 0.138 0.194 0.633 0.38 -2.86 -2.369 -0.659 -1.394 -1.8196567 -1.8815105 0.984 0.034327 0 11.19247 8 12 8 956 106
RPSA 0.591 0.723 0.293 0.445 -0.76 -0.468 -1.769 -1.167 -1.0406681 -0.9628409 0.564 0.034504 0 10 2 4 2 300 33.3
HIST1H2AK 0.087 0.409 0.414 0.298 -3.52 -1.289 -1.272 -1.749 -1.9569644 -1.5186561 1.064 0.0348 0 35.38462 5 13 3 130 14.1
IGFBP4 0.109 0.375 0.289 0.544 -3.19 -1.413 -1.789 -0.878 -1.8188547 -1.6013279 0.991 0.034952 0 36.43411 7 15 7 258 27.9
H2AFY 0.107 0.339 0.503 0.387 -3.22 -1.561 -0.996 -1.369 -1.786085 -1.4649811 0.984 0.035945 0 33.06452 10 16 10 372 39.6
XP32 0.388 0.646 0.792 0.412 -1.36 -0.631 -0.338 -1.277 -0.9024657 -0.9538593 0.499 0.036244 0.007 8 2 2 2 250 26.2
RPL15 0.397 0.542 0.528 0.166 -1.33 -0.884 -0.933 -2.591 -1.4353036 -1.1332043 0.796 0.036641 0 14.70588 3 4 3 204 24.1
VCL 0.22 0.419 0.71 0.471 -2.18 -1.257 -0.495 -1.087 -1.2558607 -1.1715083 0.7 0.037073 0 10.22928 11 15 11 1134 123.7
COL2A1 0.169 0.557 0.167 0.527 -2.56 -0.843 -2.556 -0.923 -1.7214412 -1.739237 0.969 0.037981 0 3.026227 4 6 4 1487 141.7






Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
IGFBP7 0.09 0.396 0.33 0.456 -3.47 -1.337 -1.6 -1.132 -1.8850447 -1.4682455 1.075 0.039243 0 59.21986 18 110 18 282 29.1
ANOS1 0.21 0.568 0.658 0.32 -2.25 -0.817 -0.602 -1.642 -1.3287691 -1.2297063 0.762 0.039878 0 11.17647 6 12 6 680 76.2
CHAD 0.234 0.477 0.772 0.349 -2.1 -1.067 -0.374 -1.517 -1.2641487 -1.292274 0.728 0.040304 0 9.470752 3 4 3 359 40.5
CLSTN1 0.146 0.157 0.515 0.55 -2.77 -2.676 -0.956 -0.864 -1.8165717 -1.8158096 1.049 0.040491 0 33.63914 38 121 38 981 109.7
AREG 0.133 0.603 0.307 0.45 -2.91 -0.73 -1.702 -1.151 -1.6229768 -1.4264779 0.945 0.0414 0 17.51825 4 5 4 274 30.2
RAB1 0.156 0.363 0.556 0.542 -2.68 -1.463 -0.847 -0.883 -1.4691345 -1.172934 0.857 0.041606 0 32.65306 5 13 5 147 16.8
APLP2 0.13 0.218 0.572 0.507 -2.95 -2.197 -0.805 -0.981 -1.7325747 -1.5887005 1.019 0.042461 0 35.38663 27 78 26 763 86.9
CARS 0.238 0.529 0.642 0.579 -2.07 -0.918 -0.638 -0.789 -1.1039602 -0.8534163 0.655 0.043361 0 10.75402 8 12 8 809 92
CYR61 0.179 0.429 0.548 0.594 -2.48 -1.221 -0.868 -0.753 -1.331413 -1.0444724 0.794 0.04387 0 9.186352 3 5 3 381 42
LDHA 0.233 0.726 0.447 0.534 -2.1 -0.463 -1.162 -0.904 -1.1573664 -1.0332132 0.692 0.044192 0.001 11.74699 4 4 4 332 36.7
RPL13 0.183 0.535 0.682 0.287 -2.45 -0.903 -0.553 -1.803 -1.4264702 -1.3531214 0.86 0.045187 0 27.96209 7 9 7 211 24.2
RPS13 0.277 0.701 0.448 0.673 -1.85 -0.512 -1.16 -0.57 -1.0238145 -0.8652144 0.625 0.046636 0 36.42384 7 10 7 151 17.2
FLNA 0.194 0.327 0.685 0.562 -2.37 -1.611 -0.546 -0.831 -1.3388681 -1.220533 0.821 0.047063 0 15.187 31 42 29 2647 280.6
APOB 0.293 0.164 0.757 0.425 -1.77 -2.606 -0.402 -1.235 -1.5038516 -1.5038058 0.926 0.047604 0 2.542187 13 22 9 4563 515.2
F13A1 0.176 0.765 0.402 0.387 -2.51 -0.387 -1.314 -1.37 -1.3943528 -1.3421305 0.868 0.048797 0 4.508197 3 5 3 732 83.2
S100A8 0.272 0.718 0.583 0.575 -1.88 -0.478 -0.773 -0.8 -0.9818272 -0.786326 0.614 0.049354 0.003 8.571429 1 2 1 105 11.7
LOC392748 0.215 0.352 0.834 0.44 -2.21 -1.504 -0.261 -1.184 -1.2909698 -1.3440462 0.81 0.049854 0 14.18919 2 5 2 148 16.9
APOC3 0.216 0.511 0.574 0.654 -2.21 -0.97 -0.804 -0.612 -1.1490707 -0.8866646 0.723 0.050098 0 13.67521 1 4 1 117 12.8
PPIB 0.172 0.393 0.531 0.66 -2.54 -1.346 -0.912 -0.6 -1.3492179 -1.1293051 0.849 0.050215 0 59.72222 16 41 15 216 23.7
HDGFRP3 0.179 0.497 0.524 0.612 -2.48 -1.008 -0.935 -0.709 -1.2830093 -0.9713837 0.808 0.050269 0 14.28571 3 5 3 203 22.6
TINAGL1 0.108 0.383 0.384 0.593 -3.21 -1.384 -1.382 -0.753 -1.6810931 -1.3830224 1.059 0.050284 0 18.41542 6 10 6 467 52.4
PCOLCE2 0.264 0.868 0.445 0.46 -1.92 -0.204 -1.168 -1.12 -1.1029016 -1.144166 0.702 0.051635 0 15.42169 5 6 5 415 45.7
COL1A2 0.183 0.272 0.833 0.418 -2.45 -1.879 -0.262 -1.258 -1.4631312 -1.5684602 0.938 0.052516 0 5.856515 6 8 6 1366 129.2
TARS 0.215 0.542 0.785 0.321 -2.22 -0.884 -0.349 -1.641 -1.273348 -1.2623732 0.824 0.053675 0 22.26833 16 28 16 723 83.4
MYH9 0.155 0.312 0.713 0.496 -2.69 -1.678 -0.488 -1.011 -1.4668481 -1.3445434 0.95 0.053832 0 28.92857 58 75 57 1960 226.4
GLG1 0.169 0.27 0.598 0.663 -2.56 -1.888 -0.741 -0.593 -1.4466197 -1.3145558 0.943 0.054708 0 15.69126 17 24 17 1179 134.5
IQGAP1 0.255 0.414 0.734 0.664 -1.97 -1.272 -0.45 -0.591 -1.0714518 -0.9314224 0.7 0.054955 0 8.630054 14 16 14 1657 189.1
SPTBN1 0.31 0.473 0.921 0.502 -1.69 -1.079 -0.12 -0.996 -0.9709585 -1.0371618 0.646 0.057459 0 4.395604 9 10 9 2366 274.7
ANXA1 0.336 0.805 0.71 0.37 -1.57 -0.313 -0.492 -1.433 -0.9531928 -0.9626314 0.643 0.059297 0.001 11.56069 4 5 4 346 38.7
CCT3 0.195 0.703 0.517 0.523 -2.36 -0.509 -0.956 -0.936 -1.1897182 -0.9459103 0.806 0.059888 0 13.34489 7 8 7 577 63.5
RPS23 0.262 0.322 0.92 0.492 -1.93 -1.633 -0.12 -1.024 -1.1770268 -1.3284874 0.799 0.060247 0 20.97902 3 4 3 143 15.8
ANXA2 0.313 0.643 0.799 0.584 -1.68 -0.638 -0.323 -0.776 -0.8537383 -0.7071517 0.581 0.06053 0 46.0177 19 42 19 339 38.6
ACTR2 0.143 0.485 0.589 0.52 -2.8 -1.044 -0.766 -0.942 -1.3889561 -0.9930794 0.95 0.061357 0 17.25888 6 7 5 394 44.7
EL52 0.358 0.531 0.891 0.643 -1.48 -0.913 -0.167 -0.637 -0.7997499 -0.7748178 0.55 0.061961 0 41.80328 33 66 16 732 84.6
RPS11 0.18 0.383 0.853 0.421 -2.47 -1.384 -0.229 -1.247 -1.3333998 -1.3157211 0.918 0.062287 0 43.67089 8 10 8 158 18.4
MYL12A 0.24 0.394 0.912 0.475 -2.06 -1.344 -0.136 -1.073 -1.1529587 -1.2083377 0.795 0.062515 0 23.72881 4 5 4 177 20.4
RPS19 0.212 0.713 0.575 0.522 -2.24 -0.488 -0.8 -0.938 -1.1166431 -0.8688953 0.772 0.062954 0 38.8535 9 17 9 157 17.3






Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
VCP 0.184 0.457 0.639 0.648 -2.44 -1.129 -0.646 -0.625 -1.210087 -0.8877724 0.852 0.065609 0 23.20099 16 22 16 806 89.3
ARPC5 0.248 0.495 0.714 0.696 -2.01 -1.013 -0.485 -0.523 -1.0079278 -0.7682872 0.71 0.065697 0 25.16556 6 8 5 151 16.3
ARPC2 0.196 0.523 0.531 0.727 -2.35 -0.935 -0.913 -0.461 -1.1653522 -0.9235872 0.822 0.065816 0 30 10 19 10 300 34.3
EIF4A1 0.238 0.717 0.651 0.541 -2.07 -0.481 -0.617 -0.887 -1.0143705 -0.7522239 0.725 0.068017 0 16.25616 6 9 6 406 46.1
RAN 0.194 0.352 0.907 0.464 -2.36 -1.506 -0.141 -1.107 -1.2795357 -1.306421 0.923 0.069349 0 19.23077 4 8 4 234 26.8
RPL14 0.205 0.96 0.432 0.319 -2.29 -0.059 -1.207 -1.65 -1.3011121 -1.4284858 0.939 0.069529 0.001 13.63636 2 3 2 220 23.8
ARPC4-TTLL3 0.321 0.843 0.58 0.659 -1.64 -0.246 -0.786 -0.601 -0.8185811 -0.693558 0.593 0.070016 0 24.86188 5 11 5 181 21
CLEC11A 0.211 0.369 0.803 0.625 -2.25 -1.437 -0.317 -0.678 -1.1699759 -1.0579016 0.857 0.071847 0 12.0743 3 3 3 323 35.6
VIL2 0.266 0.533 0.729 0.74 -1.91 -0.908 -0.454 -0.433 -0.9268156 -0.6808507 0.693 0.075268 0 22.1843 17 44 5 586 69.4
CASP14 0.399 0.886 0.736 0.619 -1.32 -0.175 -0.436 -0.692 -0.6569643 -0.5639884 0.493 0.075847 0 14.87603 3 3 3 242 27.7
PRMT1 0.174 0.919 0.391 0.43 -2.53 -0.121 -1.358 -1.216 -1.3052122 -1.286935 0.983 0.076703 0.001 5.121294 2 3 2 371 42.4
C8B 0.262 0.871 0.22 0.614 -1.93 -0.2 -2.141 -0.705 -1.2449281 -1.3191631 0.942 0.077441 0.001 3.384095 2 3 2 591 67
RPS14 0.171 0.752 0.522 0.509 -2.55 -0.411 -0.937 -0.973 -1.2174207 -0.9550076 0.924 0.077982 0 32.45033 5 9 5 151 16.3
LDHB 0.284 0.727 0.717 0.641 -1.81 -0.46 -0.48 -0.64 -0.8487707 -0.5602399 0.649 0.079258 0.007 5.988024 2 2 2 334 36.6
RPS26 0.107 0.695 0.548 0.319 -3.22 -0.525 -0.865 -1.651 -1.565982 -1.2579897 1.201 0.079814 0 33.91304 3 5 3 115 13
NOV 0.097 0.666 0.407 0.462 -3.37 -0.586 -1.302 -1.113 -1.5918837 -1.2071349 1.222 0.079933 0 25.77031 7 12 7 357 39.1
EPRS 0.207 0.287 1.055 0.41 -2.27 -1.802 0.077 -1.285 -1.3207196 -1.5431158 1.016 0.080314 0 8.134921 10 11 10 1512 170.5
HNRPR 0.154 0.721 0.382 0.628 -2.7 -0.471 -1.4 -0.671 -1.3099953 -1.0355014 1.008 0.080366 0 13.90205 8 11 4 633 70.9
ARF5 0.279 0.457 0.449 0.036 -1.84 -1.13 -1.15 -4.807 -2.2330934 -1.4973111 1.748 0.083572 0.001 4.366812 1 2 1 229 25.4
CCT6A 0.25 0.654 0.881 0.432 -2 -0.613 -0.185 -1.21 -1.0021186 -0.9114726 0.787 0.084219 0 10.92279 6 8 6 531 58
AMOT 0.225 0.796 0.421 0.709 -2.15 -0.329 -1.249 -0.495 -1.0562679 -0.872255 0.833 0.084942 0.086 0.738007 1 2 1 1084 118
SERPINB12 0.27 0.701 0.752 0.632 -1.89 -0.512 -0.413 -0.662 -0.8684325 -0.5868143 0.687 0.085528 0 7.654321 3 5 3 405 46.2
RPS9 0.187 0.735 0.732 0.367 -2.42 -0.445 -0.45 -1.446 -1.190981 -0.9480555 0.946 0.086429 0 40.72165 10 15 10 194 22.6
FAM53B 0.107 0.381 0.959 0.269 -3.22 -1.392 -0.061 -1.892 -1.6419413 -1.6421556 1.307 0.086697 0.049 2.606635 1 2 1 422 45.7
COLEC10 0.215 0.739 0.77 0.401 -2.22 -0.435 -0.376 -1.318 -1.0861708 -0.876626 0.867 0.087319 0.001 6.859206 2 3 2 277 30.7
CTSL2 0.193 0.529 0.802 0.571 -2.37 -0.919 -0.319 -0.807 -1.1047437 -0.8632435 0.885 0.087954 0.002 5.389222 2 3 2 334 37.3
RPS6 0.184 0.716 0.76 0.362 -2.44 -0.482 -0.396 -1.466 -1.1967271 -0.9739785 0.962 0.088634 0 21.68675 6 9 6 249 28.7
TCP1 0.187 0.496 0.851 0.536 -2.42 -1.011 -0.233 -0.9 -1.1400093 -0.9558328 0.917 0.088858 0 13.66906 9 11 9 556 60.3
EEF1D 0.253 0.959 0.265 0.611 -1.98 -0.061 -1.931 -0.711 -1.1714278 -1.3208262 0.945 0.089368 0.001 2.725968 2 3 1 697 76.5
RPS3 0.148 0.63 0.633 0.529 -2.75 -0.667 -0.66 -0.918 -1.2498693 -0.792379 1.01 0.089689 0 56.79012 14 31 14 243 26.7
DTD1 0.136 0.53 0.482 0.735 -2.88 -0.916 -1.053 -0.445 -1.3236456 -0.9841022 1.07 0.089825 0 33.97129 4 8 4 209 23.5
HSPA4 0.181 0.165 1.158 0.367 -2.47 -2.599 0.1926 -1.445 -1.5796563 -1.9559041 1.289 0.091652 0.001 4.166667 3 3 3 840 94.3
ALDOA 0.228 0.635 0.612 0.772 -2.13 -0.654 -0.708 -0.374 -0.9669619 -0.6814206 0.79 0.091867 0 56.04396 19 40 15 364 39.4
XRCC6 0.171 0.541 0.136 0.912 -2.55 -0.886 -2.884 -0.133 -1.6138967 -1.7192587 1.319 0.091892 0 21.51067 10 12 10 609 69.8
ITIH3 0.225 0.202 1.011 0.53 -2.15 -2.31 0.0163 -0.916 -1.3410081 -1.5350159 1.099 0.092464 0 6.741573 6 14 6 890 99.8
RPS10 0.216 0.411 0.944 0.58 -2.21 -1.283 -0.084 -0.786 -1.0916311 -1.0347333 0.895 0.092569 0 18.96552 5 10 5 174 19.8






Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
RPS18 0.185 0.625 0.84 0.448 -2.44 -0.678 -0.251 -1.16 -1.1318085 -0.9190195 0.947 0.096643 0 42.76316 10 20 10 152 17.7
VEGFC 0.115 0.491 0.647 0.581 -3.11 -1.027 -0.629 -0.782 -1.388158 -0.9047513 1.162 0.096861 0.001 6.443914 3 3 3 419 46.9
P4HB 0.116 0.669 0.549 0.508 -3.11 -0.581 -0.865 -0.978 -1.3828657 -0.921773 1.162 0.09756 0 30.09901 15 22 12 505 56.7
ARPC1B 0.249 0.676 0.803 0.617 -2 -0.564 -0.316 -0.697 -0.8951608 -0.6305566 0.756 0.098568 0 34.67742 11 18 11 372 40.9
AP2A1 0.226 0.749 0.632 0.671 -2.15 -0.417 -0.662 -0.575 -0.9504625 -0.6186632 0.805 0.09915 0 8.802456 9 11 1 977 107.5
AP2B1 0.163 0.818 0.637 0.415 -2.62 -0.29 -0.651 -1.269 -1.2073722 -0.9595828 1.025 0.099742 0 8.09674 9 13 9 951 105.6
RPL18A 0.173 0.608 0.804 0.502 -2.53 -0.718 -0.316 -0.993 -1.1396628 -0.8557594 0.968 0.099977 0 25.56818 4 5 4 176 20.7
RPL13A 0.348 0.657 1.048 0.398 -1.52 -0.605 0.0636 -1.331 -0.8487203 -0.9681099 0.725 0.101174 0.001 9.047619 2 4 2 210 24.2
TUBA4A 0.249 0.637 0.998 0.344 -2.01 -0.651 0 -1.541 -1.0501771 -1.0962579 0.898 0.101401 0 35.26786 11 22 3 448 49.9
RPS3A 0.142 0.692 0.669 0.476 -2.82 -0.532 -0.581 -1.071 -1.2499492 -0.825557 1.072 0.102043 0 42.42424 14 21 14 264 29.9
TPI1 0.331 0.821 0.789 0.655 -1.59 -0.285 -0.341 -0.61 -0.7074476 -0.4754413 0.607 0.102221 0 22.02797 5 7 5 286 30.8
TUBA1A 0.195 0.724 0.771 0.487 -2.36 -0.466 -0.375 -1.038 -1.0598358 -0.7522831 0.915 0.103383 0 41.46341 13 30 5 451 50.1
CCT5 0.206 0.71 0.787 0.518 -2.28 -0.493 -0.349 -0.951 -1.0187707 -0.7219269 0.88 0.103559 0 12.38447 7 7 7 541 59.6
RPS4X 0.13 0.826 0.635 0.324 -2.95 -0.275 -0.656 -1.624 -1.3752572 -1.1401538 1.191 0.104048 0 49.04943 14 23 11 263 29.6
CAPN2 0.288 0.495 0.93 0.723 -1.8 -1.014 -0.105 -0.468 -0.84632 -0.741091 0.736 0.105111 0.001 3.840878 2 2 2 729 83.1
TXLNA 0.221 0.427 1.094 0.48 -2.18 -1.226 0.1263 -1.06 -1.0848425 -1.1433792 0.946 0.105606 0.001 10.98901 3 3 3 546 61.9
DSG1 0.267 0.462 1.183 0.373 -1.91 -1.114 0.2354 -1.419 -1.0509334 -1.2668956 0.917 0.105825 0 11.05815 8 10 8 1049 113.7
NT5C2 0.193 0.757 0.641 0.614 -2.37 -0.402 -0.641 -0.704 -1.0300133 -0.672599 0.904 0.107135 0 5.525847 3 4 3 561 64.9
APOD 0.383 1.056 0.691 0.451 -1.38 0.0792 -0.534 -1.149 -0.746994 -0.841367 0.657 0.107587 0.026 2.790698 1 2 1 215 24.1
KARS 0.222 0.54 0.692 0.843 -2.17 -0.89 -0.534 -0.246 -0.9602951 -0.7117858 0.849 0.108797 0 7.872697 4 5 4 597 68
AHCY 0.24 0.867 0.603 0.648 -2.06 -0.206 -0.731 -0.626 -0.9054043 -0.6784898 0.801 0.108976 0 19.67593 8 11 8 432 47.7
IleRS 0.188 0.236 1.336 0.324 -2.41 -2.082 0.4182 -1.627 -1.4259357 -1.8548344 1.271 0.110541 0 9.929633 10 12 10 1279 146.3
RPL19 0.269 0.637 1.053 0.387 -1.89 -0.651 0.0725 -1.372 -0.9607913 -1.0117859 0.856 0.110543 0.002 8.673469 1 2 1 196 23.5
CLU 0.197 0.617 0.808 0.611 -2.34 -0.697 -0.308 -0.712 -1.0144954 -0.7043245 0.904 0.110568 0 23.83073 9 14 9 449 52.5
PLEC 0.221 0.216 1.136 0.55 -2.18 -2.214 0.1833 -0.861 -1.2667358 -1.5182617 1.153 0.115501 0 3.159693 12 13 12 4684 531.5
CCT8 0.179 0.758 0.702 0.559 -2.48 -0.399 -0.51 -0.84 -1.0568054 -0.6750686 0.966 0.116449 0 31.75182 16 21 16 548 59.6
PDIA5 0.329 0.49 1.21 0.431 -1.6 -1.028 0.278 -1.213 -0.8916343 -1.120907 0.816 0.116656 0.001 5.009634 3 4 3 519 59.6
IPO7 0.29 0.394 1.313 0.346 -1.79 -1.344 0.398 -1.528 -1.064648 -1.4357481 0.992 0.121045 0 2.793834 2 4 2 1038 119.4
RPS29 0.171 0.827 0.705 0.486 -2.55 -0.275 -0.504 -1.04 -1.0909747 -0.7717854 1.021 0.122246 0.009 14.28571 2 4 2 56 6.7
PARP1 0.323 0.86 0.805 0.66 -1.63 -0.218 -0.314 -0.599 -0.6898952 -0.4568099 0.646 0.122459 0.001 4.33925 3 3 3 1014 113
SF3B1 0.329 0.448 1.239 0.482 -1.6 -1.158 0.3055 -1.051 -0.8764153 -1.1040837 0.823 0.123171 0.001 2.300613 2 3 2 1304 145.7
HNRPK 0.157 0.274 1.076 0.6 -2.67 -1.869 0.1042 -0.737 -1.2942113 -1.3030481 1.225 0.125024 0 7.327586 3 5 3 464 51
COL18A1 0.23 0.58 1.174 0.285 -2.12 -0.787 0.2297 -1.81 -1.1212034 -1.298419 1.065 0.12596 0 2.109464 3 4 3 1754 178.1
FAU 0.111 0.558 0.996 0.343 -3.17 -0.842 -0.007 -1.544 -1.3907185 -1.1930042 1.342 0.129898 0.001 10.20408 1 3 1 98 10.9
KRT18 0.272 0.79 0.816 0.674 -1.88 -0.34 -0.303 -0.57 -0.7723257 -0.454701 0.746 0.130203 0 13.02326 6 8 5 430 48
ARPC4 0.213 0.731 0.295 1.022 -2.23 -0.452 -1.766 0.0309 -1.1042815 -1.109121 1.067 0.130372 0 18.10811 6 6 6 370 41.5






Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
EIF2A 0.196 0.748 0.926 0.436 -2.35 -0.419 -0.111 -1.199 -1.0197666 -0.8089327 0.998 0.133579 0 18.63248 9 11 9 585 64.9
ACTR3 0.133 0.821 0.681 0.486 -2.92 -0.284 -0.554 -1.042 -1.1988973 -0.7981681 1.187 0.136541 0 26.79426 9 18 9 418 47.3
HNRNPC 0.165 0.397 1.002 0.662 -2.6 -1.332 0.0024 -0.596 -1.1313406 -0.9639543 1.121 0.136822 0 19.60784 7 8 7 306 33.6
EIF5 0.177 0.594 1.093 0.406 -2.5 -0.751 0.1248 -1.302 -1.1062025 -1.0266145 1.097 0.137175 0 34.57077 14 14 14 431 49.2
JUP 0.287 0.624 1.143 0.49 -1.8 -0.681 0.1916 -1.028 -0.8296451 -0.8546506 0.826 0.138199 0 18.92617 11 13 8 745 81.7
RRBP1 0.13 0.551 0.769 0.673 -2.95 -0.86 -0.381 -0.571 -1.1898714 -0.7155878 1.188 0.138975 0 28.8961 16 21 16 1540 165.6
RPS12 0.123 0.769 0.574 0.629 -3.03 -0.38 -0.799 -0.669 -1.2184872 -0.7340307 1.218 0.139181 0 20.45455 3 5 3 132 14.5
TNC 0.29 0.198 1.417 0.404 -1.79 -2.333 0.5078 -1.311 -1.2309366 -1.5492789 1.232 0.139585 0.001 2.373489 4 4 4 2233 244.2
SYNCRIP 0.176 0.933 0.514 0.669 -2.5 -0.099 -0.966 -0.58 -1.037122 -0.7729673 1.04 0.13997 0 17.33547 9 11 5 623 69.6
ACAT1 0.083 0.4 1.228 0.296 -3.59 -1.321 0.2972 -1.755 -1.5909764 -1.5379265 1.596 0.140189 0 24.82436 9 13 9 427 45.2
C1QTNF3 0.19 0.541 0.131 1.248 -2.4 -0.885 -2.962 0.321 -1.4803717 -1.6402744 1.487 0.140504 0.001 5.769231 2 3 2 312 33.8
NACA 0.28 0.712 1.091 0.448 -1.84 -0.491 0.1272 -1.158 -0.8392361 -0.8243369 0.847 0.141669 0 1.395573 2 4 2 2078 205.3
TUBB 0.153 0.821 0.722 0.532 -2.71 -0.285 -0.47 -0.911 -1.0943331 -0.6904014 1.11 0.1431 0 25.45045 10 22 3 444 49.6
EIF1AY 0.177 0.434 1.108 0.606 -2.49 -1.204 0.1479 -0.723 -1.06867 -0.9638271 1.103 0.148124 0 26.38889 5 8 5 144 16.4
SUPT16H 0.162 0.519 1.238 0.392 -2.63 -0.948 0.3069 -1.353 -1.1558993 -1.1500848 1.21 0.152153 0 6.494747 5 5 5 1047 119.8
PLRG1 0.304 0.751 1.019 0.61 -1.72 -0.414 0.0291 -0.713 -0.7034802 -0.563173 0.741 0.153846 0.001 3.696498 2 3 2 514 57.2
CCT5 0.216 0.866 0.782 0.611 -2.21 -0.207 -0.355 -0.712 -0.8716526 -0.5332629 0.919 0.154149 0 13.08411 7 8 7 535 57.5
DSP 0.236 0.575 1.186 0.519 -2.08 -0.799 0.247 -0.946 -0.8949325 -0.872255 0.953 0.157037 0 4.667363 13 18 13 2871 331.6
ASPH 0.249 0.658 1.231 0.35 -2 -0.604 0.2996 -1.513 -0.9556132 -1.0586219 1.018 0.15719 0.001 4.221636 3 4 3 758 85.8
RPL7A 0.195 0.565 1.327 0.306 -2.36 -0.823 0.4092 -1.707 -1.1189291 -1.2646858 1.197 0.158282 0 27.06767 8 12 8 266 30
CDSN 0.193 0.515 1.091 0.622 -2.38 -0.957 0.124 -0.683 -0.9730368 -0.82002 1.042 0.158599 0 6.805293 3 6 3 529 51.5
PDAP1 0.252 0.73 1.037 0.563 -1.99 -0.454 0.0516 -0.829 -0.8051284 -0.6416218 0.868 0.16054 0 27.07182 4 5 4 181 20.6
SF3A1 0.32 0.628 1.248 0.473 -1.64 -0.67 0.3219 -1.082 -0.7681654 -0.8759897 0.829 0.160856 0.001 1.134931 1 2 1 793 88.8
CAP1 0.259 0.931 0.836 0.586 -1.95 -0.104 -0.256 -0.772 -0.7708018 -0.5142272 0.837 0.162851 0 27.36842 14 19 14 475 51.6
ARID1A 0.22 0.988 0.719 0.593 -2.18 -0.017 -0.476 -0.755 -0.8578957 -0.6156893 0.934 0.163662 0.01 0.306346 1 2 1 2285 241.9
NAA15 0.212 0.549 1.345 0.366 -2.24 -0.865 0.4293 -1.45 -1.0307035 -1.157371 1.124 0.164023 0 6.812933 7 8 7 866 101.2
DSC1 0.142 0.336 0.834 0.969 -2.82 -1.575 -0.267 -0.047 -1.1765031 -0.9208347 1.285 0.16449 0 5.592841 4 5 4 894 99.9
CACYBP 0.191 0.777 0.829 0.657 -2.39 -0.364 -0.27 -0.606 -0.9079063 -0.48527 0.999 0.166574 0 44.29825 9 13 8 228 26.2
CLIC1 0.211 0.883 0.748 0.679 -2.25 -0.18 -0.42 -0.559 -0.8513428 -0.4896064 0.943 0.168799 0 29.87552 5 11 5 241 26.9
NARS 0.154 0.9 0.709 0.593 -2.7 -0.153 -0.497 -0.755 -1.025547 -0.6258395 1.142 0.170306 0 31.38686 19 27 19 548 62.9
RPS15A 0.161 0.641 1.255 0.325 -2.63 -0.641 0.3278 -1.62 -1.1409654 -1.1301268 1.273 0.170838 0 43.84615 7 9 7 130 14.8
PRSS3 0.423 0.557 1.159 0.772 -1.24 -0.845 0.2125 -0.372 -0.5615957 -0.6083632 0.627 0.171091 0 8.502024 2 5 1 247 26.5
IGHG1 0.217 0.47 1.195 0.028 -2.21 -1.09 0.2591 -5.139 -2.0440859 -1.6484482 2.296 0.173035 0.001 5.394191 2 2 2 482 52.8
SNRPD2 0.212 0.733 0.84 0.762 -2.23 -0.448 -0.248 -0.392 -0.8305592 -0.4197971 0.94 0.175329 0.001 33.05085 3 3 3 118 13.5
RACK1 0.254 0.873 0.748 0.799 -1.98 -0.196 -0.411 -0.325 -0.7267986 -0.3676979 0.838 0.18104 0.001 7.165109 2 2 2 321 34.9






Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
RPS28 0.202 0.717 1.242 0.382 -2.31 -0.48 0.3122 -1.388 -0.9665133 -0.9340296 1.133 0.186671 0.001 17.3913 1 2 1 69 7.8
EEF1G 0.194 0.963 0.823 0.561 -2.37 -0.055 -0.282 -0.832 -0.8841961 -0.5569688 1.042 0.188169 0 13.95881 6 6 6 437 50.1
TUBB4B 0.183 0.781 0.971 0.586 -2.45 -0.356 -0.042 -0.77 -0.9054187 -0.5632157 1.074 0.190458 0 25.39326 10 16 3 445 49.8
ARG1 0.173 0.318 1.494 0.558 -2.53 -1.652 0.5788 -0.842 -1.1122378 -1.247376 1.322 0.191017 0.001 8.385093 3 3 3 322 34.7
EIF2S3 0.219 0.889 0.989 0.519 -2.19 -0.169 -0.016 -0.947 -0.8311761 -0.5581841 0.995 0.19339 0 19.70339 8 13 8 472 51.1
RPL24 0.218 0.682 1.372 0.1 -2.2 -0.551 0.4534 -3.322 -1.4041463 -1.3740113 1.682 0.193512 0 24.84076 5 7 5 157 17.8
ABCF1 0.211 0.911 0.938 0.545 -2.25 -0.134 -0.091 -0.877 -0.8371314 -0.505582 1.006 0.194751 0 12.97935 3 5 3 339 38.3
PGD 0.19 0.836 0.285 1.215 -2.39 -0.258 -1.815 0.2804 -1.0462587 -1.0363852 1.263 0.196102 0 16.14907 7 8 7 483 53.1
PA2G4 0.152 1.116 0.671 0.536 -2.72 0.1584 -0.576 -0.899 -1.0080552 -0.7376659 1.221 0.197315 0 37.56345 14 29 14 394 43.8
ILF2 0.19 1.262 0.671 0.461 -2.39 0.3353 -0.574 -1.117 -0.9370247 -0.8455911 1.14 0.198795 0 23.33333 9 19 9 390 43
EIF2S1 0.215 0.738 1.128 0.56 -2.22 -0.438 0.1722 -0.835 -0.8289976 -0.6364518 1.013 0.20014 0 12.38095 5 5 5 315 36.1
SERPINA1 0.167 0.55 1.294 0.551 -2.58 -0.862 0.3677 -0.858 -0.982682 -0.8602054 1.211 0.203034 0 21.86544 12 18 9 654 72.3
PK 0.239 0.845 1 0.645 -2.06 -0.243 0 -0.632 -0.7344675 -0.4376193 0.923 0.20972 0 42.37288 19 34 19 531 57.9
CFL1 0.38 0.856 0.924 0.871 -1.4 -0.225 -0.114 -0.199 -0.4840435 -0.2121859 0.611 0.211081 0 31.86275 7 15 7 204 22.7
KPNB1 0.186 0.298 1.522 0.645 -2.43 -1.746 0.6041 -0.63 -1.0505555 -1.1880812 1.329 0.21209 0.001 2.054795 2 2 2 876 97.1
EDF1 0.209 0.726 1.037 0.705 -2.26 -0.461 0.0506 -0.505 -0.7927807 -0.4831075 1.007 0.213524 0.001 21.62162 3 4 3 148 16.4
OGN 0.349 1.279 0.602 0.705 -1.52 0.3548 -0.731 -0.505 -0.6004344 -0.6179914 0.771 0.217434 0.001 4.775281 2 3 2 356 40.5
HLA-A 0.314 0.884 1.263 0.258 -1.67 -0.178 0.3321 -1.956 -0.8686973 -0.9253518 1.118 0.217924 0.001 11.60221 2 2 2 181 21.1
TGFBI 0.228 0.581 1.373 0.561 -2.13 -0.784 0.4619 -0.832 -0.8211434 -0.807666 1.059 0.218708 0 10.83455 7 9 7 683 74.6
PRDX2 0.303 0.48 1.447 0.623 -1.72 -1.058 0.5329 -0.684 -0.7331508 -0.8705766 0.947 0.219469 0 23.73737 4 8 3 198 21.9
CFD 0.178 0.377 1.661 0.511 -2.49 -1.409 0.7334 -0.967 -1.0340606 -1.187804 1.342 0.220858 0.007 6.538462 1 2 1 260 27.8
SNRPD3 0.224 0.873 1.088 0.549 -2.16 -0.195 0.1215 -0.866 -0.7749893 -0.5305242 1.011 0.222843 0.001 15.07937 2 4 2 126 13.9
NF110b 0.184 0.795 1.096 0.576 -2.44 -0.331 0.1321 -0.796 -0.85918 -0.563271 1.121 0.222923 0 18.70824 15 31 15 898 95.7
HLA-C 0.176 0.822 1.17 0.483 -2.5 -0.283 0.2274 -1.049 -0.9018964 -0.665844 1.19 0.226679 0 17.21311 4 6 2 366 40.8
NAMPT 0.258 0.974 0.969 0.632 -1.96 -0.037 -0.046 -0.661 -0.6754692 -0.3536191 0.903 0.231496 0 17.51527 8 10 8 491 55.5
ZNF788P 0.386 1.455 0.389 0.705 -1.37 0.5413 -1.361 -0.505 -0.6743583 -0.9328505 0.907 0.233609 0.005 5.405405 1 3 1 259 29.9
MANF 0.245 0.479 1.456 0.651 -2.03 -1.063 0.5416 -0.619 -0.7927835 -0.8412502 1.067 0.233947 0 44.86486 9 16 9 185 21.1
EIF5B 0.206 1.067 0.971 0.538 -2.28 0.0936 -0.041 -0.896 -0.780729 -0.4682976 1.091 0.247857 0 5.081967 5 6 5 1220 138.6
SSRP1 0.195 0.904 1.159 0.567 -2.36 -0.146 0.2119 -0.818 -0.7777654 -0.4821216 1.137 0.264791 0 11.14245 8 9 8 709 81
LMNA 0.19 0.668 1.352 0.643 -2.4 -0.581 0.4354 -0.636 -0.7942429 -0.6085588 1.176 0.269477 0 40.66265 24 37 24 664 74.1
LGALS1 0.248 0.971 0.982 0.733 -2.01 -0.042 -0.026 -0.447 -0.6312886 -0.2443954 0.94 0.271808 0 19.25926 4 7 4 135 14.7
S100A8 0.307 0.788 1.187 0.759 -1.71 -0.343 0.2463 -0.398 -0.5500752 -0.3706583 0.824 0.273875 0 31.1828 3 6 3 93 10.8
RPS2 0.182 1.05 1.279 0.367 -2.46 0.0706 0.3556 -1.447 -0.8699238 -0.6882334 1.322 0.279716 0 36.51877 11 14 11 293 31.3
C4A 0.148 0.502 1.215 0.939 -2.75 -0.995 0.2827 -0.091 -0.8888905 -0.5427549 1.353 0.280415 0 6.594037 12 18 2 1744 192.8
SBDS 0.397 0.554 1.794 0.363 -1.33 -0.852 0.8532 -1.461 -0.6980811 -1.092076 1.067 0.281853 0.006 10.4 2 2 2 250 28.8
PACSIN2 0.28 0.854 1.196 0.691 -1.84 -0.228 0.2582 -0.534 -0.5852491 -0.3811793 0.896 0.282522 0 10.49383 5 5 5 486 55.7
HSPA8 0.225 0.862 1.215 0.644 -2.15 -0.214 0.2808 -0.635 -0.6801497 -0.4246116 1.05 0.285927 0 34.21053 22 40 18 646 70.9






Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
CAPRIN1 0.154 0.79 1.328 0.619 -2.7 -0.34 0.4099 -0.692 -0.8299949 -0.5158411 1.328 0.299787 0 3.244006 2 4 2 709 78.3
SERPINE2 0.242 1.576 0.806 0.437 -2.05 0.6566 -0.312 -1.193 -0.7239744 -0.7525184 1.161 0.301004 0 17.8392 9 13 9 398 44
CST3 0.192 0.64 1.337 0.8 -2.38 -0.643 0.4214 -0.321 -0.7307846 -0.4820055 1.187 0.305814 0 18.49315 2 4 2 146 15.8
G6PD 0.37 0.841 1.379 0.601 -1.43 -0.249 0.4611 -0.737 -0.4898385 -0.4930426 0.799 0.307654 0 5.048544 2 4 2 515 59.3
IGHA1 0.123 0.653 2.226 0.264 -3.03 -0.615 1.156 -1.919 -1.1011001 -1.2670457 1.799 0.308232 0 8.092486 3 6 3 519 56.4
RDX 0.234 0.765 1.164 0.859 -2.1 -0.386 0.2188 -0.219 -0.6202766 -0.302399 1.016 0.309195 0 36.10169 32 69 20 590 69.3
HMGB2 0.123 0.627 1.174 0.946 -3.02 -0.673 0.2306 -0.08 -0.8859872 -0.3762184 1.473 0.31516 0 36.84211 9 11 7 209 24
GAPDH 0.268 0.674 1.265 0.887 -1.9 -0.569 0.3382 -0.174 -0.5758343 -0.3711858 0.957 0.315193 0 42.08955 11 21 11 335 36
COL4A2 0.068 0.154 3.044 0.581 -3.87 -2.702 1.6041 -0.783 -1.4389122 -1.7428199 2.396 0.315814 0 4.614486 7 10 7 1712 167.4
CCT4 0.205 0.846 1.608 0.438 -2.28 -0.242 0.6849 -1.193 -0.7584358 -0.7174362 1.273 0.319261 0 16.32653 8 8 8 539 57.9
PDIA3 0.131 0.601 1.39 0.818 -2.93 -0.734 0.4747 -0.289 -0.8688188 -0.5114349 1.46 0.319623 0 34.14634 4 9 1 123 13.5
AP2M1 0.146 1.252 1.101 0.478 -2.78 0.3243 0.1385 -1.065 -0.8455073 -0.4632903 1.429 0.321906 0 20.86957 9 13 9 460 52.3
TCEA1 0.15 0.382 2.06 0.647 -2.74 -1.387 1.0432 -0.628 -0.9278377 -1.0074021 1.578 0.324388 0 12.29236 3 3 3 301 33.9
PTGES3 0.288 0.612 1.96 0.414 -1.79 -0.708 0.9687 -1.273 -0.7016461 -0.9903665 1.199 0.326274 0.001 13.93939 2 2 2 165 19.4
TTR 0.196 0.488 1.904 0.634 -2.35 -1.034 0.9274 -0.658 -0.7787515 -0.8459525 1.349 0.331961 0.083 3.243243 1 2 1 185 20.1
NMT1 0.24 1.041 1.251 0.605 -2.06 0.0585 0.3225 -0.724 -0.599855 -0.3329222 1.068 0.34298 0 8.870968 3 5 3 496 56.8
PGK1 0.17 1.178 1.051 0.651 -2.56 0.2367 0.0721 -0.619 -0.7171425 -0.2736587 1.282 0.344756 0 46.52278 16 29 16 417 44.6
SFPQ 0.208 0.631 1.637 0.716 -2.27 -0.664 0.7124 -0.482 -0.6754231 -0.5731138 1.225 0.350557 0.005 2.404526 2 3 2 707 76.1
FKBP3 0.186 0.957 1.27 0.687 -2.43 -0.063 0.3459 -0.541 -0.6708295 -0.3020753 1.224 0.353261 0 29.46429 7 10 7 224 25.2
VIM 0.27 0.688 1.609 0.705 -1.89 -0.54 0.6857 -0.503 -0.561711 -0.5213735 1.053 0.364096 0 28.54077 12 21 10 466 53.6
IGL 0.235 0.316 2.666 0.515 -2.09 -1.662 1.4147 -0.959 -0.8241529 -1.3100265 1.564 0.369277 0 20.9205 3 5 3 239 26.2
SSB 0.133 1.093 1.161 0.705 -2.91 0.1289 0.2159 -0.504 -0.7682741 -0.1877272 1.466 0.371503 0 31.61765 14 21 14 408 46.8
HMGB3 0.184 0.635 1.912 0.61 -2.45 -0.656 0.9355 -0.714 -0.7198549 -0.6846693 1.381 0.373826 0 27.5 6 9 5 200 23
SUB1 0.2 0.577 2.039 0.591 -2.32 -0.794 1.0282 -0.758 -0.7119077 -0.7759081 1.371 0.375269 0 39.55224 5 9 5 134 15.1
S100A13 0.202 0.733 1.891 0.574 -2.31 -0.449 0.9192 -0.802 -0.6597877 -0.6253337 1.326 0.392964 0 55.10204 7 12 7 98 11.5
AHNAK 0.212 0.413 1.804 0.979 -2.24 -1.275 0.8517 -0.031 -0.6736339 -0.6532402 1.361 0.395081 0.001 2.86927 3 4 3 5890 628.7
APEX1 0.196 0.755 1.4 0.943 -2.35 -0.406 0.4854 -0.084 -0.588278 -0.245096 1.23 0.409328 0 47.79874 14 29 14 318 35.5
CSTA 0.333 0.561 2.153 0.541 -1.58 -0.833 1.108 -0.886 -0.5489928 -0.8594957 1.157 0.412485 0 53.06122 6 9 6 98 11
HNRNPA2B1 0.48 0.86 1.631 0.498 -1.06 -0.218 0.7097 -1.008 -0.3940183 -0.6129045 0.83 0.412677 0 16.14731 5 8 4 353 37.4
EECP 0.242 0.279 4.217 0.259 -2.05 -1.842 2.0762 -1.949 -0.9405293 -1.8955236 2.013 0.418985 0.002 7.211538 2 3 2 208 22.7
COL5A3 0.229 0.735 2.753 0.254 -2.13 -0.444 1.4594 -1.976 -0.7723366 -1.2103081 1.671 0.423456 0.005 0.859599 2 3 2 1745 172
LCN1 0.413 0.334 2.453 0.565 -1.28 -1.581 1.2946 -0.823 -0.5967105 -1.0503051 1.299 0.425911 0 19.88636 3 5 3 176 19.2





Log(2)Mean Log(2)Median Log(2) Two-tailed Exp. # Unique 
Gene Name n=1 n=2 n=3 n=4 n=1 n=2 n=3 n=4  AR AR Std.Dev T.Test  q-value Coverage # Peptides # PSMs Peptides # AAs MW [kDa]
HMGA1 0.126 0.886 1.69 0.778 -2.98 -0.175 0.7571 -0.362 -0.6909173 -0.2684188 1.605 0.452616 0 48.59813 7 21 3 107 11.7
ENO1 0.195 1.186 1.282 0.759 -2.36 0.2462 0.3582 -0.398 -0.538696 -0.075801 1.26 0.455344 0 37.32719 15 30 15 434 47.1
ARPC5 0.397 0.659 2.191 0.461 -1.33 -0.601 1.1375 -1.117 -0.4779211 -0.8590789 1.12 0.456032 0 21.56863 3 4 2 153 17
S100 0.304 0.778 1.987 0.57 -1.72 -0.363 0.9903 -0.812 -0.4750235 -0.5873007 1.127 0.461287 0.001 7.017544 2 3 2 114 13.2
HMGB1 0.135 0.602 2.016 0.904 -2.88 -0.733 1.0119 -0.146 -0.6876501 -0.43934 1.634 0.46171 0 32.55814 9 17 8 215 24.9
SARS 0.196 0.602 3.132 0.386 -2.35 -0.732 1.647 -1.372 -0.7019616 -1.0519769 1.702 0.469828 0 6.343284 3 5 3 536 61.3
YWHAZ 0.243 0.571 2.8 0.479 -2.04 -0.808 1.4854 -1.062 -0.6063337 -0.9353319 1.492 0.475903 0 12.19512 3 5 2 246 28
HNRPD 0.473 1.08 1.36 0.679 -1.08 0.1107 0.4438 -0.559 -0.2712461 -0.2239998 0.682 0.484462 0 17.46479 6 13 5 355 38.4
PRH1 1.323 3.595 100 0.117 0.403 1.8458 8.6707 -3.097 1.955662 1.12459238 4.934 0.485872 0 16.60377 1 7 1 265 27.9
HDGF 0.197 1.43 1.305 0.651 -2.35 0.5158 0.3849 -0.62 -0.5165421 -0.1175704 1.321 0.491381 0 52.08333 10 12 10 240 26.8
KRT78 0.223 1.779 1.209 0.492 -2.17 0.8308 0.2711 -1.024 -0.5222444 -0.3764758 1.344 0.493638 0 15.38462 10 14 6 520 56.8
MAP4 0.258 0.502 2.085 0.961 -1.96 -0.996 1.0605 -0.058 -0.4872771 -0.5265732 1.291 0.505048 0 2.481498 5 5 5 2297 245.3
S100A6 0.392 1.405 0.845 0.975 -1.35 0.4903 -0.242 -0.037 -0.2848991 -0.1397148 0.774 0.515204 0.001 34.44444 4 5 4 90 10.2
NPM1 0.177 0.871 1.828 0.907 -2.5 -0.199 0.87 -0.141 -0.4914302 -0.1697726 1.424 0.539605 0 43.87755 12 25 12 294 32.6
MTDH 0.398 1.753 4.132 1.298 -1.33 0.8098 2.0469 0.3764 0.476282 0.59310857 1.396 0.543892 0 11.34021 5 6 5 582 63.8
S100A7 0.268 0.852 1.984 0.735 -1.9 -0.232 0.9887 -0.445 -0.3965388 -0.3381601 1.184 0.550865 0.001 21.78218 2 5 2 101 11.5
COL6A1 0.242 0.392 3.87 0.539 -2.05 -1.352 1.9522 -0.892 -0.5852854 -1.121767 1.757 0.552988 0 6.906615 5 9 5 1028 108.5
NUDC 0.383 0.949 1.488 0.902 -1.38 -0.075 0.5748 -0.149 -0.2583267 -0.112061 0.818 0.572443 0.001 10.57402 3 3 3 331 38.2
CALD1 0.303 0.784 2.123 0.795 -1.72 -0.351 1.0881 -0.331 -0.3292659 -0.3409782 1.148 0.606342 0 6.179067 3 4 3 793 93.2
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